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Abstract 
Porcine reproductive and respiratory syndrome virus (PRRSV) is an economically 
important infection with no current point of care (POC) diagnostic available.  PRRSV 
causes reproductive and respiratory illness in swine with the recent emergence of 
highly pathogenic strains.  This highlights the need for measures to control the 
spread of this infection to be taken more seriously in order to reduce the economic 
impact of this virus.  Current diagnostics for PRRSV are laboratory based and 
inherently these tests are expensive and are not rapid enough for the adequate 
management of outbreaks of the virus and implementation of biosecurity 
measures.  
This study presents a novel lateral flow device (LFD), using Affimer binding proteins 
to detect the nucleocapsid protein of PRRSV within a clinical sample to provide a 
cheap, rapid and reliable diagnostic for this infection in clinical samples.  Affimer 
reagents were raised against the nucleocapsid proteins from two strains of PRRSV, 
a high pathogenic and a low pathogenic strain.  Affimers that were able to 
distinguish between the two were taken forward for assessment in lateral flow.  
The Affimers were able to bind to the nitrocellulose membrane component of the 
device and were stable once dehydrated.  The Affimers were able to migrate 
through the membrane via capillary action when rehydrated and can detect the 
viral protein at a test line within a clinical sample, swine serum.     
This study provides the basis for further investigations in to the applications of 
Affimer reagents in lateral flow devices able to detect other viral infections as well 
as medically important diseases such as cancer.  In addition to their use in 
diagnostics, this study proposes the use of Affimers raised against the nucleocapsid 
protein of PRRSV as molecular tools for the further investigation into the role of 
this protein in the viral lifecycle as well as their potential as anti-viral therapeutics 
to address the lack of these medicines against this virus.  
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1 Introduction 
1.1 Infectious diseases of livestock 
Infectious diseases of livestock have devastating effects on global economics, 
animal welfare and food security.  It is therefore important to conduct research 
into the causative agents of disease in order to improve preventative measures and 
investigate therapeutic agents.  Outbreaks of certain infectious diseases may result 
in the mass culling of exposed animals.  Implementation of a preventative cull of 
healthy animals and widespread restriction of movement are often also used to 
stem the spread of infection.  The UK foot and mouth disease outbreaks of 2001 
and 2007 are prime examples (Tildesley et al., 2009).  Other infectious diseases, 
such as bovine respiratory syncytial virus (BRSV) (Snowder et al., 2006), classical 
swine fever (Boklund et al., 2009) and porcine reproductive and respiratory 
syndrome virus (PRRSV) (Nieuwenhuis et al., 2012) cause more subtle economic 
effects.  These infections are often overlooked with regard to testing and control, 
although the losses accrued globally as a result can be hugely economically 
damaging and result in the preventable deaths of thousands of animals.  Therefore, 
one of the most important factors in the control of an outbreak of an infectious 
disease is the ability to detect infection in a cost effective and rapid manner, in 
order that further control procedures may be executed.  However, it is often the 
case that infectious diseases are difficult to detect with clinical symptoms not 
presenting before the disease has spread rapidly amongst a population.  The 
implementation of a rapid, in-field or point of care (POC) biosensor is an ideal 
method to replace the need for lengthy, laboratory-based tests.  This study aims to 
produce a POC diagnostic test incorporating novel non-antibody components 
which could be utilised in both the agricultural and healthcare settings.   
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1.2 Virus classification 
1.2.1 Baltimore classification of viruses 
All viruses are categorised under the Baltimore classification, placing them into 
similar groups based upon their genome and mode of replication.  There are 
currently seven classes, table 1.1 shows this classification system (Baltimore, 1971).  
Table 1.1 Classification of viruses according to the Baltimore Classification system (Baltimore, 
1971). 
Class Genome Translation of viral 
genome 
Example viruses 
Class I dsDNA DNA to mRNA Herpesvirus 
Class II ss(+)DNA ss(+)DNA to ds(+/-
)DNA to mRNA 
Parvovirus 
Class III dsRNA dsRNA to mRNA Reovirus 
Class IV ss(+)RNA ss(+)RNA to (-)RNA to 
mRNA 
Arterivirus 
Class V ss(-)RNA ss(-)RNA to mRNA Paramyxovirus 
Class VI ss(+)RNA-RT  ssRNA to (-)ssDNA to 
(+/-)dsDNA to mRNA 
Retrovirus 
Class VII dsDNA-RT dsDNA to mRNA Hepadnavirus 
  
This study focuses on the Class IV RNA virus, porcine reproductive and respiratory 
syndrome virus (PRRSV), a single stranded, positive sense RNA virus.  The genome 
is translated directly with the positive sense genome serving directly as an mRNA.  
These viruses encode an RNA dependent RNA polymerase for genome replication, 
which synthesises minus RNA strands that are used as a template for positive 
strands of new genomic RNA (Baltimore, 1971).  The molecular biology of this virus 
will be discussed in detail in later sections.   
1.3. Nidovirales 
1.3.1. Introduction to the Nidovirus order 
PRRSV is an arterivirus and a member of the Nidovirlaes order. The Nidovirales are 
a diverse order of single stranded, positive sense RNA viruses that can be further 
subdivided into two categories, based upon the size of their genomes: large RNA 
genomes including coronaviruses (vertebrate hosts), mesoniviruses (invertebrate 
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hosts) and roniviruses (invertebrate hosts), whose genomes are between 20 and 32 
Kb, and viruses with smaller RNA genomes including arteriviruses (vertebrate 
hosts), whose genomes are between 13 and 16 Kb.  Nidoviruses are responsible for 
a number of economically important livestock infections and so there is a vested 
interest in research into these viruses, table 1.2 provides a summary of these 
infections and the associated virus family.  
Table 1.2 Economically important livestock Nidoviruses 
Family Virus Host Reference 
Arterivirus PRRSV Swine (Wensvoort et al., 
1991) 
Coronavirus Bovine respiratory coronavirus Bovine (Mebus et al., 1973; 
Storz et al., 2000) 
Coronavirus Porcine epidemic diarrhoea virus Swine (Wood, 1977) 
Coronavirus Porcine transmissible gastroenteritis virus Swine (Brian et al., 1980) 
Coronavirus Infectious bronchitis virus Poultry (Boursnell et al., 
1987) 
 
1.3.2. Nidovirus hosts 
As previously mentioned, Nidoviruses can infect a range of hosts, primarily 
mammals (coronaviruses, toroviruses and arteriviruses), however, coronaviruses 
can also infect avian hosts, and roniviruses infect invertebrate hosts (Pasternak et 
al., 2006).  Roniviruses include the Okaviruses, yellow head virus (YHV) and gill-
associated virus (GAV) which primarily infect crustaceans (Wijegoonawardane et 
al., 2008).  Recently a new family of viruses in the Nidovirale order has been 
proposed which also infect invertebrate hosts, the mesonviridae; of which there 
are currently two mosquito borne viruses, Nam Dinh virus and Cavally virus (Lauber 
et al., 2012).  The majority of Nidoviruses are host specific, however, certain 
Nidoviruses possess tropism for a number of hosts.  A phylogenic tree of the 
Nidovirus order is shown in figure 1.1 (Lauber et al., 2012).  
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Figure 1.1 Phylogenic tree of Nidovirale order (adapted from Lauber et al 2012). The Nidovirus tree 
shows the members of the arterivirus (green), mesonivirus (orange), ronivirus (red) and coronavirus 
(blue) and the coronavirus subfamily torovirus (yellow) (Lauber et al 2012). 
 
1.3.3. Nidovirus genome 
The genomes of all Nidoviruses are flanked with a 5’ cap structure and a 3’ poly (A) 
tail (Gorbalenya et al., 2006).  The flanking UTRs are suggested to play a role in the 
replication of the viral genome and the translation of viral proteins (Matthew A 
Kappes and Faaberg, 2015).  As well as the UTR regions of the viral genome, the 
coding open reading frames (ORFs) are located in the intermediate region of the 
Nidovirus genome.  A representative genome of the Nidovirale order (PRRSV) 
(figure 1.2) illustrates the main coding ORFs (Gorbalenya et al., 2006). 
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Figure 1.2 Representative Nidovirus genome (Porcine Reproductive and Respiratory Syndrome 
Virus).  The viral genome is split into two regions, the non-structural protein genes (ORF1a and 
ORF1b) and the structural genes, envelope protein (E), glycoproteins (GP), membrane protein (M) 
and nucleocapsid protein (N).  ORF1a and ORF1b are translated into polyproteins with ORF1b 
translated as a result of a ribosomal frame shift (RFS) and is proteolytically cleaved into the viral 
non-structural proteins.  The structural genes are translated as a nested set of subgenomic RNAs.  
The genome is flanked by two non-coding regions, one at the 5’ end and one at the 3’ end of the 
genome (edited from Gorbalenya et al 2006). 
 
The Nidovirales encode their own replicative machinery, including an RNA 
dependent RNA polymerase (RdRp) a common feature of positive sense RNA 
viruses.  Expression of the RdRp is controlled by a ribosomal frame shift and 
cleavage of the subsequent polyprotein by a chymotrypsin-like protease and 
papain-like proteases (Koonin, 1991; Beerens et al., 2007).  The 3’-proximal 
structural proteins are expressed as a nested (Latin nidus= nest) set of subgenomic 
RNAs.  This genomic region also contains accessory proteins in larger Nidoviruses 
that allow for the adaption of host specificity (Gorbalenya et al., 2006).  The 
number of structural proteins encoded in the genome and produced by the 
synthesis of subgenomic RNAs is virus dependent, as illustrated in figure 1.2 with 
arteriviruses encoding 7-9 non-structural proteins, whereas coronaviruses 
sometimes encode more than 9 non-structural proteins (Gorbalenya et al., 2006).  
1.3.4. Nidovirus virion architecture 
Due to the varied nature in size of Nidovirus genomes, the virion architecture 
varies between the different families in the order.  Coronavirus virions are between 
120-160 nm in diameter to encapsulate the larger genome with a fringe of 
projections from the surface of the virus particle with helical and extended 
nucleocapsids (Graham et al., 2013).  Arteriviruses are much smaller owing to their 
smaller genomes, 60 nm in diameter with a 35 nm isometric or pleomorphic 
nucleocapsid (Snijder et al., 2013).  Toroviruses are more pleomorphic in shape, 
being spherical, rod shaped or disk shaped measuring 100-140 nm in length and 35-
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42 nm in width (Kroneman et al., 1998).  All Nidovirus virions are enveloped using 
cellular membranes derived from the endoplasmic reticulum and golgi bodies and 
the envelope is studded with viral glycoproteins (Ziebuhr and Siddell, 2003). 
1.3.5. Members of the Nidovirus order 
1.3.5.1. Coronaviridae 
Coronaviruses are able to infect a range of vertebrate hosts, although evidence of 
transmission of infection between species is currently limited.  Severe acute 
respiratory syndrome coronavirus (SARS-CoV) was identified in 2003, following the 
transmission of respiratory illness between humans.  The animal reservoirs are 
thought to be ferrets, Civet cats and domestic cats, although the coronavirus 
isolated from these animals remains distinct from the SARS-CoV, another potential 
reservoir is the Chinese horseshoe bat (Lau et al., 2005; Lo et al., 2006).  The 
recently identified Middle East respiratory syndrome coronavirus (MERS-CoV) is 
thought to have been transmitted from the main reservoir in camels or bats to 
humans through close proximity living arrangements with limited human to human 
transmissions currently observed (Alagaili et al., 2014; Ithete et al., 2013).  The 
tropism of these viruses is mediated by the viral proteins themselves, with the 
envelope proteins playing a key role in cell infectivity, specifically the spike 
glycoprotein (S), located on the viral envelope, is involved in binding of viral 
proteins to cell membranes via receptor sites and can bind to proteinaceous 
receptors or cellular carbohydrates (Millet and Whittaker, 2015).  As shown in table 
1.2, the economically important agricultural coronaviruses include bovine 
respiratory coronavirus, porcine epidemic diarrhoea virus, porcine transmissible 
gastroenteritis virus and infectious bronchitis virus.   
1.3.5.2. Toroviridae 
Toroviruses are a sub-family of the coronaviruses and primarily infect mammals 
(Snijder and Horzinek, 1993), of which there are currently four recognised virus 
species, human, bovine, porcine and equine toroviruses.  The equine torovirus 
(EToV) and Berne virus (BEV) are the most thoroughly studied, although the mode 
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of infection and tropism of these viruses is currently poorly understood, as the 
virus grows poorly in cell culture conditions (Maestre et al., 2011). 
1.3.5.3. Mesoniviridae 
In 2012, a new family of viruses in the Nidovirales order was proposed.  These are 
mosquito borne viruses isolated in the Ivory Coast and Vietnam, termed Cavally 
virus (CAVV) and Nam Dinh virus.  Their genomes are intermediary in size between 
coronaviruses and arteriviruses (Lauber et al., 2012).   CAVV was identified in the 
Ivory Coast in 2004 and the virion structure is similar to that of coronavirus virions.  
The virus has only been isolated from female mosquitos and is likely to require a 
vertebrate as an amplification host during its lifecycle (Zirkel et al., 2011).  Nam 
Dinh virus was discovered in Vietnam in 2003 during a study into acute encephalitis 
syndrome (AES) associated with Japanese encephalitis virus, which causes 40% of 
cases of AES.  It is currently unknown if Nam Dinh causes symptoms in humans 
(Nga et al., 2011).  
1.3.5.4. Arteriviridae 
The family of viruses focussed upon in this study are the arteriviruses in particular 
PRRSV.  Other members of this family include lactate dehydrogenase elevating 
virus (LDV), simian haemorrhagic fever virus (SHFV) and equine arterivirus (EAV).  
They are all host specific during natural infection.  Arteriviruses are thought to 
enter the host cell via clathrin-mediated endocytosis, however, unlike with the 
spike glycoprotein from coronaviruses, there is currently no convincing evidence to 
pin point the viral proteins involved in the tropism of arterivirus infection (Snijder 
et al., 2013).  The target cells for all arteriviruses appear to be the macrophages of 
the respective species host (Plagemann and Moennig, 1992).  The arterivirus family 
will be discussed extensively below.  
1.3.6. Arteriviruses 
Arteriviruses infect a range of mammalian hosts: mice, horses, pigs and primates.  
The viruses themselves are highly host specific and cause both persistent and 
asymptomatic infections as well as acute disease with symptoms that include 
haemorrhagic fever, respiratory illness and abortions (Snijder et al., 2013).  Until 
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recently there were four members of the arterivirus family (section 1.3.5.4).  This 
set of viruses were recognised as a new member in the order Nidovirales in the late 
1990’s at the Xth International Congress of Virology (Jerusalem, 1996) (Snijder and 
Meulenberg, 1998).  In the past five years there have been a number of tentative 
additions to the arterivirus family including wobbly possum disease virus (WPDV), 
African pouched rat virus 1, and viruses distantly related to SHFV (Dunowska et al., 
2012; Jens H Kuhn et al., 2016; Lauck et al., 2013).  WPDV is the first arterivirus 
found to infect a non-eutherian host (Jens H. Kuhn et al., 2016).  These tentative 
new additions to the family of arteriviruses have resulted in the suggested 
reorganisation of the family to accommodate the complexity (Jens H Kuhn et al., 
2016). 
1.3.6.1. Genome organisation 
The genome of this family of viruses is small in relation to other families in the 
nidovirale order with member genomes of between 12-16 kb.  The genomes of the 
four members of the arterivirus family are shown in figure 1.3. (adapted from 
Snijder et al., 2013). 
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Figure 1.3 Arterivirus genomes. The genomes of arteriviruses EAV, LDV, PRRSV and SHFV are 
translated in two separate ways.  ORF1a and ORF1b are translated from genomic RNA as 
polyproteins and are proteolytically cleaved by viral proteins at the locations indicated by arrows.  
The RNA dependent RNA polymerase (RdRp) is encoded by these ORFs.  The 3’ end of the viral 
genome contains the structural genes and these are translated from a nested set of subgenomic (sg) 
mRNAs.  These are produced in constant but non-equimolar quantities and the genes encoded on 
the sgmRNAs overlap (Snijder et al., 2013). 
 
The positive sense RNA genomes are polycistronic and the 10-15 ORFs are flanked 
by non-translated regions (NTRs) at the 3’ and 5’ ends.  These NTRs are variable in 
length dependent on the virus and range from 5’, 156-224 nucleotides (nt) and 3’, 
59-117 nt (Snijder et al., 2013).  The 5’ proximal region of the genome encodes the 
large replicase ORFs 1a and 1b and make up three quarters of the viral genome, the 
polymerase gene resembles the polymerase gene of the related coronaviruses.  
ORF1a and 1b overlap and are translated using a -1 ribosomal frameshift (RFS), the 
overlap in EAV is 19 nt (den Boon et al., 1991).  These ORFs yield translated 
proteins of 1727-2502 amino acids (aa) and 3175-3959 aa respectively and upon 
translation are proteolytically cleaved to produce a large number of proteins 
(Snijder et al., 2013; Fang et al., 2012).  Recently, a previously unidentified protein 
was discovered in PRRSV ORF1, using a programmed -2 RFS at a conserved 
G_GUU_UUU sequence in the central region of ORF1a.   This RFS mechanisms 
produces a previously unidentified protein, termed nsp2TF, which comprises the N-
terminal two thirds of nsp2 and 169 aa C-terminal region encoded by the newly 
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identified TF ORF, which is conserved in the genomes of all arteriviruses (Fang et 
al., 2012).  Nsp2TF is proposed to be involved in the down-regulation of Swine 
Leukocyte Antigen Class 1 (SLA-1), reducing the cell-mediated immune response 
during infection (Cao et al., 2016).  The replicase polyproteins of PRRSV are 
processed into at least 16 non-structural proteins and four proteinases (Matthew A 
Kappes and Faaberg, 2015).  
The 3’-proximal genome region encodes the viral structural proteins.  These are 
generally small ORFs which overlap with each other and are expressed as a nested 
set of subgenomic (sg)mRNAs in non-equimolar but constant amounts (Snijder et 
al., 2013).  This is a characteristic of coronaviruses and arteriviruses, as each of the 
sgmRNAs contains a leader sequence at the 5’ end (approximately 200 nt) that is 
identical to the 5’ leader sequence of the genome (de Vries et al., 1990).   
1.3.6.2. Arterivirus lifecycle 
The tropism of arteriviruses is very narrow and this is thought to be due to the viral 
proteins themselves, present on the surface of the virions.  The method of entry 
into the cell by arteriviruses has long been known to occur via clathrin-mediated 
endocytosis, endosome acidification and membrane fusion (Kreutz and Ackermann, 
1996).   The lifecycle is outlined in figure 1.4 and covers the entire infectious cycle 
from viral entry to release (Snijder et al. 2013).   
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Figure 1.4 Arteriviral infection cycle.  The virus enters cells via receptor-mediated endocytosis and 
the virus particle is disassembled in the endosome.  The viral genome is released into the cytoplasm 
the replicase polyproteins pp1a and pp1b are translated from ORF1a and ORF1b.  These 
polyproteins are cleaved by internal viral proteases to produce the viral proteins required to 
assemble the replicase complex (RdRp).  The replication and transciption complex (RTC) begins 
minus strand RNA synthesis of the whole viral genome, including the minus strand sgmRNAs for the 
synthesis of the viral structural proteins.  These minus strands of viral genome are then transcribed 
into positive strands and the complete genomes are packaged into new viral particles.  The positive 
strand sgmRNAs are used as templates for the translation of the viral sturctural proteins which are 
then available for the assembly of new virions.  The RTC associates with cellular membranes such as 
the endoplasmic reticulum (ER), where viral structural proteins mature before packaging.  The 
newly synthesised viral genome encapsidated by the nucleocapsid (N) protein bud from smooth ER 
and become enveloped with the viral structural proteins and leave the infected cell via the exocytic 
pathway (Snijder et al. 2013).    
 
The lifecycle of the virus occurs in the cytoplasm of the host cell and through the 
formation of replication and transcription complexes (RTCs).  Upon viral genome 
entry into the host cytoplasm, ORFs 1a and 1b are translated to produce pp1a and 
pp1b that are proteolytically cleaved by viral proteinases, PCP1α, PCP1β, CP2 and 
3CLSP (further discussed in section 1.3.6.4.1) to produce a number of non-
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structural proteins which form the RTCs (van der Meer et al., 1998).  It is the RTCs, 
associated with double membrane vesicles induced by the expression of the 
proteins encoded in pp1a and pp1b to provide a scaffold structure, that are the 
location of minus strand RNA synthesis used for the subsequent synthesis of the 
new positive strand RNA genome (Posthuma et al., 2008).  RTCs are a widely used 
strategy in viral replication, being adopted by a number of viruses (den Boon et al., 
2010; Romero-Brey and Bartenschlager, 2014; Paul and Bartenschlager, 2013)  with 
the use of viral proteins as initiators of the formation of the RTCs (Ahlquist, 2006).  
The confinement of the replication process of viruses into compartments is 
favourable for optimum viral production, forming micro-environments that 
concentrate viral proteins and precursors and anchor the process to a location 
where enzymes are able to function efficiently.  RTCs may also delay detection of 
viral replication by the host immune system (van der Hoeven et al., 2016; Gürtler 
and Bowie, 2013).   
In the case of arteriviruses, the RTC produce both full length and sg length minus 
strands of RNA with the sg length RNA used for the synthesis of the positive sense 
sgmRNAs required for the synthesis of the viral structural proteins.  The sgmRNAs 
are translated into the viral structural proteins that are involved in the production 
of new viral particles containing newly synthesised viral genomes (Pasternak et al., 
2006).  The viral genomes are encapsulated by the nucleocapsid (N) protein, which 
is then coated with a lipid envelope (55 nm bilayer) studded with further structural 
proteins that include the glycoproteins and membrane proteins (Snijder and 
Meulenberg, 1998).  Viral particles appear to be assembled at the site of 
replication, with the nucleocapsid encapsulated genome being wrapped by the 
smooth endoplasmic reticulum (ER) or Golgi complex studded with the viral 
structural proteins.  The formation of the viral particles at the ER allows them to 
enter into the secretory pathway and be transported to the cell membrane where 
they undergo exocytosis and release for infection of further host cells (Magnusson 
et al., 1970; Wood et al., 1970).  Recently, it has been suggested that this arteriviral 
secretory pathway also involves plasma membrane cholesterol, at least in the case 
of PRRSV (Sun et al., 2011; Q. Yang et al., 2015).  Cholesterol and lipid metabolism 
is also known to be important for the life cycles of a wide variety of viruses, where 
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components of the lipid synthesis pathways are hijacked for viral maturation and 
secretion.  Other viruses that use lipid and cholesterol metabolism include hepatitis 
C (Popescu et al., 2014), canine coronavirus (Pratelli and Correspondence, 2016), 
HIV (Bukrinsky and Sviridov, 2006), Semliki forest virus (Marquardt et al., 1993), 
FMDV (Martín-Acebes et al., 2007) and Herpes Simplex Virus (Wudiri et al., 2014). 
1.3.6.3. Arterivirus virion 
The arterivirus virion is spherical and enveloped and the virus particles are 
between 40-60 nm in diameter consisting of an isometric core, which is 
approximately 80% of the virion diameter.  A schematic of the virion is shown in 
figure 1.5. (Snijder et al., 2013; Spilman et al., 2009). 
 
 
Figure 1.5 Structure of arterivirus virion.  (a) Schematic diagram of the arterivirus particle.  The 
virus particle is approximately 50-60 nm in diameter and roughly spherical.  The nucleocapsid 
protein surrounds the viral genome which is then surrounded by the viral envelope.  The envelope 
contains the structural glycoproteins as well as the M and E proteins as indicated. (b) Cryo-EM 
image of PRRSV virion with measurements of the viral dimensions indicted.  A putative spike protein 
complex is also shown on the left of the virion. Edited Snijder et al. 2013; Spilman et al. 2009.   
 
A breakdown of the virion size, genome size and structural proteins of the 
arteriviruses are listed in table 1.3.  
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Table 1.3 Structural proteins of arteriviruses 
Virus Diameter 
(nm) 
Genome 
size (kb) 
Structural protein Gene Size (aa) Reference 
EAV 50-60 12.7 E 
Gp2b 
Gp3 
Gp4 
Gp5 
M 
N 
2a 
ORF2b 
ORF3 
ORF4 
ORF5 
ORF6 
ORF7 
67 
227 
163 
152 
255 
162 
110 
(Zhang et al., 
2008) 
LDV 55 14.2 Minor Gp 
  
  
VP3 
M 
N 
ORF2 
ORF3 
ORF4 
ORF5 
ORF6 
ORF7 
227 
191 
175 
199 
172 
116 
(Palmer et al., 
1995) 
PRRSV 45-55 15.1 Gp2 
E 
Gp3 
Gp4 
ORF5a 
Gp5 
M 
N 
ORF2a 
ORF2b 
ORF3 
ORF4 
ORF5a 
ORF5 
ORF6 
ORF7 
255 
73 
265 
183 
51 
201 
173 
128 
GenBank: 
KC771271.2 
SHFV 45-50 15.7 Minor Gp 
Minor Gp 
Minor Gp 
E 
Minor Gp 
Minor Gp 
Minor Gp 
Hypothesised 
protein 
Large Gp 
M 
N 
ORF2a 
ORF2b 
ORF3 
ORF4a 
ORF4b 
ORF5 
ORF6 
ORF7a 
ORF7 
ORF8 
ORF9 
223 
202 
166 
81 
204 
195 
171 
58 
232 
162 
111 
(Bailey et al., 
2014) 
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The virion comprises the viral RNA encapsulated by the N protein, which forms the 
core structure of the virus.  The core is then coated in a lipid bilayer that is studded 
with the viral structural proteins.  As mentioned in section 1.3.6.1, these structural 
proteins are expressed from the sgmRNAs produced during viral transcription 
(Pasternak et al., 2006).  The proportion of these proteins present within the lipid 
bilayer is virus dependent and some of the viral proteins are not confirmed to be 
expressed, for example the protein encoded by ORF7a in SHFV (Bailey et al., 2014). 
It has been shown that the structural proteins in EAV required for virion assembly 
are Gp5, M and N proteins with the particles forming in the absence of E, Gp2b, Gp3 
and Gp4.  These particles were seen to contain viral genomic RNA (Wieringa et al., 
2004).  In the wild type virus N, M and Gp5 are the major virion components, with E 
occurring at intermediate amounts and the remaining Gps as minor structural 
proteins (Wieringa et al., 2004).  The interactions between the structural proteins 
of the arteriviruses are thought to be important in the infectivity of the viral 
particles.  For example, heterodimerisation of Gp5 and M protein via a disulphide 
linker has been shown to be essential for the infectivity of the virus (Snijder et al., 
2003).   
1.3.6.4. Arteriviral proteins 
The number of proteins encoded in the viral genome is virus dependent, however 
there are a number of conserved proteins within the arterivirus family; 
polyprotein1ab (pp1ab), RdRp, N protein, E protein, M protein and glycoproteins, 
each of which will be discussed as general groups.  
1.3.6.4.1. Polyprotein1ab 
As with all Nidoviruses, the arterivirus pp1ab is encoded by ORF1a and ORF1b.  The 
proteins produced from these ORFs are subsequently cleaved into between 12 and 
15 smaller functional proteins by viral encoded proteinases, shown in table 1.4. 
(Gorbalenya et al., 2000). 
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Table 1.4 Viral proteinases of arteriviruses (Gorbalenya et al., 2000). 
Proteinase Alternative names Associated end-
protein 
Principle nucleophile 
PCP1α  nsp1α, nsp1 in EAV Cys (Lys in EAV) 
PCP1β PCP for EAV nsp1β, nsp1 in EAV Cys 
CP2 CP, nsp2 proteinase nsp2 Cys 
3CLSP nsp4, SP nsp4 Ser 
 
The cleavage of ORF1a and ORF1b is virus specific, with some arteriviruses 
encoding a higher number of functional proteins within this region of the genome 
than others.  The cleavage of PRRSV pp1ab results in the production of at least 14 
functional proteins, most of these proteins have been characterised, but there are 
some with as yet unknown functions.  These proteins are summarised in table 1.5 
along with their known or predicted functions (Fang and Snijder, 2010).  
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Table 1.5 PRRSV pp1ab cleavage products adapted from (Fang and Snijder, 2010). 
Cleavage 
product 
Known or predicted nsp function/properties Reference 
nsp1α Zinc finger protein, accessory protease PCPα, regulator 
of sg mRNA synthesis and potential interferon (IFN) 
antagonist. Crystal structure solved 
(Kroese et al., 2008) 
nsp1β Accessory protease PCPβ, potential IFN antagonist (Kroese et al., 2008) 
nsp2 Accessory protease CP, deubiquitinating (DUB) 
enzyme, potential IFN antagonist, transmembrane 
protein, involved in membrane modification and 
suppression of innate immune response 
(van Kasteren et al., 2013) 
nsp3 Transmembrane protein, involved in membrane 
modification 
(Snijder et al., 2001) 
nsp4 Main protease SP (3CLSP) (van Dinten et al., 1999) 
nsp5 Transmembrane protein, potentially involved in 
membrane modification 
(Music and Gagnon, 2010) 
nsp6 Unknown (Music and Gagnon, 2010) 
nsp7α Unknown (van Aken et al., 2006) 
nsp7β Unknown (van Aken et al., 2006) 
nsp8 Unknown (Snijder and Meulenberg, 
1998) 
nsp9 RNA dependent RNA polymerase (Beerens et al., 2007) 
nsp10 NTPase, RNA helicase; contains putative zinc-binding 
domain 
(Bautista et al., 2002) 
nsp11 Endoribonuclease (NendoU) (Music and Gagnon, 2010) 
nsp12 Unknown (Music and Gagnon, 2010) 
 
1.3.6.4.2. RdRp 
The replication of all Nidoviruses is dependent on cytoplasmic RNA dependent RNA 
synthesis carried out by the RNA dependent RNA polymerase (RdRp), encoded by 
all of the Nidoviruses.  This protein is encoded in pp1ab and is the cleavage product 
of nsp9.  Polymerases are enzymes that are involved in the catalysis of templated 
synthesis of new polynucleotide sequences in a 5’-3’ direction.  These proteins are 
encoded by all organisms and RNA viruses (Lehmann et al., 2016).  The structure of 
these proteins resemble a cupped hand with finger, palm and thumb domains 
which are used to guide the substrates and metal ions into the catalytic domain 
(Ferrer-Orta et al., 2006).  The EAV RdRp is the best characterised arteriviral RdRp 
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and de novo RNA synthesis by this protein has been extensively investigated.  The 
EAV protein requires Mn2+ and Mg2+ (can function with one or the other but 
optimal function is observed with 2 mM Mn2+ and 4 mM Mg2+ in in vitro studies), 
and was shown to be catalytically active without the requirement of other viral and 
host proteins in a de novo manner, relying on poly-uridine or poly-cytidine single 
stranded RNAs (Beerens et al., 2007).  This, however, is not a conserved feature of 
Nidoviruses RdRps, where coronaviruses RdRps have been shown to synthesise 
RNA with the requirement of primer sequences (Beerens et al., 2007; Cheng et al., 
2005).   
1.3.6.4.3. Nucleocapsid protein 
The N protein of arteriviruses is encoded by the sgRNAs of ORF7.  This is a crucial 
viral protein as it encapsulates the viral genome within the virion.  The N protein 
and the viral genome are the main components of the arterivirus nucleocapsid 
core.  The nucleocapsid of PRRSV and EAV are one of the more widely studied 
arteriviral N proteins and electron microscopic (EM) analysis has shown that the 
PRRSV virion is approximately 52 nm in diameter, figures 1.5a and 1.6.  The core of 
the virion, the N protein surrounding the viral genome, is on average 39 nm with a 
gap of around 3 nm between this core and the viral envelope.  The envelope-core 
interactions are weak and flexible.  Transmembrane (TM) spanning density can also 
be seen, which is thought to be the TM regions of M and Gp5 envelope proteins 
(Spilman et al., 2009; Snijder et al., 2013).   
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Figure 1.6 EM analysis of PRRSV viral particles.  The PRRSV virion is spherical and consists of a core 
containing the genome surrounded by the N protein (dense region in the centre of the virion). The 
viral envelope can be seen as well as a spike complex indicated by the black arrow (Spilman et al., 
2009).   
 
It has been hypothesised that the N protein of arteriviruses forms a dimeric 
structure when crystallised in isolation (Doan and Dokland, 2003; Deshpande et al., 
2007).  However, recent EM analysis of the virion suggests that this is more likely to 
be a double layer of N protein in a linked chain with interactions between the viral 
RNA and the N-terminal region of the N protein, the structure of which is yet to be 
elucidated (figure 1.6).  Moreover, the use of structure prediction software 
suggests that the N-terminal region of the arteriviral N protein is helical which 
would allow for an extended conformation that fits with the observed structure of 
the viral nucleocapsid core (Spilman et al., 2009).   
The structure of the viral N proteins of PRRSV (C-terminal 65 amino acids) and EAV 
are shown in figure 1.7 (Deshpande et al., 2007; Doan and Dokland, 2003).  The 
structure of these proteins is similar despite the sequence homology being only 
16% in the N-terminal region of the protein and 35% in the C-terminal region, as 
well as the EAV protein being shorter by 13 amino acids (Deshpande et al., 2007).  
The RNA binding to these proteins is currently unknown, however, in PRRSV the 
binding of RNA is thought to occur through the lysine enriched region 34-51 aa 
(Wootton and Yoo, 2003), although interestingly these are absent in the EAV N 
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protein.  Although the structure of these proteins is similar, their conformations 
within the context of the virus appear to be subtly different resulting in the dimer 
formed by the EAV N protein being a tighter structure than that of the PRRSV N 
protein (Deshpande et al., 2007). 
 
Figure 1.7 Crystal structure of PRRSV and EAV N proteins. (a) PRRSV N protein dimer, monomers 
shown in blue and red ribbons.  The structure of this protein does not include the N terminal 57 
amino acids which were removed to aid crystalisation (Doan & Dokland 2003). (b) EAV N protein 
dimer, monomers shown in pink/yellow and green/blue.  The overall structural of the two dimers is 
similar despite sequence differences (Deshpande et al. 2007).  
 
A more in depth review into the PRRSV N protein is discussed in section 1.4.3 with 
regards to its role in the context of PRRSV infection.  
1.3.6.4.4. Glycoproteins 
As with the N protein, the viral glycoproteins (Gp) are encoded by the sg RNAs of 
arteriviruses at the 3’ end of the viral genome.  The number of Gp genes varies 
within the arteriviral family despite the small genome size of these viruses, 
previously listed in table 1.3.  The Gps are found within the envelope of the virion 
and interact with other viral structural proteins as well as host cell proteins, where 
they function in virus entry (Van Breedam et al., 2010), although the mechanisms 
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by which this occurs are not fully understood. It is thought that Gp5 interacts with 
the M protein to form a major Gp complex (figure 1.8) within the envelope and 
Gp2/Gp3/Gp4 interact to form the minor Gp complex as shown in figure 1.9 (Veit 
et al., 2014; Wieringa et al., 2003).  The complex of Gp5/M interacts by a disulphide 
bond between the N-terminal region of the M protein (cysteine 8) and the N-
terminal region of Gp5 (cysteine 27) (Snijder et al., 2003).  Gp5 is a variable protein 
which can differ in length between viruses and in sequence homology between 
virus strains, however, the overall membrane topology is thought to be the same 
between arteriviruses (Veit et al., 2014).  The membrane topology of Gp5 is 
predicted to result in a structure that spans the membrane three times, although 
this is yet to be confirmed in the context of the virus.   
 
Figure 1.8 Glycoprotein 5 interaction of EAV with M protein.  The N termini of the M and Gp5 
proteins are joined by a disulphide bond (cystine 8 of M and cystine 27 of Gp5) with putative 
transmembrane domains (TMR) indicated.  Dimerisation of these proteins is important for their 
transport from the ER to the golgi apparatus and then onto the infectious viral particle (Veit et al., 
2014).   
 
The complex of Gp5 and M is involved in the binding of sialoadhesin receptor in a 
sialic acid-dependent manner, where the sialic acids are found on Gp5, to mediate 
the entry of the virus into the host cell (Van Breedam et al., 2010).  The 
glycoproteins of arteriviruses are N-linked glycosylated, and these proteins have 
been implicated in viral assembly, viral attachment to cells, virus neutralisation and 
protection from the immune system (Ansari et al., 2006; Wissink et al., 2004; Jiang 
et al., 2007; Fan, Liu, et al., 2015; Thaa et al., 2013; Wissink et al., 2005).   
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As well as the major Gps found in the envelope of the virion, the minor 
glycoproteins also play a key role in the virus lifecycle, determining viral tropism in 
cell culture (Tian et al., 2012).  The structure of the complex of the minor Gps is 
shown in figure 1.9, the glycoproteins contain an N terminal signal domain and a 
single transmembrane region, in the case of Gp2 and Gp4.  The branches indicate 
the glycosylation sites on the proteins.  Gp3 also has an N terminal signalling 
peptide, glycosylation sites and a hydrophobic region.  The number of glycosylation 
sites on the glycoproteins is dependent on the virus or strain of virus  (Veit et al., 
2014).   
 
Figure 1.9 Arterivirus minor glycoproteins.  A complex is formed via disulphide bonds between 
Gp2/3/4 as indicated -s-s- in EAV.  Glycosylation is shown with the branches on the lumenal 
branches with expected TMR and hydrophobic regions (HR) indicated (Veit et al., 2014). 
 
1.3.6.4.5. M protein 
The viral M protein is encoded by ORF6 of PRRSV, EAV and LDV and ORF8 of SHFV.  
As previously discussed in section 1.3.6.4.4 it forms a heterodimer with Gp5 via a 
disulphide link (Snijder et al., 2003).   This protein is between 18 and 19 kDa in size 
and the PRRSV M protein is known to have three membrane spanning domains 
(Music and Gagnon, 2010).  The M protein also forms homodimers which may be 
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involved in the building of the functional Gp5/M protein complex (de Vries et al., 
1995).      
1.3.6.4.6. E protein 
The E protein is encoded by ORF2 in the arteriviral genome of EAV (ORF2a) 
(Wieringa et al., 2004) and PRRSV (ORF2b) (Music and Gagnon, 2010) and ORF4 
(Bailey et al., 2014) of SHFV, and along with the glycoproteins is found in the virion 
envelope.  The protein itself is small (8 kDa) with three domains, although the 
structure is not known, it is predicted that there is a hydrophobic transmembrane 
domain and a hydrophilic C-terminal domain (Snijder et al., 1999).  Two 
conformations have been proposed for the insertion of the E protein into the virion 
membrane, one with a single pass and the exposure of either the N- or C-terminus 
of the protein to the virus core, or a hairpin conformation with the N- and C-
terminus being exposed at the same side of the membrane (Thaa et al., 2009).  It 
has also been shown that the E protein is able to form homo-oligomers which 
function as an ion channel in the viral envelope to mediate the uncoating of the 
virus and release of the genome into the cytoplasm (Lee and Yoo, 2006).  The E 
protein has been shown to be essential for the production of infectious virus but is 
not essential for the assembly and budding of viral particles, at least in EAV 
(Wieringa et al., 2004). 
1.3.6.5. Arteriviral pathogenesis 
Arteriviruses cause infections which are associated with symptoms ranging from 
respiratory disease, abortion or lethal haemorrhagic fever although they have been 
known to be implicated in the establishment of persistent infection within a 
population due to asymptomatic infection of animals (Snijder et al., 2013).   
The viral proteins previously discussed in table 1.5 can be implicated in the evasion 
or activation of the immune response.  The innate immune response to arteriviral 
infections have been widely explored with the investigation into individual viral 
proteins but not as a general viral response.  Viral non-structural proteins such as 
nsp1α and nsp1β have been implicated in the modulation of the immune response 
and these will be discussed in respect of PRRSV in sections 1.4.1.1 – 1.4.1.7. 
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1.3.6.5.1. Arteriviral innate immune response 
The response of the innate immune system to an arteriviral infection is generally 
poor, which is why the viruses are able to establish persistent infections.  It is 
thought that these viruses evade the innate immune response by modulating the 
proteins within this system to reduce its activation and this is carried out mainly by 
the viral non-structural proteins (Snijder et al., 2013).  The targets for these 
proteins are cytokine signalling pathways, including interferons and interleukins 
(Sun et al., 2012). 
1.3.6.5.2. Humoral immune response 
The antibody response to arteriviral infection is very early and high levels of 
antibodies are produced, they are generally raised in response to the majority of 
the viral proteins, however the levels of each depend on the virus species (Snijder 
et al., 2013).  For example in PRRSV infection, the antibody response to the N 
protein is first and strongest (Darwich et al., 2010).   
1.3.6.5.3. Cell-mediated immune response 
Arteriviral cell-mediated immune responses remain poorly characterised, however, 
it is thought that PRRSV induces a T cell response between 2 and 8 weeks post 
infection, but this response is highly variable between animals with apparently no 
correlation with the viral load in the lymphoid tissues (Snijder et al., 2013; Darwich 
et al., 2010). 
1.4. Porcine reproductive and respiratory syndrome 
virus (PRRSV) 
Porcine reproductive and respiratory syndrome virus (PRRSV) is an example of an 
arteriviral livestock infection affecting swine.  PRRSV was first identified in the late 
1980’s and early 1990’s in Canada and North America (genotype 2) as mystery 
swine disease and swine infertility and reproductive syndrome and in Europe 
(genotype 1) as blue ear disease or PRRS (Dea et al., 1992; Terpstra et al., 1991; 
Wensvoort et al., 1991).  The first description of PRRSV in Europe was in Denmark 
in 1990/1991 with the outbreak of mystery swine disease, which was affecting 
breeding sows and their litters.  Sows were feverish and anorexic, with their 
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offspring being aborted late in gestation (day 110 of 115) or being born mummified 
or stillborn, with those that did survive being weak and sickly and at risk of 
respiratory disease (Wensvoort et al., 1991).  The causative agent of this infection 
was isolated as Lelystad virus in Europe (Wensvoort et al., 1991; Terpstra et al., 
1991) and VR-2332 in the US and Canada (Collins et al., 1992; Dea et al., 1992).  
Following the identification of this new viral agent, a positive sense, enveloped RNA 
virus with a genome size of 15 kb was assigned as a member of the Arteriviridae 
family in the Nidovirale order (Meulenberg et al., 1993).  
25 years later, the virus is more commonly known as PRRSV and is in circulation 
worldwide as the most prevalent disease of swine.  As a result there is the potential 
for the establishment of persistent, endemic infections within populations due to 
the lack of suitable control measures (Lunney et al., 2010).  In 2005 the economic 
losses as a result of PRRSV infection were estimated to be in excess of $560 million 
in America alone per annum (Neumann et al., 2005), in 2012, this value increased 
to $668.58 million (Zimmerman et al., 2012) a value which can be vastly escalated 
when incorporating the losses to the worldwide agricultural industry as a whole. 
A key feature of RNA viruses like PRRSV, is their rapid mutation rates, attributed to 
the lack of proof reading normally carried out by the RNA dependent RNA 
polymerase.  This can result in spontaneous mutations at a rate of about one 
mutation per genome per replication (Drake and Holland, 1999).  The virus is 
therefore highly prone to virulence mutations and in the last decade there have 
been a number of highly virulent strains of PRRSV emerging in the US and Asia with 
much higher morbidity and mortality rates, up to 100%, than the previously 
circulating strains (Li et al., 2007; X. Wang et al., 2015; Tong et al., 2007; Zhou et 
al., 2011; Ni et al., 2012; Shi et al., 2013).  Therefore, targeting the virus with 
antivirals or vaccines and developing reliable diagnostics is difficult due to random 
mutations occurring within the numerous viral proteins.  
1.4.1. PRRSV clinical presentation and pathogenicity  
PRRSV, like all viruses is able to manipulate immune responses of infected hosts 
with evasion of the innate immune system being key to viral pathogenicity.  PRRSV 
preferentially infects and replicates in host pulmonary alveolar macrophages 
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(PAMs).  This infection results in the alteration of a number of cellular pathways 
and ultimately cellular apoptosis (Duan et al., 1997; Thanawongnuwech et al., 
1997).  Pathogenicity is important when considering a virus such as PRRSV.  Low 
pathogenic strains have a low mortality and morbidity rate and the infection is 
generally a self-limiting respiratory illness, with only a small impact on the 
economics of a farm.  However, a highly pathogenic (HP) strain of PRRSV can result 
in morbidity and mortality rates of 100% and up to 80% in infected sows and their 
offspring, respectively (Liu et al., 2017).  PRRSV infection is also associated with 
secondary bacterial infections which may be attributed to the loss of macrophages 
in the lung, pulmonary intravascular macrophages (PIMs) which normally perform a 
bactericidal function (Thanawongnuwech et al., 1997).  Pathogenicity and immune 
evasion is also important with regards to the establishment of a persistent 
infection lasting around four weeks post infection, where naive animals introduced 
into the heard become infected by the seemingly healthy animals suffering 
persistent infection (Wills et al., 1997).   
1.4.1.1. Evasion of the immune response 
PRRSV evades the immune system using a number of mechanisms; such as 
modulation of cellular signalling pathways including interferon and NF-κB, delaying 
detection of the virus, cytokine modulation, modulation of apoptosis, hijacking 
host microRNAs (miRNAs), impairment of antigen presentation, T-cell modulation 
and antibody dependent enhancement (ADE).  These will be further discussed in 
the following sections.  
1.4.1.2. Modulation of cellular signalling pathways 
Modulation of host cell signalling pathways is a key feature of all pathogens seeking 
to avoid the immune response, by targeting pathways which lead to the activation 
of the immune system.  The interferon signalling pathway is a prime example of a 
pathway targeted by PRRSV.  This is a key signalling pathway in the innate immune 
response of host cells and high level production of interferons is induced in 
response to the detection of a pathogen by the sensing Toll-like receptors on the 
cell and endoplasmic surfaces.  These receptors then go on to activate a number of 
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pathways within the cell, which in turn initiate the transcription of interferon genes 
(figure 1.10) (Theofilopoulos et al., 2004). 
 
Figure 1.10 Interferon signalling pathway response to PRRSV infection.  ssRNA is detected by Toll-
like receptors (TLR) 7 and 8 and a signalling cascade is activated to initiate the transcription of IFN-β 
(Theofilopoulos et al., 2004). 
 
Interferons are involved in blocking viral replication via the induction of antiviral 
proteins, therefore, making it a crucial pathway to be inhibited by the invading 
virus (Huang et al., 2015).   
The PRRSV non-structural proteins (nsp) are directly involved in the evasion of the 
host immune system via modulation of the interferon signalling pathway, including 
nsp1, nsp2, nsp11, nsp4, as well as the structural protein N (Huang et al., 2015; Sun 
et al., 2012; Huang et al., 2014; Chen et al., 2014).  Nsp1 is an inhibitor of IRF3 
phosphorylation and nuclear translocation and inhibits NF-κB activation and 
suppression of IFN-β (Beura et al., 2010; Song et al., 2010).  Nsp2 also contributes 
to the inhibition of interferon regulatory factor 3 (IRF3) with nsp1 (Li et al., 2010).  
A highly pathogenic strain of PRRSV has recently been shown to inhibit the 
induction and signalling of IFN-α and β in porcine alveolar macrophages.  Here nsp4 
blocks the IRF3 signalling pathway, in addition it also disrupts RIG-I signalling 
(Huang et al., 2016; Huang et al., 2014).  Nsp11 is able to inhibit NF-κB signalling 
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due to its deubiquitination activity of IκBα and the subsequent attenuation of NF-
κB target genes, due to reduced proteosomal degradation and inhibition of NF-κB 
nuclear translocation (D. Wang et al., 2015).  Nsp11 and the protease 3CLSP also 
function to degrade IPS-1, a mitochondrial antiviral-signalling protein resulting in 
the inhibition of IFNβ expression (Sun et al. 2012; Chen et al. 2015).  A summary 
illustration of the inhibition of cellular pathways by PRRSV nsp is shown in figure 
1.11 adapted from (Wang and Zhang, 2014). 
 
Figure 1.11 Inhibition of interferon pathways by PRRSV.  Viral dsRNA is formed during PRRSV 
replication.  The proteins in red are PRRSV proteins known to inhibit these pathways.  Nsp11 inhibits 
IRF-3 phosphorylation and nuclear translocation by degrading IPS-1 mRNA, nsp1α inhibits IRF-3 
association with CREB-binding protein (CBP) and enhances its degradation. It also interferes with IκB 
degradation.  Nsp1β and nsp2 inhibit IRF-3 phosphorylation and nuclear translocation. Nsp2 
interferes with IκB polyubiquitination and prevents its degradation. 3CLSP also degrades IPS-1 
(Wang and Zhang, 2014). 
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Whilst they will be discussed separately, it is important to consider that the 
modulation of host cell signalling pathways by the virus is intimately linked to the 
following methods of immune evasion.   
1.4.1.3. Modulation of other host cytokines 
PRRSV proteins also modulate other host cytokines, including interleukin-10 (IL-10) 
and tumor necrosis factor-α (TNFα).  Nsp1 and GP5 have been implicated in the 
upregulation of IL-10 expression which in turn causes a reduction in the expression 
of interferon-γ (IFNγ) in vitro and in vivo (Zhou et al., 2012; Wongyanin et al., 
2012).  The expression of TNFα from macrophages and activated T cells is 
attributed to the induction of an antiviral response in nearby uninfected cells and 
so the down regulation of TNFα by viral infections is paramount in the evasion of 
the host immune system (Smith et al., 1994).  Interestingly, it has recently been 
shown that there is differential expression of TNFα, dependent on the PRRSV 
strain, with highly pathogenic strains of the virus inducing a lower TNFα response in 
porcine alveolar macrophages (PAMs).  These are therefore better at suppressing 
its production via extracellular signal regulated kinase (ERK) signalling, than the low 
pathogenic counterparts (He et al., 2015; Hou et al., 2012).  
1.4.1.4. Hijacking of host miRNAs   
Host micro RNAs (miRNAs) are also important mediators of cellular antiviral 
responses (Lecellier et al., 2005; Harris et al., 2013) and PRRSV has been shown to 
manipulate the function of host miRNAs to its advantage.  Although the 
downregulation of the NF-κB signalling pathway has previously been discussed 
(section 1.4.1.2) with regards to PRRSV, the role of this pathway in PRRSV infection 
is disputed.  There is recent data suggesting that the activation of this pathway 
during PRRSV infection results in the upregulation of host cell miRNA, miR-30c.  
miR-30c is in turn involved in the inhibition of the interferon-I (IFN-I) signalling 
pathway via JAK1 targeting (figure 1.12) which enhances PRRSV infection in vitro 
and in vivo (Zhang et al. 2016).  ssc-miR-30d-R_1 has also been shown to be 
decreased in the lungs of animals infected with PRRSV.  This miRNA is ordinarily 
involved in the negative regulation of NF-κB signalling via TLR4, reducing PRRSV 
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replication.  However, upon infection the virus downregulates this miRNA resulting 
in the activation of the NF-κB pathway (C. Wang et al., 2016).  The differential data 
presented regarding the NF-κB pathway may be due to the changing requirements 
of the virus during its lifecycle. 
 
Figure 1.12 PRRSV and host miRNAs.  PRRSV upregulates miR-30c to enhance viral replication by 
evading IFN-I–initiated innate immunity.  During PRRSV infection, miR-30c is upregulated dependent 
on the NF-κB pathway.  miR-30c interferes with IFN-I signalling by repressing JAK1 expression, 
leading to viral escape from the host innate-immunity response ( Zhang et al. 2016).  
 
miRNAs have also been shown to be involved in PRRSV-mediated modulation of 
argonaute protein-2 (Ago-2), by nsp1α and nsp11 in conjunction with short hairpin 
RNAs and double stranded RNAs to disrupt RNA silencing processes (Chen et al. 
2015).  The microRNAome has been characterised in pulmonary alveolar 
macrophages during PRRSV infection with a number of miRNAs found to be either 
up or downregulated.  However, the downstream effects of these miRNA 
alterations is yet to be further investigated with regards to PRRSV replication (Hicks 
et al., 2013). 
1.4.1.5. Modulation of T-cell response 
Highly pathogenic strains of PRRSV have been shown to suppress  T-helper 17 
(Th17) cells in infected piglets, when compared to piglets infected with a viral strain 
of lower pathogenicity, which can predispose the piglets to secondary bacterial 
infections (Zhang et al. 2016).  Further PRRSV-mediated modulation of the immune 
system via T-cells has been shown in vivo with the infection of piglets with two 
32 
 
strains of the virus resulting in the atrophy of thymus, the location of T-cell 
maturation, and the increase in the number of cells expressing TNFα and 
interleukin-10 (IL-10) (Amarilla et al., 2016).  Modulation of T-cells by PRRSV has 
also been shown in vitro to occur by the expression of the N protein, where N 
protein expression in porcine monocyte-derived dendritic cells results in the 
significant increase in T-reg lymphocytes and IL-10 expression (Wongyanin et al., 
2012).  Regulatory T-cells are also targeted by PRRSV as they are 
immunosuppressive, they are responsible for the regulation of the immune 
response to viral infection (Huang et al., 2015).  The ability of the virus to control T-
reg cells appears to be strain specific with EU strains showing no effect on the 
induction of T-reg cells, compared to American PRRSV strains (Silva-Campa et al., 
2010).   
1.4.1.6. Delayed detection of virus 
Recently, it has been suggested that a physical evasion of the immune system may 
also occur during PRRSV infection.  Here the virus uses a nanotube network to 
facilitate intercellular infection without the release of infectious virus particles from 
the cell, preventing a neutralising antibody response mediated by the humoral 
immune system (Guo et al., 2016).  This is highly advantageous to the virus, 
resulting in the rapid spread of viral particles throughout a tissue, uninterrupted by 
the host extracellular immune response.  As well as intracellular transport of viral 
particles, PRRSV also uses replication vesicles, which provide a region within the 
infected cells for RNA replication as previously discussed (section 1.3.6.2).   
1.4.1.7. Antibody dependent enhancement 
Antibody-dependent enhancement (ADE) of viral infection is a mechanism 
employed by a number of viruses which capitalises on the presence of antiviral 
antibodies to facilitate the efficient entry of viral particles into host cells.  This is 
utilised by flaviviruses (Peiris and Porterfield, 1979), HIV (Robinson et al., 1988), 
ebola virus (Takada et al., 2003), respiratory syncytial virus (Ponnuraj et al., 2003), 
rabies virus (King et al., 1984) and PRRSV (Yoon et al., 1997), among others.  It is 
hypothesised that this phenomenon occurs when a viral particle of one serotype is 
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bound by antibodies against another serotype.  Ordinarily this would be known as a 
neutralising effect of the antibody and the virus would fail to bind to the surface 
receptor of the host cell (Takada and Kawaoka, 2003).  However, in the case of 
ADE, antibodies binding to the virus particle also bind to the F-region antibody 
receptor (FcyR), on the surface of the host cell (Halstead et al., 1977).  PRRSV has 
been shown to infect macrophages via the ADE mechanism, resulting in the down 
regulation of a number of cellular signalling pathways leading to the disruption of 
the antiviral response as previously discussed with regards to IRF, TNFα and NF-κB 
(sections 1.4.1.2 – 1.4.1.3) (Bao et al., 2013).   
1.4.1.8. Clinical manifestation of PRRSV 
The mechanisms by which PRRSV modulates the immune system are important 
when considering the clinical manifestation of the infection.  As discussed in 
section 1.4.1 the pathogenicity of the viral strain is important for mortality and 
morbidity rates of infection, with these intimately linked to the type and scale of 
the immune response induced.  The scale of the immune response mounted by the 
infected animal is also linked to the ability of the animal to clear the virus and the 
establishment of a persistent infection (figure 1.13) (Chand et al., 2012). 
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Figure 1.13 Establishment of persistent infection in an animal.  Persistent infection is established 
when the infected animal fails to fully clear the infection from its system.  This may be due to the 
animal having a weakened immune system due to age or as a result of other illnesses.  The virus is 
able to continue replicating within this animal and shed infectious virus to other naive animals in 
the herd and allowing the establishment of persistent infection (Chand et al 2012).   
 
The most evident symptom of PRRSV infection is foetal death, as respiratory illness 
in both adult and young animals can be difficult to diagnose and is generally a self-
limiting symptom of this virus.  Nevertheless, there is a risk of secondary 
complications such as bacterial infection and loss of daily live weight gain that can 
result in significant losses for the agricultural industry.  Although the pathogenesis 
of foetal death is not yet understood, it has been hypothesised that 
histopathological lesions on the maternal/foetal interface is a contributing factor, 
as well as the viral load (Novakovic et al., 2016; Karniychuk and Nauwynck, 2013).  
As shown in figure 1.14 it is proposed that infection of monocytes adhered to the 
endothelial cells of the endometrium and subsequent viral replication causes 
apoptosis of infected cells and subsequent infection of cells within the 
endometrium.  This allows the virus to cross the uterine epithelium and 
trophoblast and reach the foetal organs via the umbilical circulation.  The infection 
of cells within the placenta can result in the detachment of the trophoblast from 
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the uterine epithelium which causes degeneration of the placenta and foetal death 
(Karniychuk and Nauwynck, 2013).  The degeneration of the placental tissue post 
infection is also proposed as a contributing factor in the birth of weak and sickly 
piglets in particular.  If infection occurs in the very late stages of gestation, the 
lesions that appear at the maternal/foetal interface may not be sufficient to cause 
foetal death but may cause pre-term labour and the subsequent birth of sick 
piglets.  
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Figure 1.14 Infection of the maternal-foetal interface during PRRSV infection.  1. Maternal blood 
vessel. 2. Endometrial connective tissue. 3. Uterine epithelium. 4. Trophoblast. 5. Foetal placental 
mesenchyme. 6. Foetal blood vessel. (A) During viremia PRRSV attaches, enters and replicates in 
susceptible monocytes adhering to the endothelial cells of the endometrial vessels. Infected 
monocytes enter the endometrium from the maternal blood. (B) PRRSV replicates in the 
endometrial macrophages causing apoptosis in infected and surrounding cells during replication. 
PRRSV crosses the uterine epithelium and trophoblast, likely in association with maternal 
macrophages. (C) Focal, highly efficient PRRSV replication occurs in the foetal placental 
macrophages. PRRSV reaches foetal internal organs through the umbilical circulation. PRRSV causes 
apoptosis in infected and surrounding cells during replication in the placenta. (D) Maternal 
immunity (most probably CD8
+
 endometrial NK cells) suppresses PRRSV replication within the 
endometrium, however there is highly efficient PRRSV replication in the placenta. (E) Focal 
detachment of the trophoblast from the uterine epithelium and focal degeneration of the placenta, 
at the places of virus replication and in the adjacent sites. (F) Multifocal degeneration and full 
degeneration of the placenta, at the places of virus replication, and in the adjacent sites (Karniychuk 
and Nauwynck, 2013). 
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The pathogenicity of PRRSV can also result in different clinical manifestations 
during infection.  Initially, the majority of PRRSV strains in worldwide circulation 
were of low pathogenicity, causing significant but not life threatening losses to the 
infected animals.  However, in the early 2000’s, the emergence of highly 
pathogenic (HP) PRRSV strains in both America and China resulted in a huge 
increase in the mortality rates seen within infected herds, thereby increasing the 
losses felt by the industry in monetary terms.  The most recent economic 
evaluations into the cost of PRRSV infection put the losses in Denmark between 
€59 and €379 per sow per 18 week period outbreak, with the cost post outbreak 
between €3 and €160 per sow, depending on the methods used to tackle the 
disease (Nieuwenhuis et al., 2012).  Although this does not sound significant when 
discussed in € per/animal, it can be devastating during an outbreak which may 
affect hundreds of animals over many farms.  It is difficult to assess the cost of the 
infection in Asia as the agricultural industries here are less well-regulated and 
infections are likely to be vastly under-reported.  There are many reports of 
outbreaks of HP strains of PRRSV in the literature, resulting in high mortality rates.  
For example, images of gross pathological findings in pigs suffering from PRRSV 
infection can be seen in figure 1.15 (Snijder et al. 2013).   
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Figure 1.15 Clinical symptoms of PRRSV infected pigs. (a) Infected piglet with high fever. (b) 
Aborted foetuses. (c) Severe lesions on the kidney of an infected pig indicated by red arrows. (d) 
Severe lesions on the lungs of an infected pig which is unique to highly pathogenic PRRSV infection 
(Snijder et al. 2013). 
 
Recently, HP-PRRSV has been shown to induce cellular apoptosis in the bone 
marrow of infected piglets as well as the thymus, both key features of the immune 
system, increasing the risk of secondary infections and leading to the increased 
mortality rates associated with this viral strain (Tong et al. 2016; Wang et al. 2015).  
This was previously discussed in section 1.4.1.   
1.4.2. PRRSV genome 
The PRRSV genome is broadly similar to that of other Nidovirus/arterivirus 
genomes that have previously been discussed in section 1.3.3 and so the in depth 
details of the genome of PRRSV will not be discussed in further detail here.  The 
length of the PRRSV genome varies dependent on the viral strain but is generally 
between 14.9 kb to 15.5 kb, the discrepancies are as a result of additions or 
deletions in the ORFs encoding the structural and non-structural proteins.  As well 
as the ORFs there are two non-coding untranslated regions in the genome, the 
5’UTR and 3’UTR.  The genome and expression profiles of the ORFs are shown in 
figure 1.16 (Kappes & Faaberg 2015). 
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Figure 1.16 PRRSV genome transcription and translation.  The first regions of the genome to be 
translated are polyproteins from the 5’ end of the genome. The 4 polyproteins produced are pp1a, 
pp1a-nsp2N, pp1ansp2TF and pp1ab.  Pp1a-nsp2N and pp1a-nsp2TF are translated by ribosomal 
frame shifts.  These 4 polyproteins encode the non-structural proteins which are produced by the 
cleveage of the polyprotein by viral encoded proteinases (PLP1α, PLP1β, PLP2 and SP which are 
encoded where indicated on each polyprotein).  Other viral proteins encoded in these polyproteins 
are the RdRp, a zinc finger domain (Z), a helicase domain and a Nidovirus uridylate specific 
endoribonuclease (U).  The sgRNAs which are produced for the translation of the viral structural 
proteins are produced by a co-terminal discontinuous transcription strategy using a negative strand 
intermediate. The genes encoded by each sgRNA are indicated. The proteins appear to be encoded 
in the genome in the order in relative to the quantity required in the completed genome, with the N 
protein being required in large amounts, therefore, encoded in all of the sgRNAs (Kappes & Faaberg 
2015). 
 
An important feature regarding the PRRSV genome is the method of translation 
that occurs via the direct translation of ORF1a and ORF1b to produce the non-
structural proteins, as well as the transcription and translation of the sgRNAs which 
encode the viral structural proteins at the 3’ end of the genome (van Marle et al., 
1999).  The nested set of sgRNAs are produced in a discontinuous transcription 
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strategy and each sgRNA encodes a number of the structural proteins 
(polycistronic), apart from sgRNA7.  As shown in figure 1.15 this allows the virus to 
produce more transcripts encoding the most vital structural proteins, such as the M 
and N proteins, which are encoded for by five out of six and six out of six sgRNAs 
respectively.  
1.4.3. Nucleocapsid protein 
The nucleocapsid protein will be the main focus of this study.  This is a key 
structural protein of many viruses as it protects the viral genome.  In PRRSV, the 
protein itself is approximately 15 kDa in size and comprises approximately 40% of 
the virion, making it a very good target for research purposes due to its large 
quantities and immunogenic potential (Meulenberg et al., 1995).  Although the 
structure of the complete N protein of PRRSV is not known, a C-terminal clone of 
the protein was expressed in E.coli and a crystal structure successfully obtained 
(Doan and Dokland, 2003) as previously mentioned in section 1.3.6.4.3, along with 
the organisation of the N protein in the virion.  Importantly, the role of the PRRSV 
N protein is not restricted to just the structural integrity of the virus, it is also 
involved in the activation of NF-κB (Luo et al., 2011; Chen et al., 2017),  and it may 
be involved in the regulation of viral RNA production by recruiting host cell proteins 
(Liu et al., 2016) and enhancement of IL-10 expression (Fan, Li, et al., 2015; Yu et 
al., 2017).  The PRRSV N protein is also known to traffic in and out of the nucleus of 
infected cells and contains a number of nuclear localisation signal (NLS) sequences 
as shown in figure 1.17 (Rowland and Yoo, 2003). 
In vitro studies using over-expressed PRRSV N protein have shown it can localise to 
the nucleus and the nucleolus in the absence of other viral proteins or RNA, 
presumably by trafficking through the nuclear pore complex.  The movement of the 
N protein is seen to be faster when imported into the nucleus compared to the 
export of the protein.  However, trafficking is dynamic and the protein does not 
appear to be sequestered in the nucleus or nucleolus and is constantly exchanged 
between the two and the nucleus and cytoplasm (You et al., 2008).  This trafficking 
appears to be vital for the lifecycle of the virus, as removal of the N protein nuclear 
localisation signals has a negative impact on viral replication, with viral titres 100-
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fold lower and a shorter duration of viremia than wild type virus when studied in 
vivo.  The importance of this process in viral replication and infectivity was also 
observed by the reversion of the mutant virus to produce functional nuclear 
localisation signals in the N protein during infection (Lee et al., 2006; Pei et al., 
2008).   
 
 
Figure 1.17 Nuclear localisation signals of the PRRSV nucleocapsid protein.  The N protein contains 
a number of putative nuclear localisation signal (NLS) regions and has been shown to traffic to the 
nucleus and nucleolus of infected cells.  There are NLS at amino acids 10-13 and 41-47 and nucleolar 
localisation signals (NoLS) at amino acids 41-72.  There is also a nuclear export signal (NES) at aa 
106-117. Cysteine 20 is involved in the formation of N protein dimers via covalent disulphide bonds 
(Rowland and Yoo, 2003).  
 
Stable isotope labelling with amino acids in cell culture (SILAC) analysis of PRRSV N 
protein interactions with cellular proteins has identified over 50 potential cellular 
interaction partners of the N protein, with binding partners having functions in RNA 
binding, translation, mRNA stability, nuclear ribonucleoproteins, splicing and RNA 
helicases (Jourdan et al., 2012).  It is possible that the N protein is involved in the 
recruitment of cellular proteins, particularly via its shuttling through the 
nucleus/nucleolus, that are vital for viral replication, however this has not been 
thoroughly investigated.   
Recently it has been shown that the PRRSV N protein interacts with viral nsp9 and 
the cellular protein DHX9 in order to regulate viral RNA synthesis.  DHX9 was 
previously identified in the SILAC analysis carried out by Jourdan et al 2012.  It is 
thought that the recruitment of this cellular protein by the two viral proteins aids in 
the production of both sgRNAs, vital for structural protein production, as well as 
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the synthesis of new genomic RNA (Liu et al., 2016).  Another cellular protein that 
interacts with PRRSV N protein is PARP-1, in the context of the virus it has been 
shown that inhibiting this cellular protein using a small molecule inhibitor resulted 
in a decrease in the production of viral genomic and subgenomic RNAs, as well as 
an overall decrease in viral titre (Liu et al., 2015). 
The PRRSV N protein is a major immunogenic protein within the virion and so it 
was chosen for this study, as it is likely to be present in high quantities in the blood 
of infected animals, making it an ideal candidate for direct detection of viral 
infection (Dea et al., 2000).  As well as being highly immunogenic, the N protein 
sequence is also highly conserved between viral strains.  The two strains of the 
virus used in this study are examples of a low (strain NVSL 97-7895) and a high 
pathogenic (strain SD16) strain from genotype 2 PRRSV and the amino acid 
sequences are shown in alignment in figure 1.18.  The sequences are broadly 
conserved with a number of single mutations throughout the sequence, in total 
there are eight amino acid differences highlighted in red.  The conserved nature of 
the protein makes it an ideal candidate for the identification of detection reagents, 
as it is likely that they will function to identify multiple strains at once without the 
need for complex devices.  
 
Figure 1.18 Sequence alignment of PRRSV N proteins.  The conserved nature of the proteins 
between PRRSV strains can be seen with mutations within the protein highlighted in red.  The 
mutations between high and low pathogenic strains are distributed throughout the genome.  
 
The two genotypes of PRRSV are European (Type 1) and North American (Type 2) 
with a predicted divergence of between a decade to a century prior to clinical 
identification and therefore with a period of independent evolution on the two 
continents(Kappes and Faaberg, 2015).  The two strains used in this study are 
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members of genotype 2 which is also prevalent in China and Asia and has been 
shown to mutate into highly pathogenic strains as illustrated by strain SD16 in this 
study.  Therefore as well as identifying between a high and low pathogenic strain of 
PRRSV, the diagnostic proposed in this study may also be able to distinguish 
between the two genotypes which could be further investigated as a result of this 
study.   
1.4.4. Entry of PRRSV into permissive cells  
As previously discussed in section 1.3.6, arteriviruses are very host specific and 
PRRSV is known only to infect porcine cells in vivo.  However, it is able to replicate 
in MARC-145 cells (derived from African green monkey cells) (Kim et al., 1993), 
primary porcine alveolar macrophages (Wensvoort et al., 1991) and differentiated 
porcine monocytes (Delputte et al., 2007) in cell culture.  It is widely accepted that 
the entry of the virus into these cells occurs via receptor-mediated endocytosis via 
clathrin coated vesicles (Pensaert et al., 1999), which is facilitated by siloadhesins 
on the surface of these permissive cells (Vanderheijden et al., 2003).  This receptor 
had previously been identified on the surface of macrophage cells isolated from the 
lungs, thymus, tonsils, spleen and lymph nodes of infected pigs (Duan et al., 1998). 
1.4.5. Control and current diagnostics  
The current controls and diagnostic approaches for PRRSV infection within a 
population are limited and often poorly implemented, allowing for the rapid spread 
of infection.  The economic burden of this infection is hard to analyse because the 
losses are not always clear, particularly in endemically infected herds and so it is 
difficult to evaluate the efficient use of biosecurity and diagnostic measures 
(Nathues et al., 2017).   This is partly due to the lack of point of care diagnostics 
and the reliance on laboratory testing of clinical samples and partly due to the lack 
of suitable vaccinations and biosecurity measures employed as a result of animal 
movements.  
1.4.5.1. Vaccination 
There are a number of commercially available vaccines against PRRSV, however, as 
highlighted so far in this study, RNA viruses are highly mutagenic meaning that the 
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vaccines can quickly become redundant during an infection.  One such vaccine is 
manufactured against PRRSV strain DV, a European isolate, under the name 
Porcillis PRRS by MSD Animal Health.  Ingelvac PRRS®MLV, Inglevac PRRS®ATP and 
ReproCyc® PRRS EU, all manufactured by Boehringer Ingleheim, provide cross 
protection against a number of strains of PRRSV including the European Lelystad 
strain.  Inglevac PRRS®MLV is known to provide delayed protection, with antibodies 
normally detectable 3-4 weeks post vaccination, this is not ideal for the vaccination 
of herds as movement is likely to be required at shorter time frames.  This vaccine 
has however been shown to reduce viremia and virus shedding, as well as 
improving growth performance if administered during an outbreak or to 
endemically infected animals (Charerntantanakul, 2012).  The Boehringer Ingleheim 
vaccines have also been combined with other vaccines, for example ReproCyc® 
PRRS-PLE, which protects against heterologous PRRSV, Parvo Leptospiria and 
Erysipelothrix.  These vaccines contain a modified live PRRSV component against 
various strains of the virus and claim to provide duration of immunity (DOI) of at 
least 4 months post vaccination.  Although they cannot be used on PRRSV naive 
herds but are safe for sows and gilts.  There is also an inactivated vaccine available, 
PROGRESSIS®, manufactured by Merial.   
Research carried out into the efficacy of these vaccines, shows that they do not 
provide complete protection against PRRSV infection, even when the vaccines are 
administered to animals challenged with the correct strain.  Notably, the vaccines 
are unable to elicit a sufficient and rapid enough antibody response to prevent the 
infection and instead serve to reduce the severity of the infection.  In addition, a 
number of these vaccines must be administered regularly in order to retain any 
immunity, which is vital for example in breeding animals (Delrue et al., 2009; Ko et 
al., 2016).  Vaccines have been trialled against highly pathogenic strains of PRRSV, 
however, as observed with the low pathogenic strains of the virus targeted by the 
previously mentioned commercially available vaccines, the efficacy of the vaccines 
is not ideal and the reduction in severity of the disease was the primary outcome of 
the vaccinations (Iseki et al., 2017). 
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A great deal of investment is now being made into the research of improved 
vaccines against PRRSV, which can protect against multiple strains of the virus.  
Most approaches focus on using highly conserved regions of viral proteins or 
combining multiple viral proteins into the vaccine, circumventing any mutations 
which may occur in the circulating strains.  Virus-like particles (VLPs) are also 
attractive candidates for replacement of attenuated or inactivated vaccines, as 
they mimic the viral particle in terms of dimensions and protein content.  However, 
they lack the essential viral genome and so are effectively disabled and have a 
major advantage over live attenuated vaccines due to no possibility of reversion to 
wild type (Noad and Roy, 2003).  The proteins which are incorporated into the VLP, 
as well as being similar in sequence between viral strains, have to be able to 
promote a sufficient immune response from the host cell in order to function as a 
vaccine.  Efficacy of this approach has been previously shown with the successful 
human papillomavirus vaccine (Campo and Roden, 2010).  A number of PRRSV 
vaccines based on VLPs have been produced, although currently no available 
vaccines of this kind are in clinical use (Binjawadagi et al., 2016; Garcia Duran et al., 
2016; Van Noort et al., 2017; Uribe-Campero et al., 2015; Murthy et al., 2015). 
1.4.5.2. Biosecurity 
Biosecurity within the agricultural setting is a vastly underutilised method of 
control of any infection and is not limited to PRRSV.  In the UK, animals placed into 
quarantine before and after movement in order to monitor disease status is 
exploited with regards to economically devastating diseases, such as FMDV 
(Delgado et al., 2016).  These methods would be equally successful in the 
prevention of infections, such as PRRSV.  Vaccination of animals and the correct 
quarantine procedures, as well as cleanliness within the herd, can be successfully 
implemented to reduce the spread of PRRSV especially when faced with a novel 
strain of the virus (Arruda et al., 2016).  At present however, this is not routinely 
carried out with regards to most infection risks, particularly in developing 
countries, primarily due to a lack of knowledge surrounding biosecurity and 
availability of resources to perform adequate quarantines and vaccination 
schedules.   
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1.4.5.3. Genetic modification of animals 
As well as the prophylactic response to viral infection using vaccines, a study has 
produced genetically modified PRRSV resistant animals using CRISPR-Cas9 gene 
editing approaches removing CD163.  This protein has been proposed as a host 
cellular receptor required for the entry of the virus into host cells.  The animals 
were followed for 35 days post infection and none showed any clinical signs of 
infection (fever or respiratory), viremia or antibody response although the 
reproductive response was not investigated (Whitworth et al., 2015; Burkard et al., 
2017).  The production of a gene-edited animal is highly controversial and is 
currently not an economically or ethically viable method of controlling a viral 
infection, such as PRRSV.  Although the genetic modification of animals for human 
consumption cannot currently be carried out using gene editing, selective breeding 
based on molecular markers of resistance may be an underutilised route for the 
breeding of animals with a higher disease resistance to PRRSV and other livestock 
infections (Prajapati et al., 2017).  
1.4.5.4. Current diagnostics for PRRSV 
The current diagnostic methods for PRRSV infected animals are based upon visual 
assessment to identify the clinical symptoms outlined in section 1.4.1.8 or the 
direct diagnosis of infection, by taking a clinical sample and subsequent analysis in 
a laboratory setting.  The World Organisation of Animal Health outlines laboratory 
procedures which can be performed on serum, whole blood, tissue samples 
including lungs, spleen, lymph nodes, and tonsils of infected animals with 
specimens used for direct virus isolation (Zeman et al., 1993), RT-PCR (Spear and 
Faaberg, 2015; S. Xiao et al., 2014; Drigo et al., 2014; Suarez et al., 1994) and 
serological tests for antibody detection (Y. Wang et al., 2016; Y.H. Xiao et al., 2014).  
These are routinely used by veterinary surgeons although they are time consuming 
and costly.  For example, an ELISA test to detect the presence of antibodies within 
a clinical sample is required to be transported to a laboratory, undergo processing 
to remove contaminants and subsequent incubation with the ELISA plate and the 
detection reagent.  A recently devised ELISA test to detect antibodies against the 
viral Gp5 protein was required to be performed for 30 minutes for incubation of 
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serum sample and additional 10 minutes incubation with the detection reagent (Y. 
Wang et al., 2016).  The commercial cost for an ELISA diagnosis of EAV is £15 per 
test and a commercial diagnosis of PRRSV using PCR is £25 per sample or £27 for a 
pool of 5 samples. (BioBest UK).   
1.5. Biosensors 
‘Biosensor’ is a vague term for devices that are used for the detection of biological 
molecules and other compounds in samples, using biological reagents such as 
antibodies, nucleic acids and enzymes (Higgins and Lowe, 1987).  They normally 
work based on electrochemical (Hammond et al., 2016), optical (Borisov and 
Wolfbeis, 2008), thermal (Ramanathan and Danielsson, 2001), magnetic (Rocha-
Santos, 2014) and piezoelectric (Skládal, 2016) transducers or are 
immunochromatographic for example lateral flow devices (LFDs) (Posthuma-
Trumpie et al., 2009), in order to give a read out of the presence of a target within 
a sample.  Biosensors can be incorporated into LFDs and microfluidic lab-on-a-chip 
(LOC) devices (Temiz et al., 2015), including DNA chips (Nestorova et al., 2016) and 
are used in a wide variety of circumstances for example, medical care (Patel et al., 
2016), food production (Thakur and Ragavan, 2013), animal management 
(Neethirajan et al., 2017), environmental monitoring (Pol et al., 2017) and security 
and defence (Matatagui et al., 2014). 
Point of care (POC) biosensor diagnostics are vital to the health and veterinary care 
settings not only for diagnosis but also for monitoring disease progression, for 
example detection of hallmarks of cancer and so they are required to be cheap, 
portable reliable, rapid and easy to use (Syedmoradi et al., 2017).  
1.5.1. Lateral flow devices 
POC diagnostics are attractive alternatives to laboratory testing of samples in 
veterinary care.  The most user friendly POC diagnostic is the lateral flow device 
(LFD).  The most widely known of these is the human pregnancy test, first filed for 
patency in 1977 in its earliest form (Patent number US 4123509 A).  Ideally POC 
devices need to avoid the preparation of a sample so that the clinical sample can 
be applied directly to the device.  There are a number of modifications that can be 
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made to devices in order to process a clinical sample within the test itself and these 
include the addition of filter components to remove undesirable constituents in the 
test sample (Songjaroen et al., 2012).  LFDs are very simple to design and produce 
and have the same basic set up as shown in figure 1.19a, adapted from Biagini et 
al. 2006.  The main component of the device is the nitrocellulose membrane which 
is striped with two antibodies, a test antibody against the protein of interest, and a 
control antibody against the conjugate antibody (this antibody is conjugated to a 
gold nanoparticle).  The conjugate antibody is contained within the conjugate pad, 
which is layered on top of the nitrocellulose membrane below the test line.  A 
sample pad is then placed on top of the conjugate pad.  At the other end of the 
nitrocellulose membrane, an absorbance pad is placed to collect excess sample.  
This device is then encased in a plastic housing with a hole where the sample is 
loaded as well as windows for viewing the test result (figure 1.19b).  Test A shows 
an unperformed test, test B shows a negative result (only a control line appears) 
and test C shows a positive result (test and control lines are visible). 
 
Figure 1.19 Diagram of lateral flow device. (a) The Lateral flow device is based upon a nitrocellulose 
membrane which contains 2 lines, a control line and a test line.  The conjugate pad is a second 
membrane which contains the detection reagent conjugated to gold nanoparticles placed directly 
under the sample pad.  The absorbent pad at the end of the membrane absorbs any excess sample.  
This assembles test strip is then placed in a plastic housing to prevent damage.  (b) An example of a 
lateral flow device (A) a device before sample is added. (B) A negative test device where the control 
line has appeared to confirm the test was successfully performed. (C) A positive test device with the 
control and test lines visible (Biagini  et al. 2006). 
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The finer details of the LFD are shown in figure 1.20, for descriptive purposes a 
pregnancy test will be described with the detection of human chorionic 
gonadotrophin (hCG).  The sample is loaded onto the sample pad and if hCG is 
present in the sample it will bind to the anti-hCG antibody in the conjugate pad.  
This complex will migrate down the nitrocellulose membrane by capillary action 
until the sample reaches the test line.  Here the antibody recognises the hCG at a 
different epitope on the protein to the conjugate antibody.  The complex is 
captured by this antibody and a positive test line appears on the nitrocellulose 
membrane by changes in surface plasmon resonance as a result of GNP 
aggregation (Zhao et al., 2008).  The sample continues to migrate down the 
nitrocellulose membrane to the control line where the excess conjugate antibody is 
captured by an antibody against the species in which the conjugate antibody was 
raised.     
 
Figure 1.20 Mechanism of lateral flow device.  The sample is loaded onto the sample pad, directly 
above the conjugate pad containing a reagent conjugated to GNP which can detect the molecule of 
interest in the sample. The sample moves up the device by capillary action and reaches the test line 
on the membrane where the molecule of interest in the sample is detected.  Presence of the 
molecule of interest in the sample results in the formation of a complex between the conjugate 
molecule-molecule of interest-test line molecule and the appearance of a positive test line.  The 
excess sample migrates further up the sample to the control line where excess conjugate molecule 
is detected and the appearance of a control line indicates the test was successful (adapted from 
Biagini et al. 2006). 
 
The GNP conjugation to the antibody is commonly used because of the colour 
change observed upon binding to the test and control line antibodies, however, 
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alternatives are available including carbon (Qiu et al., 2015), selenium (Wang et al., 
2014) and fluorescent molecules (Lee et al., 2013; Xu et al., 2014).  These 
alternative reagents can be used to increase sensitivity of the device (carbon) or to 
reduce costs or allow for quantification of the result by using fluorescence and 
computer analysis of the strip.  GNPs are also easy to modify for the addition of 
reagents and so are often used in LFDs.    
1.5.2. Microfluidic lab-on-chip (LOC) devices 
Microfluidic lab-on-chip (LOC) devices are more complex than the LFDs as they 
analyse the sample using other means than a visible colour change at a test and 
control line, as well as including another layer of complexity regarding the 
introduction of microfluidics.  These devices can be used to analyse very small 
volumes of sample material due to the design of the device.  Using microfluidics, 
there is a reduced time taken to transport the sample to the analysis elements as 
well as reduced distances over which this occurs.  This allows for single drops of 
blood or indeed single cells to be analysed using microfluidic LOC devices (Lafleur 
et al., 2016).  There are a number of methods by which the signal can be detected 
in an enzyme based LOC device, such as electrochemical, affinity based, 
fluorescence and magnetic detection.   A basic schematic of a microfluidic LOC 
device is shown in figure 1.21 (Conde et al., 2016). 
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Figure 1.21 Lab on Chip - A simple schematic of a fully integrated LOC device.  The sample is loaded 
at the inlet along with any fluidics required for sample preparation (buffers). The target in the 
prepared sample is recognised by the probe at the molecular recognition site and binding occurs.  
Excess target and sample flows to the outlet.  The signal from the molecular recognition events can 
be amplified to give a larger signal for detection and therefore improve sensitivity of the sensor and 
can include the use of enzymes, fluorophores or nanoparticles.  The signal passes through a 
transducer to convert the recognition event into a measurable signal; electrical, optical, magnetic, 
colourimetric (Conde et al., 2016). 
 
1.5.2.1. Electrochemical LOC 
Electrochemical impedance spectroscopy is increasingly used in biosensors and can 
detect variations of resistance and capacitance seen upon binding events 
(Hammond et al., 2016).  Amperometric biosensors transduce the biological 
recognition events caused by an electroactive species at the sensing surface, into a 
current signal, to quantify an analyte present in a sample and are a simple design 
that can be used in low cost, portable devices.  The main example of a LOC device is 
the home glucose monitor used by diabetics (Newman and Turner, 2005).  
Impedimetric biosensors use electrochemical impedence spectroscopy (EIS) where 
impedance is measured over a range of alternating current (AC) frequencies (100 
kHz – 1 mHz) and this has been incorporated into sensors to detect cancer (Han et 
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al., 2016) and other disease markers (Sharma et al., 2016), bacteria (Bekir et al., 
2015) and viruses (Hushegyi et al., 2016).  Carbon-nanotube-based electrochemical 
biosensors have also been used to increase the sensitivity of biosensors and have 
been incorporated into biosensors to detect for glucose (Guiseppi-Elie et al., 2002) 
and cholesterol (Carrara et al., 2008).   
1.5.2.2. Enzyme LOC  
Enzymes can be integrated into LOC devices to catalyse chemical reactions with the 
electroactive species produced or consumed being detected by current changes 
(Lafleur et al., 2016).  Glucose detection has used this approach, as well as devices 
able to detect Epstein-Barr virus (EBV) (Horak et al., 2014) and cholesterol (Ali et 
al., 2013). 
1.5.2.3. Fluorescence LOC 
Fluorescence based biosensors are a popular microfluidic biosensor because they 
offer high selectivity, low detection limits and are easy to use (Lafleur et al., 2016). 
They have been used in sensors able to detect E.coli (Chung et al., 2015), cancer 
biomarkers (Kim and Kim, 2014) and cholera toxin (Bunyakul et al., 2015).  
1.5.2.4. Affinity based LOC 
Affinity based biosensors use electrochemical signalling from a binding event to 
detect an analyte in a sample, however it is common for sample preparation to be 
required to make the analyte available to the sensor or remove other interfering 
molecules within a sample (Bunyakul and Baeumner, 2014).  Real samples from 
milk to detect antibiotics (Daprà et al., 2013), stool (Bunyakul et al., 2015) and 
blood (Ferguson et al., 2013) have been analysed using affinity biosensors. 
1.5.2.5. Magnetic LOC 
Magnetic transduction is used to detect magnetic microbeads and work by 
detecting the change in magnetic field of the sensor and detecting the change in 
voltage produced by the sensor components (Lafleur et al., 2016).  These have 
been used to detect hepatitis B virus (Zhi et al., 2014) and bacteria (Fernandes et 
al., 2014).   
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1.5.3. Biosensors and non-antibody binding protein detection 
reagents  
The common theme of the majority of biosensors is the inclusion of an antibody 
detection mechanism which is raised against the protein or molecule of interest.  
The use of antibodies has recently been challenged by a number of alternative 
binding proteins which show potential as substitute reagents in the previously 
mentioned biosensor devices.  Antibodies have long been vital tools for research, 
however they has been long standing concern over their lack of validation and 
renewability (Bordeaux et al., 2010; Bradbury and Plückthun, 2015).  In a 2008 
study, less than 50% of 6000 commercially available antibodies recognised their 
specific targets or performed poorly in certain applications (Berglund et al., 2008). 
These new non-antibody reagents aim to address these issues whilst also 
improving sensitivity and reaction time in molecular research applications.  These 
alternatives will be discussed in detail below.  
As previously discussed (section 1.5.1) LFDs ordinarily use antibody components as 
the detection reagents for proteins in the clinical samples.  However, due to the 
ethical issues and economics of antibody production, there has been an increased 
interest in the development of alternative reagents that can replace antibodies.  
Replacement of antibodies has been demonstrated with the use of peptide 
aptamers in enzyme-linked immunosorbent assays (ELISAs) (Chen and Yang, 
2015b), chemical or nucleic acid ligand replacement in LFDs (Chen and Yang, 
2015a), peptide aptamers used in immunochemical assays; immunoprecipitation, 
Western blotting, cytofluorimetry (Skerra, 2007) and Affimers used in microscopy 
(Tiede et al., 2017) to name a few.  This project focusses on the use of non-
antibody binding proteins as antibody replacements and the scope for production 
of these reagents is vast. 
1.5.3.1. Nanobodies 
Nanobodies are a single domain protein, derived from camelid antibodies, with a 
molecular mass of around 15 kDa, around 10 times smaller than a conventional 
antibody and they can be cloned into bacterial expression systems.  Nanobodies 
are highly diverse research tools and are able to perform comparably to antibodies 
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whilst being adaptable with regards to modification and easily produced at high 
quantities (Beghein and Gettemans, 2017).  However, the production methods for 
nanobodies still requires the initial immunisation of camelids for the harvest of 
peripheral blood mononuclear cells (PBMC) to isolate the mRNA which can be 
entered into phage display (Dmitriev et al., 2016).  They therefore suffer the same 
ethical issues as traditional antibody production.  
Nanobodies can be chemically and genetically modified and can be reliably 
expressed in mg/L of culture at reproducible properties.  They have also been 
shown to bind to their target proteins with nanomolar affinity (Dmitriev et al., 
2016; Skottrup et al., 2011; De Genst et al., 2006).  Nanobodies are also highly 
soluble due to their water exposed hydrophilic regions on the FRs (Beghein and 
Gettemans, 2017).  They have been used in a number of molecular biology 
applications including: immunolabelling and antigen manipulation in live cells to 
investigate their potential for use in immunotherapy (Herce et al., 2017), primary 
detection reagents in fluorescent microscopy, fluorescence-activated cell sorting 
(FACS), magnetic-activated cell sorting (MACS) and immunohistochemistry (de 
Bruin et al., 2016), super-resolution microscopy (Ries et al., 2012; Platonova et al., 
2015).  They can also be used in mass spectrometry to investigate macromolecular 
assemblies (Shi et al., 2015).  Nanobodies can be expressed intracellularly as an 
alternative to RNAi to knockout protein functions (Newnham et al., 2015; Bertier et 
al., 2017).  Nanobodies are also useful tools for X-ray crystallography, where they 
can be used as chaperones to stabilise the structure of proteins which are 
otherwise difficult to crystallise (Rasmussen et al., 2011; Staus et al., 2016).   
Nanobodies are based upon the heavy chain-only antibodies produced by camelids 
which can be produced recombinantly, these domains are antigen-recognising 
(Hamers-Casterman et al., 1993).  These heavy chain-only antibodies were 
originally termed nanobodies but are also known as variable domains (VHHs) or 
single domain antibodies, the region of the camelid antibody which derives the 
nanobody is shown in figure 1.22 (Dmitriev et al., 2016). 
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Figure 1.22 Comparison between an IgG antibody (a) and a heavy chain only camelid antibody (b).  
(a) Antibodies consist of two heavy chains (VH/CH1) and two light chains (CL/VL) and antibody 
binding is determined by the complementarity determining regions in these domains. The Fc region 
of the antibody is involved in cell surface interactions. (b) The heavy chain only antibody of camelids 
lack the light chains whilst retaining binding and specificity to antigens.  As highlighted by the box, 
these antibodies can be further truncated to retain only the variable antigen binding domains (VHH) 
which are termed nanobodies (Dmitriev et al., 2016). 
 
Nanobody structure includes three complementarity-determining regions (CDRs), 
organised into three loops which are structured by a framework region (FR), the 
loop regions are generally quite ridged which favours high antigen binding affinities 
(figure 1.23) (Beghein and Gettemans, 2017). 
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Figure 1.23 Crystal structure of a Nanobody.  The nanobody has 3 CDR regions and four framework 
regions (FRs) the CDR regions are shown in yellow, pink and red.  This nanobody recognises gelsolin, 
an actin binding protein (PDB ID 2X1O).  The FR regions contain hydrophilic residues to aid solubility 
of the nanobodies (Beghein and Gettemans, 2017).  
   
1.5.3.2. AdNectins™ 
Originally termed Monobodies, AdNectins™, are approximately 10 kDa proteins 
based on the 10th fibronectin type III domain which bind to therapeutically relevant 
targets with high affinity and can be produced to a high yield in bacterial 
expression systems, the structure of these proteins are shown in figure 1.24 
(Lipovsek, 2011; Koide and Koide, 2007).  
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Figure 1.24 Crystal structure of AdNectins™.  The VH domain (a) provides a comparison of the 
antibody antigen recognition site compared to the basic AdNectin™ structure. (b) The antibody 
vairable domains of 
10
Fn3 are two anti-parallel beta sheets with solvent-accessible loops inbetween. 
Unlike VH regions of antibodies, 
10
Fn3 have no di-sulphide bonds or free cysteine residues which 
allows the protein to retain high thermostability (Lipovsek, 2011).   
 
AdNectins™ have been shown to have therapeutic potential as anti-tumour 
properties in mice (Mamluk et al., 2010) and a number have now reached the 
clinical trial stage.  AdNectin™ CT-322 is a VEGFR-2 inhibitor and was successfully 
administered to patients with solid tumours resulting in an anti-tumour effect in 
phase I trials (Tolcher et al., 2011).  An ongoing American trial investigating 
AdNectin™ BMS-986089 is studying the safety and tolerability of this treatment for 
Duchenne Muscular Dystrophy and is expected to be completed in 2020 by Bristol-
Myers Squibb.  AdNectins™ have not been used in molecular biology techniques.  
These proteins have also been suggested to show improved tissue penetration and 
decreased immunogenicity compared to antibodies as well as being well suited for 
multi-functionality due to the ability to oligomerise (Weidle et al., 2013).    
As well as therapeutic functions, AdNectins™ have been shown to function as 
crystalisation chaperones and due to their high affinity and isoform specificity they 
have been proposed as tools for the investigation into cellular functions of their 
targets, for example human small ubiquitin-related modifier (SUMO) proteins 
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(Gilbreth et al., 2011).  They have also been used in the in vitro and in vivo imaging 
of tumours expressing cancer biomarker hEphA2 (Kim et al., 2017).  AdNectins™ 
are also tools for the investigation of ion channel function (Chavan et al., 2017) and 
modification of enzyme specificity (Tanaka et al., 2015). 
1.5.3.3. Designed Ankyrin repeat protein 
Designed Ankyrin repeat protein (DARPin) libraries have been designed to produce 
high affinity binders to target proteins.  A library was designed in 2004 containing 
DARPins of differing repeat numbers (either two or three repeats) which were 
expressed using ribosome display, the theoretical library size was 5.2 x1015, library 
with two repeats and 3.8 x1023, library with three repeats (Binz et al., 2004).  This 
library was screened against E.coli maltose binding protein (MBP) and validated 
DARPins which could be purified up to 200 mg/l in E.coli culture, with high affinity 
(nanomolar) they were shown to function in competition ELISA assays and were 
successfully co-crystallised with their target protein. A representation of the 
structure of the DARPins is shown in figure 1.25 (Binz et al., 2004). 
 
 
Figure 1.25 Crystal structure of maltose binding protein (MBP) DARPin (off7).  The potential 
interaction sites are shown in red (stick mode).   The AR module is 26 residues with 6 randomised 
potential interaction residues of any aa except cysteine, glycine or proline with randomised 
framework residues (asparagine, histidine or tyrosine) (Binz et al., 2004). 
 
DARPins have since been designed to function as molecular biology tools for 
example, fluorogen-activating designed AR proteins (FADAs), which have been used 
Position of binding library residues (red) 
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to image proteins on the cell surface or cytosol (Schütz et al., 2016), study of 
biological processes such as the conformational changes of p-ERK in mouse embryo 
fibroblasts (Kummer et al., 2013) or apoptosis (Schilling et al., 2014).  They have 
also been shown to be successful chaperones for crystalisation of target proteins 
(Bukowska and Grütter, 2013; Schilling et al., 2014), and can be applied in 
diagnostics for immunohistochemistry (Theurillat et al., 2010) and in vivo imaging 
of tumours (Kramer et al., 2017).  Recently they have been proposed as tools for 
affinity purification as a direct replacement for antibodies (Hay et al., 2015).       
1.5.3.4. Anticalin 
Anticalins, also known as lipocalins, are a diverse family of extracellular proteins of 
between 150-190 amino acids, larger than other antibody alternatives, in a single 
polypeptide chain which has a common 6 or 8 stranded β-barrel as shown in figure 
1.26 (Richter et al., 2014; Grzyb et al., 2006). 
 
 
Figure 1.26 Crystal structure of five Anticalins based on the human Lcn2 scaffold.  Anticalins are 
depicted in complex with the peptide ligands (Blue). αAβ40 (orange; to be published) and hepcidin 
(yellow; to be published), the small hapten-like molecule Y
III
·DTPA (green; PDB code 4IAX) and with 
the two protein targets ED-B (magenta; PDB code 4GH7) and CTLA-4 (red; PDB code 3BX7).  The 
anticalins share the conserved beta-barrel structure (Richter et al., 2014; Grzyb et al., 2006). 
 
60 
 
Rather than being used as molecular biology reagents, these proteins are proposed 
as replacements for therapeutic antibodies and have been raised against a number 
of biologically relevant proteins, such as cytotoxic T lymphocyte-associated antigen 
4 (CTLA-4) (Mocellin and Nitti, 2013), vascular endothelial growth factor A (VEGF-A) 
(Mross et al., 2014) and hepatocyte growth factor receptor (HGFR) (Olwill et al., 
2013). 
1.5.3.5. Affibody 
Affibodies are derived from the B domain of the immunoglobulin binding region of 
staphylococcal protein A which is a cysteine free, 6.5 kDa, 58 amino acid peptide 
folded into a three-helical structure (Löfblom et al., 2010; Myers and Oas, 2001).  
The three helical structure of an affibody is shown in figure 1.27 (Ståhl et al., 2017).   
 
 
Figure 1.27 Crystal structure of affibody.  Large ‘naïve’ libraries of affibody molecules are 
constructed via combinatorial protein engineering of typically 13 positions (green) in helices one 
and two (H1/H2) of the 58-residue cysteine-free three-helix bundle Z-domain scaffold (brown).  
Modifications can be made at the N and C termini (indicated) to add functional groups such as 
fluorophores (Ståhl et al., 2017).  
 
Affibodies have been proposed as tools in both therapeutics and molecular biology, 
they can be used in in vivo imaging (Sörensen et al., 2014; Choi et al., 2016; 
Sörensen et al., 2016), therapeutic delivery by liposomes (Beuttler et al., 2009; 
Alavizadeh et al., 2016), targeted drug delivery to tumours (Alexis et al., 2008; 
61 
 
Orlova et al., 2010), microscopy (Moon et al., 2016), flow cytometry (Wang et al., 
2015). 
1.5.3.6. Affilin 
Affilins are binding proteins based on the β-sheet of human γ-β-crystallin where a 
universal binding site was created through the randomisation of eight solvent 
exposed amino acid residues, the structure of Affilin SPC-1-G3 (PDB accession code 
2JDG) is shown in figure 1.28 (Ebersbach et al., 2007).  
 
 
Figure 1.28 Crystal structure of Afillin.  In red is the wild-type γ-B-crystallin and in blue is the IgG-Fc 
binding Affilin (SPC-1-G3).  The different in amino acid sequence at 8 residues in the N terminal 
region does not alter the overall structure (Ebersbach et al., 2007).  
 
Affilins have also been used as tumour targeting molecules like affibodies, DARPins 
and AdNectins™ (Lorey et al., 2014) and have also been raised against human 
papillomavirus E7 protein and shown to inhibit cellular proliferation when 
expressed intracellularly.  These molecules have not been used as molecular 
biology tools but have been taken forward as potential therapeutics by Scil Proteins 
GmbH.   
1.5.3.7. Avimer 
Avimers are based on the A-domains of proteins of cell surface receptors which are 
each approximately 35 amino acids (4 kDa) separated by linkers of approximately 5 
amino acids, avimers exploit the multiple binding sites resulting from these A-
domains to produce high affinity and specificity in binding (Silverman et al., 2005).  
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The structure of the avimer is shown in figure 1.29 (Vazquez-Lombardi et al., 2015; 
Silverman et al., 2005). 
 
Figure 1.29 Structure of an Avimer.   (a) (Ca
2+
 ion green, SO4  ion red/yellow).  The ribbon 
illustration of an Avimer against IL-6. (b) The first region binds to IgG and the remaining structure 
binds to different epitopes of IL-6 (Vazquez-Lombardi et al., 2015; Silverman et al., 2005). 
 
Avimer AMG-220, which targets IL-6 had been entered into clinical trials for 
evaluation in patients suffering from Crohn’s disease, however, the trial was halted 
and subsequent data was not made available (Vazquez-Lombardi et al., 2015).  
1.5.3.8. OBodies 
The oligonucleotide/oligosaccharide (OB) fold is a 5 stranded beta-barrel domain 
with a concave binding face for ligand binding and are found in diverse organisms 
with little sequence conservation (Murzin, 1993; Steemson et al., 2014).  The barrel 
structure can be seen in the naïve protein structure and the evolved structure 
where the OBody is bound to hen egg-white lysozyme (HEL) as shown in figure 1.30 
(Steemson et al. 2014). 
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Figure 1.30 Obody bound to hen egg white lysozyme. (a) A model of Pyrobaculum aerophilium 
aspartyl tRNA synthetase (AspRS) wild type protein on which the design for the library was based. 
(b) Model of the structure of the newly designed Obody NL8 in complex with HEL. The beta barrel 
structure is conserved and the binding is occuring on the concave face as expected (Steemson et al. 
2014).  
 
OBodies have been trialled in the bioengineering of bacteria for affinity purification 
like DARPins and nanobodies (Hay et al., 2015).  They have the potential to be used 
as molecular biology reagents as well as point of care diagnostics, however there is 
currently no published work to demonstrate their efficacy. 
1.5.4. Affimers 
The reagent used in this study is a non-antibody binding protein called an Affimer, 
previously referred to as an Adhiron (figure 1.31) (Tiede et al., 2014).  Affimers are 
small proteins based on the phytocystatin consensus sequence.  They have high 
thermostability, Tm up to 101°C and are produced using phage display and E.coli 
expression and are highly stable and expressed at high concentrations (Tiede et al., 
2014).  First published in 2014, there have now been over 350 successful screens 
performed by the Bioscreening Technology Group (BSTG) at the University of 
Leeds, producing reagents for a number of applications within molecular biology 
(Tiede et al., 2017).   
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Figure 1.31 Crystal structure of an Affimer.  The structure is based upon an alpha helix and 4 anti-
parallel beta sheets with two loop regions which are the locations of the variable regions of the 
protein (Tiede et al., 2017).  
 
The Affimer library is diverse, with a library size of approximately 1.3x1010. The 
sequence does not contain any cysteines, allowing for the insertion of a single 
cysteine at the C-terminus of the protein that is available for post purification 
modification.  The Affimers were constructed using a consensus phytocystatin 
sequence (derived from 57 sequences from Orysa sativa, Zea mays and Helianthus 
annuus) which possessed a number of ideal attributes required for antibody 
alternatives; small (approximately 100 aa), highly soluble and stable, absence of 
disulphide bonds so no structural modification was needed, and they are 
monomeric (Tiede et al., 2014).  The variable loop regions were inserted into the 
Val Val Ala Gly and Pro Trp Glu loops of the consensus sequence and these new 
loops each contained a randomised nine amino acid sequence as well as being 
truncated.  The modified sequence was then cloned into a phagemid vector 
developed by the BSTG that allows the Affimer to be fused on a truncated pIII 
protein of the M13 phage when expressed in ER2738 E.coli in the presence of 
helper phage.  The Affimer expressing phage are entered into phage display 
Binding loops 
65 
 
screening against target proteins and more specific and higher affinity binders are 
identified through repeated screening rounds (Tiede et al., 2014).  
1.5.4.1. Affimer diversity 
The Affimer scaffold has been shown to successfully function as a molecular tool in 
a number of techniques ranging from dissection of cellular pathways to microscopy 
techniques.  The broad range of target proteins already entered into Affimer 
screening and the success of these, as previously mentioned (section 1.5.4), holds 
the Affimer scaffold as a viable direct replacement for antibodies with the correct 
modification of current methods.  A number of these have been reported in a 
recent eLife publication utilising Affimers (Tiede et al., 2017). 
1.5.4.2. Affimer dissection of intracellular signalling pathways 
Affimers were raised against 5 growth factor receptor bound protein 2 proteins 
(Grb SH2 domain), using Affimers for this purpose allows for the inhibition of 
individual SH2 domains which is not possible with the use of siRNA knockdown, this 
removes the function of entire proteins containing multiple SH2 domains.  
Therefore, by inhibiting individual domains whilst maintaining the overall function 
of a protein, it allows the dissection of the signalling mechanism of these proteins 
at a more detailed molecular level.  The Affimers were raised to the SH2 domains 
using domains engineered with N terminal biotin acceptor proteins which could be 
used to capture the proteins from cell lysate and used in the phage display 
screening.  Results comparing cross reactivity between Affimers raised against Grb2 
SH2 domain and other Grb protein SH2 domains (Grb 7, 10, 14), showed that 
Affimers have specificity to Grb2 SH2 domains with very little cross-reactivity 
(figure 1.32) (Tiede et al., 2017). 
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Figure 1.32 Grb2 Affimer specificity. (a) The 24 monoclonal Affimers raised against Grb2 SH2 
domains were tested for specificity against other Grb SH2 domains and show specificity to Grb2 SH2 
domains and no cross reactivity to other SH2 domains.  (b) The Affimers are able to pull down 
endogenous Grb2 when bound to cobalt magnetic beads and incubated with cell lysate (Tiede et al., 
2017). 
 
1.5.4.3. Affimer inhibition of extracellular receptor function 
Inhibition of cell receptor functioning using Affimers against vascular endothelial 
growth factor receptors (VEGFRs) has also been investigated.  VEGFRs are 
important in angiogenesis, lymphangiogenesis and arteriogenesis and can be 
therapeutic targets in diseases such as cancer.  Affimers were raised against 
VEGFR2 and their binding was shown in immunohistochemistry staining (in 
comparison to VEGFR2 antibody staining), as well as inhibition seen when 
incubated with cells in tissue culture, as demonstrated by a decrease in VEGFR-
dependent tubule length in a tubulogenesis assay (figure 1.33) (Tiede et al., 2017).   
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Figure 1.33 Affimer inhibition of extracellular receptor function. (a) Affimer binding in 
immunohistochemistry staining.  When compared to the staining obtained by antibody binding to 
VEGFR2 the staining is identical when using the two Affimer proteins (A9 and B8).  Darker staining 
can be seen at cell membranes as expected as highlighted by the arrows. (b) The tubulogenesis 
assay shows a significantly reduced tubular length in cells incubated with Affimer B8 compared to 
the control Affimer (Tiede et al., 2017).  
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The use of Affimers in immunohistochemistry and microscopy techniques (section 
1.5.4.5) may also allow for greater sensitivity of these techniques when compared 
to antibodies due to increase number of binding events, resulting from the reduced 
size of the Affimer verses the antibody.  
1.5.4.4. Affimers to modulate ion channel function 
Ion channel modulation has been shown using Affimers raised against Transient 
Receptor Potential Vanilloid 1 (TRPV1) channels.  Thirteen Affimers were identified 
against a peptide derived from an outer pore domain of TRPV1, as the purification 
of entire, functional and structurally intact membrane proteins is difficult.  One 
Affimer (Affimer 2) of the thirteen previously identified was able to stain full length 
TRPV1 expressing U2-OS cells, shown in comparison to TRPV1 antibody staining 
where colocalisation of the two reagents was observed (figure 1.34a).    The 
modulation of the channel by the Affimers was also observed by measuring 
intracellular calcium levels post Affimer treatment and capsaicin activation, 
resulting in significantly enhanced channel activation (figure 1.34b) (Tiede et al., 
2017). 
 
 
69 
 
 
Figure 1.34 Affimers in the modulation of ion channels. (a) Affimers (green) are able to colocalise 
with Antibody (red) staining of TRPV1 channels in fluorescence binding assays.  The sensitivity of the 
Affimer appears to be greater than the antibody counterpart in this assay. (b) The treatment of cells 
with Affimers 5, 35, 45, 79, 86 and 96 showed a significant increase in the activation of TRPV1 upon 
capsaicin activation compared to capsaicin treatment alone (Tiede et al., 2017).  
 
1.5.4.5. Affimers in imaging techniques 
As previously mentioned with regards to immunohistochemistry (section 1.5.4.3), 
the small size of Affimers compared to their antibody counterparts may allow them 
to be employed to increase the sensitivity of imaging techniques.  This is due to the 
potential increase in binding events resulting from decreased stearic hindrance.   
In vivo imaging techniques were successful using an Affimer against tenascin C 
(TNC), which is associated with cancer progression.  Affimers were injected 
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intravenously and tissue sections from sacrificed animals probed for Affimer 
binding (figure 1.35).  As well as showing potential as in vivo imaging reagents, it is 
thought that the clearance of the Affimers from the body would be much quicker 
than antibody counterparts, providing a lower background reading from unbound 
reagent (Tiede et al., 2017).  
 
Figure 1.35 In vivo imaging using Affimer reagents.  Rhodamine labelled Affimers against TNC were 
injected intravenously and tissue samples evaluated for Affimer binding 24 and 48 hours later.  
Affimer binding was seen in the tumour as well as the liver and kidney, suggesting metastasis of the 
cancerous cells (Tiede et al., 2017).  
 
Affimers can also be used in microscopy techniques as direct replacements for 
antibodies using fixed cells.  They have been shown to function successfully in fixed 
cell staining with fluorescence detection of Herpes Virus of Turkeys (HVT) infected 
cells when compared to antibody detection (figure 1.36a).  In this case, Affimers 
were able to distinguish between infected and vaccinated animals.  Moreover, they 
have been shown as potential reagents for single particle tracking in super 
resolution microscopy due to their small size in comparison to their antibody 
counterparts.  Here, Affimer binding to human epidermal growth factor 4 receptor 
(HER4) are shown in figure 1.36b compared to antibody staining in both wide field 
and dSTORM images.  Figure 1.36c shows an Affimer binding to polymerised 
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microtubules in dSTORM image compared to the antibody counterpart where the 
staining pattern is similar  (Tiede et al., 2017).   
 
Figure 1.36 Affimers is microscopy techniques (a) Affimer staining of fixed cells using GFP and 
streptavidin-800.  Affimers were raised against HVT and Affimers incubated with viral infected cells 
and Affimer 6 inparticular showed the same distribution within the cells infected with HVT as shown 
when the virus was detected using an antibody.  There was no cross reaction with other related 
viruses.  (b) Super resolution microscopy of HER4 using Affimers, (top) antibody staining in wide 
field view, (middle) Affimer staining with wide field view, (bottom) dSTORM image if Affimer 
staining (c) 3D STORM imaging of antibody and Affimer stained tubulin (Alexa Fluor-647) (Tiede et 
al., 2017).  
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1.5.4.6. Other examples of Affimer applications 
As well as biologically relevant proteins, Affimers have also been raised against 
small organic compounds, in this case 2,4,6-trinitrotoluene (TNT).  Using a TNT 
analogue, Affimers were able to distinguish between TNT and also two analogues 
of DNT (Tiede et al., 2017). 
Affimers can also be used to investigate the binding motifs of proteins for example 
HIF-1α/p300.  In this case an Affimer was raised to probe the interaction between 
HIF-1α and p300.  This will help to better inform decisions regarding inhibition of 
this interaction when designing small molecule inhibitors (Kyle et al., 2015).  They 
have also been used in the manipulation of nanoparticle synthesis to produce cubic 
nanoparticles rather than the conventional spherical shapes (Rawlings et al., 2015).  
Affimers can also function as peptide anchors, allowing for the study of proteins 
which may not have a stable structure (Stadler et al., 2014) and could also be 
implemented as co-crystalisation partners for proteins which do not crystalise 
easily due to structural integrity or solubility issues.  Affimers have also been used 
in the development of electrochemical biosensors (Raina et al., 2015; Sharma et al., 
2016).  Recently Affimers have been shown to function in an Affimer-antibody 
combined diagnostic kit for the biomarker for hepatocellular carcinoma, glypican-3 
(Xie et al., 2017).      
1.5.4.7. Why use Affimers? 
As discussed with other non-antibody scaffolds, excluding nanobodies as these rely 
on initial camelid involvement, there is a complete removal of the requirement for 
animal use in the production of Affimers, as they can be produced recombinantly 
from the first stage of the process.  This makes them a desirable reagent for the 
direct replacement of antibodies within the molecular biology setting and as 
previously discussed they have been shown to function in a wide ranging number 
of techniques.  The Affimers can be purified to a concentration between 50-100 
mg/l of culture and the purification success rate is greater than 95% (Tiede et al., 
2014).  When compared to the purification of antibodies this is an improvement to 
the complicated precipitation and chromatography steps needed to obtain 
antibodies of similar purities and concentrations (Fisher, 2011).  Unlike most 
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antibodies, Affimers can be produced ‘in house’ once identified using techniques 
and equipment available in most laboratory settings. 
1.5.5. Aims of the project- Advantages and limitations and why they 
need improving 
PRRSV is a highly contagious livestock infection which can cause significant losses 
to the agricultural industry and so it is vital that it can be rapidly detected on site 
with a relevant POC diagnostic.  The aim of this project was to produce a novel 
Affimer-based LFD which was able to directly detect the presence of the PRRSV N 
protein within a sample.   
The project involved the cloning and expression of two PRRSV N proteins from a 
low pathogenic and a high pathogenic strain of the virus in order to investigate if an 
Affimer-based sensor could be produced to detect the presence of viral proteins 
and to distinguish between viral strains.  
A library of Affimer reagents was screened using phage display technology using 
the two N proteins as target proteins to obtain a pool of specifically binding 
Affimers.  These Affimers were characterised for their binding against both of the 
target N proteins to further assess their binding specificity with the intention of 
reducing the original pool of reagents to those which could bind one or the other N 
protein and a smaller pool which could bind both N proteins.   
The final pool of Affimer reagents were incorporated into a simple LFD as direct 
replacements for the antibody reagents ordinarily used in these devices to 
determine if they were suitable alternatives for this application.  The use of Affimer 
reagents in this application will have wide reaching implications and pave the way 
for their use in POC diagnostics for a number of clinically relevant diseases in both 
human and animal healthcare.     
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2 Materials and methods  
2.1. Growth and maintenance of bacteria 
2.1.1. Bacterial strains 
A number of bacterial strains of E.coli (table 2.1) were used in this study to exploit 
their specific functions, for example transformation and replication of plasmid 
DNA, or protein expression.  
Table 2.1 Genotypes of Competent bacteria used in this study.  All bacteria were grown at 30 °C 
unless otherwise stated 
E.coli strain Genotype Source 
DH5α F
–
Φ80lacZΔM15Δ(lacZYA-
argF)U169 recA1 endA1 hsdR17(rK,mK+) phoA supE44λ
–
 thi-1 gyrA96 relA1 
ThermoFisher 
Scientific 
BL21(DE3) F
–
 ompT hsdSB(rB
–
, mB
–
) gal dcm (DE3) New England 
Biolabs®Inc 
BL21(DE3)pLysS F
– 
ompT hsdSB(rB–, mB–) gal dcm (DE3) pLysS (CamR) Promega 
BL21-Gold(DE3) F
–
 ompT hsdS(rB
–
 mB
–
) dcm
+
 Tetr gal λ(DE3) endA The Agilent Technologies 
BL21-CodonPlus-
RIL 
F
–
 ompT hsdS(rB
–
, mB
–
) dcm
+
 Tetr gal λ(DE3) endA Hte 
[argU ileY leuW Camr] 
Agilent Technologies 
BL21-CodonPlus-
RP 
F
–
ompT hsdS(rB
–
, mB
–
) dcm
+
 Tetr gal endA Hte [argU 
proL Camr] 
Agilent Technologies 
ER2738 (F’proA
+
B
+
,lacIq,Δ(lacZ)M15,zzf::Tn10(TetR)/fhuA2 glnV 
Δ(lac-proAB) thi-1 Δ(hsdS-mcrB)5) 
Lucigen 
 
Cultures were grown in Luria broth (LB) [1 % (w/v) tryptone, 0.5 % (w/v) NaCl, 0.5 % 
(w/v) yeast extract] with shaking at 30 °C or colonies grown on Luria broth agar 
(LBA) [LB with 1.5 % agar] at 37 °C.  
2.1.2. Preparation of rubidium chloride chemically competent 
bacteria 
A glycerol stock of the relevant bacterial strain was streaked onto LBA (containing 
selection antibiotic if necessary) and grown overnight at 37 °C.  A single colony was 
picked and used to inoculate 5 ml of LB media (selective if necessary) which was 
incubated overnight at 37 °C, 230 rpm.  0.5 ml of this culture was used to inoculate 
50 ml LB media (selective if necessary) and the culture incubated at 37 °C, 230 rpm 
until an OD600 of 0.4-0.6 was reached.  Cells were pelleted by centrifugation at 3545 
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xg for 5 minutes at 4⁰C.  The pellet was resuspended in 40 ml filter sterilised, ice 
cold Transformation buffer 1 (TBF1) [30 mM KOAc, 10 mM CaCl2, 50 mM MnCl2, 
100 mM RbCl, 15% (v/v) glycerol, adjusted to pH 5.8 with acetic acid] and 
incubated on ice for 5 minutes.  The cells were pelleted at 3545 xg for 5 minutes at 
4 ⁰C, resuspended in 2 ml filter sterilised, ice cold TFB2 buffer [10 mM MOPS, 75 
mM CaCl2, 10 mM RbCl, 15 % (v/v) glycerol adjusted to pH 6.5 with KOH] and 
incubated on ice for 15-60 minutes.  The cells were aliquoted into 150 µl samples 
and stored at -80 °C.   
2.2. DNA protocols 
2.2.1. Bacterial expression plasmids 
A number of expression plasmids were used in this study for the expression of 
target recombinant proteins and Affimers, these plasmids are listed in table 2.2, 
along with a brief description of their key features. 
Table 2.2 Native and recombinant plasmids used in this study 
Plasmid Description Source 
pTriEx™ 1.1 An expression vector, containing C-terminal HSV tag™ and 
His8 tag™, which enables gene expression in mammalian 
(CMVie promoter), bacterial (T7lac promoter) and 
baculovirus infected insect cells (p10 promoter) 
Novagen® 
pET28a An expression vector, containing a N-terminal His6-tag 
(plus an optional C-terminal His6-tag) and T7 promoter for 
bacterial protein expression  
Novagen® 
pET28aSUMO A pET28a derived plasmid with a N-terminal His-SUMO 
tag (plus an optional C-terminal His6-tag) and T7 promoter 
for bacterial protein expression.  
Modified from 
Novagen® (Ariza 
et al., 2013) 
pCR®-Blunt II-
TOPO® 
A vector used for the cloning of blunt ended DNA 
products containing the M13 primer sites for sequencing 
or PCR screening.  
ThermoFisher 
Scientific 
pET11a A bacterial expression vector with a BamHI cloning site 
and T7 promoter 
Novagen® 
pGEX-6P-1 A bacterial expression vector for the expression of GST-
tagged recombinant proteins via a tac promoter.  
Thrombin recognition site for cleaving of the desired 
protein from the GST-tag. 
GE Healthcare 
pBSTG1 A phagemid cloning vector based derived from pHEN1 
vector.  Sequences cloned into this vector create a fusion 
sequence for expression of Affimers in bacteriophage 
M13. 
(Tiede et al., 2014; 
Hoogenboom et 
al., 1991) 
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2.2.2. Polymerase chain reaction (PCR) 
PCRs were performed in 0.2 µl PCR tubes (Axygen), using a TC-412 thermal cycler 
(Techne™). Reactions were set up as follows using Platinum® Pfx DNA polymerase: 
1x Reaction Buffer, 1 mM MgSO4, 10-50 ng DNA template, 0.3 µM each dNTP, 0.3 
µM forward primer, 0.3 µM reverse primer, 1 U Platinum® Pfx DNA polymerase and 
nuclease free dH2O added up to 50 µl.  The conditions of PCR reactions are shown 
in table 2.3.      
Table 2.3 Thermal cycling programs for PCR 
Step Process Condition 
1 Initial denaturation 95 °C for two minutes 
2 Denaturation 95 °C for 15 seconds 
3 Annealing 55 °C for 30 seconds 
4 Extension 68 °C for 1 minute per kb 
5  30 cycles of steps 2-4 
6 Maintenance 4 °C 
 
2.2.3. Agarose gel electrophoresis 
DNA samples were mixed with an appropriate volume of 10x DNA loading buffer 
[30 % (v/v) glycerol, 0.25 % (w/v) Orange G] and 5 µl of each sample was loaded 
onto a 0.7 % (w/v) agarose gel in TBE [2 mM EDTA, 80 mM boric acid, 90 mM Tris-
base] containing 5 µg/ml ethidium bromide (ThermoFisher Scientific) together with 
a 1 kb plus DNA ladder (ThermoFisher Scientific).  Electrophoresis was performed in 
Mini-Sub Cell GT apparatus (Bio-Rad) in TBE buffer at 120 V and bands were 
visualised under UV using the GeneGenius bio-imaging system (Syngene).  
2.2.4. Purification of DNA from agarose gels 
Agarose gels were visualised on a transilluminator and DNA fragments were 
excised from the gel using a scalpel.  To maintain DNA integrity, UV exposure was 
kept to a minimum.  Extraction of the DNA was performed using the QIAquick gel 
extraction kit (QIAGEN), following the manufacturer’s instructions.  DNA was eluted 
in 50 µl dH2O and stored at -20 °C.   
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2.2.5. Plasmid purification from E.coli 
Single colonies grown on LBA plates were used to inoculate an appropriate volume 
of LB containing selective antibiotic(s) and grown overnight at 37 °C, 230 rpm.  
Plasmid purification was performed using QIAprep Spin Miniprep and QIAGEN 
Plasmid Maxiprep kits (QIAGEN) according to manufacturers’ instructions.  DNA 
was eluted in the appropriate volume of nuclease free H2O and stored at -20 °C.  
2.2.6. DNA sequencing 
Purified DNA was diluted to 100 ng/µl and sequencing performed by GATC biotech 
using universal primers as shown in figure 2.4. 
Table 2.4 Sequencing primers 
Plasmid Forward primer Reverse primer 
pTriEx™ 1.1 T7 promoter  T7 terminator 
pET28a T7 promoter  T7 terminator 
pET28aSUMO T7 promoter  T7 terminator 
pCR®-Blunt II-TOPO® M-13 forward M-13 reverse 
pET11a T7 promoter  T7 terminator 
pGEX-6P-1 pGex fwd pGex rev 
pBSTG1 M-13 forward M-13 reverse 
 
2.3. Molecular cloning 
2.3.1. pCR®-Blunt II-TOPO® 
Zero Blunt® TOPO® PCR cloning kit (Life Technologies) was used for the highly 
efficient cloning of blunt ended DNA products in this study.   
All genes cloned into pCR®-Blunt II TOPO® were done so in accordance with the 
manufactures’ protocol; 2 µl of PCR product was added to 1 µl of salt solution with 
1 µl of the linearised TOPO® cloning vector in a total volume of 6 µl.  The reaction 
was incubated for 30 minutes at room temperature.  The reaction was added to 50 
µl of DH5α cells and transformed as described in section 2.4.1. 
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2.3.2. Cloning into expression vectors 
Bacterial expression vectors pTriEx™ 1.1, pET28a, pET28aSUMO, pET11a and pGEX-
6P-1 were used in this study and the appropriate genes were cloned into these 
vectors from pCR®-Blunt II TOPO® as indicated in table 2.5.   
Table 2.5 List of primers, enzymes and parent vectors used in the construction of the Target 
expression constructs used in this study (restriction sites highlighted in red) 
Recombinant 
vector 
Parent 
Vector 
Intermediate 
vector 
Forward Primer 
Sequence (5’-3’) 
Primer sequence 
(5’-3’) 
Restriction 
Enzyme 
pET28aSumo-
NLP 
pTriEx 1.1 pCR®-Blunt II 
TOPO®  
GGATCCATGCC
AAATAACAACG 
AACGCCGGCGTTA
CGCTGATGATGG 
BamHI/NotI 
pET28aSumo-
NHP 
TArget 
Clone 
pCR®-Blunt II 
TOPO®  
CCCGGATCCATG 
CCAAATAACAAC 
GGCAAGCAG 
AAAGCGGCCGCA
TCATGCTGAGGGT
GATGCTGTGGC 
BamHI/NotI 
pET11a (with 
cysteine) 
pBSTG1 pCR®-Blunt II 
TOPO®  
ATGGCTAGCAA
CTCCCTGGAAAT
CGAAG 
TTACTAATGCGGC
CGCACAAGCGTCA
CCAACCGGTTTG 
NheI/NotI 
pET11a 
(without 
cysteine) 
pBSTG1 pCR®-Blunt II 
TOPO®  
ATGGCTAGCAA
CTCCCTGGAAAT
C GAAG 
TACCCTAGTGGTG
ATGATGGTGATGC 
NheI/NotI 
pGEX-6P-1-NHP TArget 
Clone 
pCR®-Blunt II 
TOPO®  
CCCGGATCCATG
CCAAATAACAAC
GGCAAGCAG 
AAAGCGGCCGCA
TCATGCTGAGGGT
GATGCTGTGGC 
BamHI/NotI 
pTriEx 1.1-NHP TArget 
Clone 
pCR®-Blunt II 
TOPO®  
CCGGATCCCATG
CCAAATAACAAC
GGCAAG 
AATAGCGGCCGCT
GCTGAGGGTGAT
GCTGTGGC  
BamHI/NotI 
pET28a-NHP TArget 
Clone 
pCR®-Blunt II 
TOPO®  
CCCGGATCCATG 
CCAAATAACAAC 
GGCAAGCAG 
AAAGCGGCCGCA
TCATGCTGAGGGT
GATGCTGTGGC 
BamHI/NotI 
      
2.3.3. Restriction enzyme digest 
Restriction digests were performed according to the manufacturer’s instructions 
(New England Biolabs) in a total volume of 50 µl: 1 U restriction enzyme(s), 1 µg 
DNA, 1x NEBuffer, nuclease free dH2O added to 50 µl.  Reactions were incubated 
for two hours at 37 °C and double digests were performed where possible in a 
compatible buffer.  The restriction enzymes used are shown in table 2.5.  The 
resulting DNA fragments (vector and insert) were analysed on 0.7 % (w/v) agarose 
gels and then excised and purified from the gel (section 2.2.4.).   
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2.3.4. DNA ligation 
The insert and vector were then used in ligation reactions, performed according to 
manufacturer’s instructions in a total volume of 10µl containing 1x Ligase buffer 
(NEB), 50-100 ng linearised vector DNA and varying molar ratios of insert DNA 
fragments (generally this was a 1:3 ratio).  Reactions were performed for a 
minimum of 1 hour at 16 °C using a TC-412 thermal cycler (Techne™).  5 µl of the 
ligation reaction was added to 50 µl DH5α and a transformation performed (section 
2.4.1.).   
2.4. Protein over-expression and purification  
2.4.1. Transformation of chemically competent bacteria      
50 µl aliquots of chemically competent bacteria (per transformation) were thawed 
on ice, 50ng of plasmid DNA was added to the aliquot and incubated on ice for 5 
minutes.  The cells were heat shocked at 42 °C for 30 seconds and returned to ice 
for 5 minutes.  200 µl of antibiotic free LB was added to each transformation 
reaction and these were incubated at 37 °C for 1 hour 230 rpm.  The bacteria were 
then plated onto LB agar plates containing the appropriate antibiotic(s) (kanamycin 
or ampicillin at 50 µg/ml, chloramphenicol at 34 µg/ml) and incubated at 37 °C 
overnight.   
2.4.2. Expression of recombinant proteins 
Expression of recombinant proteins was performed in the appropriate E.coli strain 
(table 2.1).  Plasmids were transformed into chemically competent cells (section 
2.4.1.), single colonies were used to inoculate 10 ml selective LB media and cultures 
grown overnight at 37 °C, 230 rpm.  The following day, overnight cultures were 
used to inoculate a larger culture volume at a 1/100 dilution.  Cultures were grown 
to an OD600 0.4 - 0.6 at 30 ⁰C, 230 rpm and induced with a final concentration of 0.1 
mM IPTG and cultured overnight at 30 °C, 230 rpm.  The induced bacteria were 
then harvested by centrifugation at 3545 xg at 4 °C for 10 minutes in an Eppendorf 
5804R centrifuge.  Bacterial cell pellets were stored at -20 °C or lysed directly after 
harvesting. 
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2.4.3. Protein purification 
Cell pellets were resuspended in lysis buffer [For recombinant His6-tagged viral 
proteins: PBS, 150 mM NaCl, 50 mM imidazole, 0.1 % (v/v) Triton X-100, 5 U DNase, 
5 U RNase,  100µg/ml lysozyme, for Affimers: 50 mM NaH2PO4, 300 mM NaCl, 20 
mM imidazole, 5 U DNase, 5 U RNase,  100µg/ml lysozyme, for GST-tagged 
recombinant viral proteins: PBS, 150 mM NaCl, 0.1 % (v/v) Triton X-100, 5 U DNase, 
5 U RNase,  100µg/ml lysozyme].  Cells were lysed by sonication (Sanyo Soniprep 
150) on ice by the following cycle: 6x (10 seconds on, 20 seconds off) sample rested 
on ice for five minutes and the sonication repeated. 
The lysate was transferred to micro-centrifuge tubes (removing a sample for SDS-
PAGE analysis) and centrifuged at 13,000 xg for 30 minutes at 4 °C (Eppendorf 
5418R).  The supernatant was removed and filtered using a 0.45 µm Amicon 
syringe filter.  A sample of the pellet and the supernatant was taken for SDS-PAGE 
analysis.   
2.4.3.1. Nickel ion affinity chromatography-Sepharose His-Trap 
HP columns for purification of recombinant viral proteins 
For purification of His-tagged proteins from large volumes, a 5 ml Ni2+ sepharose 
HisTrap HP column (GE Healthcare) was used.  Purification was performed at 4 ⁰C 
with the column attached to a peristaltic pump, maximum flow rate 1 ml/minute.   
Columns were prepared by washing with five column volumes of dH2O and 
equilibrated with 5 column volumes of lysis buffer [PBS, 150 mM NaCl, 50 mM 
imidazole, 0.1 % (v/v) Triton X-100].  The filtered bacterial cell lysate (section 2.4.3.) 
was loaded onto the column and the flow through collected.  The column was then 
washed with five column volumes of wash buffer [PBS, 150 mM NaCl, 50 mM 
imidazole] wash fractions were collected.  To elute the bound recombinant 
proteins, three column volumes of each buffer was added to the column and 
fractions collected, each buffer contains an increasing concentration of imidazole, 
[PBS, 150 mM NaCl and 80/160/240/320/400 mM imidazole].  The previously 
indicated elution fractions as well as whole cell, soluble, insoluble and wash 
fractions were mixed with an equal volume of 2x Laemmli buffer and analysed by 
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SDS-PAGE (section 2.4.4.1) followed by Coomassie blue staining (section 2.4.4.2) 
and western blotting (section 2.4.4.3.).   
The used columns were stripped using 3 column volumes of 1x stripping buffer (4x 
strip buffer: 2 M NaCl, 80 mM Tris-HCl pH 7.9, 4 M imidazole) and stored in 20% 
ethanol in dH2O at 4 °C. 
2.4.3.2. Nickel ion affinity chromatography- Batch method for 
purification of Affimers 
For purification of His6-tagged Affimers from small volumes the Ni-NTA batch 
method was used.  An appropriate volume of Ni2+-NTA (QIAGEN) beads were 
prepared at 4 °C by centrifuging the beads at 800 xg (Eppendorf 5804R) for five 
minutes and removing the supernatant.  The beads were washed three times in 
lysis buffer [50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 7.4] with 
centrifuging at 800 xg (Eppendorf 5804R) for three minutes between washes and 
removing the supernatant.  The filtered bacterial cell lysate was loaded onto the 
beads and incubated for two hours at 4 °C.  The lysate containing the beads was 
added to a 1 ml polypropylene column (QIAGEN) and allowed to flow through 
under gravity, collecting the flow through.  The column was then washed with 
three column volumes of wash buffer [50 mM NaH2PO4, 500 mM NaCl, 20 mM 
imidazole, pH 7.4] collecting wash samples.  The protein was eluted four times in 2 
ml elution buffer [50 mM NaH2PO4, 500 mM NaCl, 300 mM imidazole, pH 7.4].  
Fractions of the purification were analysed on SDS-PAGE (section 2.4.4.1) followed 
by Coomassie blue staining (section 2.4.4.2).   
2.4.3.3. GST purification of recombinant viral proteins 
For purification of GST-tagged recombinant viral proteins a batch method using 
glutathione sepharose 4B beads was used.  The appropriate volume of glutathione 
sepharose 4B was prepared at 4 °C by centrifugation at 800 xg using an Eppendorf 
5804R centrifuge removing the supernatant and washing three times with lysis 
buffer [PBS, 150 mM NaCl, 0.1 % (v/v) Triton X-100].  The filtered bacterial cell 
lysate was loaded onto the beads and incubated for two hours at 4 °C.  The lysate 
containing the beads was added to a 1 ml polypropylene column (QIAGEN) and 
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allowed to flow through under gravity, collecting the flow through.  The column 
was washed with three column volumes of wash buffer [PBS, 500 mM NaCl, pH 7.4] 
collecting wash samples.  The protein was eluted four times in 2 ml elution buffer 
[PBS, 500 mM NaCl, 10 mM reduced glutathione, pH 7.4].  Fractions of the 
purification were analysed on SDS-PAGE (section 2.4.4.1) followed by Coomassie 
blue staining (section 2.4.4.2). 
2.4.4. Protein analysis techniques 
2.4.4.1. SDS-PAGE analysis 
All gels used contained 15 % polyacrylamide made as described by Green et al., 
2012 and consisted of a stacking gel overlaying a resolving gel.  Protein samples 
were boiled for five minutes in 2x Laemmli buffer [4% SDS, 20% glycerol, 10% 2-
mercaptoethanol, 0.004% bromophenol blue and 0.125 M Tris HCl, pH approx. 6.8] 
and loaded onto the gel in addition to Precision Plus Protein™ Dual Colour Standard 
protein ladder (BioRad).  Electrophoresis was carried out in BioRad Mini-Protean 
Tetra System tanks containing 1x tris-glycine running buffer [ 10x stock: 0.1 % (w/v) 
SDS, 250 mM Tris-base, 192 mM glycine] at 180 V for approximately 45 minutes.   
2.4.4.2. Coomassie blue staining of SDS-PAGE gels 
Gels were stained with Coomassie blue [50% (v/v) methanol, 10 % (v/v) acetic acid, 
0.05 % (w/v) Brilliant Blue R-250] for one hour before destaining [50 % (v/v) 
methanol, 10 % (v/v) acetic acid] for one hour.  
2.4.4.3. Western blotting of SDS-PAGE gels 
Proteins were transferred from SDS-PAGE polyacrylamide gels onto Protran 0.45 
nitrocellulose membrane (GE Healthcare) using Bio-Rad Mini-Protean 3 cell tanks 
according to the manufacturer’s instructions.  The nitrocellulose membrane and 
polyacrylamide gel were sandwiched between Whatman 3mm filter paper (GE 
Healthcare) soaked in transfer buffer [20% (v/v) methanol, 25 mM Tris-base, 190 
mM glycine] and placed in the tank.  Transfer was carried out at 100V, for one hour 
in transfer buffer.  The transferred membrane was incubated in 5% (w/v) milk 
powder in TBS-T [500 mM NaCl, 20 mM Tris-base, 0.1 % (v/v) Tween-20] for one 
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hour.  The membrane was incubated in primary antibody diluted in TBS-T for a 
minimum of one hour and washed for three five minute intervals.  The membrane 
was incubated in secondary antibody diluted in TBS-T for a minimum of one hour 
before being washed for three five minute intervals. The blots were covered with 
EZ-ECLA and EZ-ECLB mixed 1:1 and incubated for two minutes before visualisation 
with Hyperfilm ECL™ (GE Healthcare) in a Konica SRX-101A developer. 
2.4.4.4. Protein concentrations 
The concentrations of purified proteins were determined using a Bradford Assay 
(BioRad) according to manufacturer’s instructions.  
2.4.5. Labelling of expressed recombinant proteins 
2.4.5.1. Biotinylation of recombinant proteins 
2.4.5.1.1. Method 1: EZ-Link® NHS-SS-biotin to label amine 
containing proteins 
EZ-Link® NHS-SS-Biotin (ThermoFisher Scientific) was warmed to room temperature 
and immediately before use, a 5 mg/ml solution prepared in DMSO.  An 
appropriate volume of NHS-SS-biotin was added to a 1 mg/ml protein solution in a 
total volume of 100 µl PBS (PBST for hydrophobic proteins), amount of linker 
required was altered according to molecular weight, and incubated at room 
temperature for one hour.  Any excess biotin was removed using a Zeba™ Spin 
Desalting Column, 7K MWCO (ThermoFisher Scientific) according to the 
manufacturer’s instructions.  The sample was then mixed with an equal volume of 
80 % (v/v) glycerol and stored at -20 °C. 
2.4.5.1.2.  Method 2: Peptide disulphide bonds reduced with 
TCEP disulphide reducing gel and labelling of available 
sulfhydryl groups 
An appropriate volume of TCEP (tris(2-carboxyethyl)phosphine) Disulphide 
Reducing Gel (ThermoFisher Scientific) was centrifuged at 1000 xg for 1 minute and 
the supernatant discarded.  The gel was washed 3 times with PBS containing 1 mM 
EDTA with centrifuging at 1000 xg for 1 minute between washes.  PBS with 50 mM 
EDTA was added to the gel with an appropriate volume of a 1 mg/ml solution of 
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peptide.  The sample was incubated at room temperature for one hour with 
rotation to keep the gel in suspension.  To recover the supernatant containing the 
reduced peptide, the sample was centrifuged for one minute 1000 xg immediately 
before labelling with biotin.  
A 5 mg/ml maleimide-Biotin (ThermoFisher Scientific) stock solution was prepared 
in DMSO.  An appropriate volume of stock solution was added to an appropriate 
volume of reduced peptide and the reaction incubated at room temperature for 
two hours or overnight at 4 °C.  Excess label was removed using Zeba™ Spin 
Desalting Columns 7K MWCO according to manufacturer’s instructions.  The 
sample was mixed with an equal volume of 80 % (v/v) glycerol and stored at -20 °C.  
2.4.5.1.3. EZ-Link™ maleimide activated horseradish peroxidase 
labelling of single cysteine containing Affimers 
The single cysteine residues of the Affimers were reduced using the TCEP method 
(section 2.4.5.1.2) and the activated maleimide-HRP conjugated to the Affimer 
according to the manufacturer’s instructions (ThermoFisher Scientific) where the 
reduced protein was incubated with maleimide-HRP overnight at room 
temperature.  
2.4.5.1.4. Alexa Fluor® C5 maleimide labelling of single cysteine 
containing Affimers 
 The single cysteine residues of the Affimers were reduced using the TCEP method 
(section 2.4.5.1.2) and the activated Alexa Fluor®C5 maleimide conjugated to the 
Affimer according to the manufacturer’s instructions (ThermoFisher Scientific) 
where the reduced protein was incubated with Alexa Fluor®C5 maleimide 
overnight at room temperature.  Excess label was removed using Zeba™ Spin 
Desalting Columns 7K MWCO according to manufacturer’s instructions. 
2.4.6. ELISA to check labelling of proteins 
2.4.6.1. Biotinylated proteins 
1, 0.1, 0.01 µl of biotinylated targets were added to Nunc-Immuno™ MaxiSorp™ 
Strips (ThermoFisher Scientific) containing 50 µl PBS and incubated overnight at 4 
°C.  The wells were washed three times with PBST on a plate washer and blocked 
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with 250 µl 10x blocking buffer (Sigma-Aldrich-Aldrich) and incubated for three 
hours at 37 °C.  The wells were washed three times with PBST on a plate washer.  
The wells were then incubated with High Sensitivity Streptavidin-HRP diluted 
1:1000 in 2x blocking buffer (10x blocking buffer diluted in PBST) for 1 hour at room 
temperature on a vibrating platform.  The wells were washed 6 times with PBST on 
a plate washer and incubated with Seramum Blau® fast TMB/substrate solution 
(Seramum) and allowed to develop for three minutes at room temperature.  The 
absorbance was measured at 620nm using a Multiskan Ascent 96/384 Plate Reader 
(MTX Lab Systems Inc). 
2.4.6.2. HRP labelled proteins 
1, 0.1, 0.01 µl of HRP labelled targets were added to Nunc-Immuno™ MaxiSorp™ 
Strips (ThermoFisher Scientific) containing 50 µl PBS and incubated overnight at 4 
°C.  The wells were washed three times with PBST on a plate washer.  The wells 
were incubated with Seramum Blau® fast TMB/substrate solution (Seramum) and 
allowed to develop for three minutes at room temperature.  The absorbance was 
measured at 620nm using a Multiskan Ascent 96/384 Plate Reader (MTX Lab 
Systems Inc). 
2.4.6.3. Fluorescence labelled proteins 
1, 0.1, 0.01 µl of Alexa Fluor® labelled targets were added to Nunc-Immuno™ 
MaxiSorp™ Strips (ThermoFisher Scientific) containing 50 µl PBS and incubated 
overnight at 4 ⁰C.  The wells were washed three times with PBST on a plate washer.  
The fluorescence was measured using a plate reader (PolarStar Optima). 
2.5. Phage display techniques 
All reactions for phage display were carried out in Eppendorf Protein LoBind Tubes 
unless otherwise stated.  The protocol for phage display is outlined in figure 2.1.  
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Figure 2.1 Phage display protocol for screening of Affimers. Target proteins were screened using 
the Affimer phage library for a total of three panning rounds, with the Affimers from the final 
panning round taken forward for sequencing to identify unique loop region sequences. 
 
2.5.1. First panning round 
ER2738 cells were grown overnight on selective LBA (12 µg/ml tetracycline) at 37 
°C.  A single colony was used to inoculate 5 ml 2TY media (10 % (w/v) yeast extract, 
16 % (w/v) tryptone, 0.5 % (w/v) NaCl) with 12 µg/ml tetracycline overnight in an 
orbital incubator 230 rpm at 37 °C.  Streptavidin coated (HBC) 8-well strips 
(ThermoFisher Scientific) were blocked using 2x blocking buffer overnight at 37 °C, 
a total of four wells for each target.  The wells were washed once with PBST on a 
plate washer and fresh 2x blocking buffer added to the wells.  The phage library 
was pre-panned three times against the streptavidin coated plates: the phage 
library was added to the first pre-pan well and incubated at room temperature for 
one hour on a vibrating platform shaker.  The blocking buffer was removed from 
the second pre-panning well and the phage containing supernatant from the first 
88 
 
well removed to the second and incubated for one hour at room temperature 
shaking.  This was repeated a third time.  During the pre-panning steps, the 
biotinylated target, diluted 1:200 in 2x blocking buffer, was bound to the panning 
well for two hours at room temperature on a vibrating platform shaker.  The wells 
containing the biotinylated target were washed six times with PBST and the pre-
panned phage transferred from the appropriate pre-panning well into the well 
containing the target and incubated at room temperature for two hours shaking.  
One hour before elution of phage from panning wells, a dilution of the overnight 
ER2738 cells was set up to give an 8 ml culture per target at A600 of 0.6 at time of 
infection.   
2.5.1.1. Elution of phage and infection of ER2738 cells 
The final panning wells were washed six times with PBST on a plate washer and the 
phage eluted and used to infect ER2738 cells.  The phage was eluted in 0.2 M 
glycine, pH 2.2 for ten minutes at room temperature followed by neutralisation 
with 1 M Tris-HCl, pH 9.1 before addition to the aliquot of ER2738 cells.  The 
remaining phage was eluted in triethylamine for six minutes at room temperature 
and neutralisation with 1 M Tris-HCl, pH 7 before addition to the aliquot of ER2738 
cells.  The infected cells were incubated at 37 °C for one hour with no shaking and 
were mixed at least once during the incubation.   
2.5.1.2. Plating out ER2738 cells and preparation of phage 
1µl of phage infected ER2738 cells were plated onto LB agar carbenicillin plates 
(100 µg/ml carbenicillin).  The remaining cells were centrifuged for five minutes at 
3,000 xg and resuspended in a smaller volume and plated onto LB agar carbenicillin 
plates as ‘remaining’ sample.  The plates were incubated at 37 °C overnight. 
The following day, the number of colonies on the plate with the 1 µl inoculation 
were counted and this number multiplied by 8000 to determine the number of 
cells on the remaining cells plate.  The ER2738 cells were then scraped from the 
plates containing the ‘remaining’ samples using 2TY media with carbenicillin (100 
µg/ml).  The absorbance of a 1:10 dilution was measured and used to calculate the 
dilution required for a fresh 8 ml culture with an A600 of 0.2.  The cells were then 
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diluted in 2TY media with carbenicillin (100 µg/ml) and incubated at 37 °C for one 
hour 230 rpm.  0.32 µl of M13K07 helper phage (titre ca. 1014/ml) was added and 
the cells incubated for 30 minutes at 37 °C, 90 rpm before the addition of 400 µg 
kanamycin and incubation overnight at 25 °C, 170 rpm.   
The following day the phage infected cultures were centrifuged at 3,500 xg for ten 
minutes and the phage containing supernatant transferred to fresh falcon tubes.  
The required volume of phage containing supernatant was removed for use in the 
second panning round.  PEG-NaCl [20% (w/v) PEG 8000, 2.5 M NaCl] was added to 
the remaining phage containing supernatant to precipitate the phage and the 
reaction incubated overnight at 4 °C.  The phage was pelleted by centrifugation at 
4,816 xg for 30 minutes and the supernatant removed.  The pellet was 
resuspended in TE [10 mM Tris, 1 mM EDTA pH 8] and transferred to 
microcentrifuge tubes and centrifuged at 16,000 xg for ten minutes.  The 
supernatant was removed and diluted with 40-50 % glycerol and stored at -80 °C.   
2.5.2. Second panning round 
ER2738 cells were grown in 2TY media with 12 µg/ml tetracycline overnight, at 37 
°C, 230 rpm.  20 µl beads per target, (Dynabeads® MyOne™ Streptavidin T1, 10 
mg/ml), were blocked with 100 µl 2x blocking buffer and incubated overnight at 
room temperature, 20 rpm (Stuart SB2 fixed speed rotator).  The appropriate 
number of wells were blocked in the plates for the KingFisher Flex, panning wells 
were blocked with 1 ml 2x blocking buffer in a deep 96 well plate (ThermoFisher 
Scientific) and elution wells were blocked with 300 µl 2x blocking buffer in two 
KingFisher (200µl) 96 well plates (ThermoFisher Scientific), the plates were 
incubated overnight at 37 °C.  Sufficient wells were prepared in 4x deep 96 well 
plates with 950 µl 2x blocking buffer directly before use.  
Pre-panning of the phage was carried out using pre-blocked streptavidin coated 
beads.  The pre-blocked streptavidin beads were centrifuged at 800 xg for one 
minute and immobilised on a magnet before removing the 2x blocking buffer.  The 
2x blocking buffer was replaced and the beads resuspended, 100 µl per 20 µl 
beads.  125 µl of phage containing supernatant from pan one was mixed with 125 
µl 2x blocking buffer (or 5 µl purified phage with 245 µl 2x blocking buffer) and 25 
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µl pre-blocked streptavidin beads and incubated for one hour at room temperature 
on the rotator.  The beads were centrifuged at 800 xg for one minute and placed 
on a magnet.  The supernatant containing the phage was added to a fresh tube and 
another 25 µl pre-blocked streptavidin beads were added and again incubated for 
one hour at room temperature on the rotator.   In parallel, the biotinylated target 
protein was incubated with 50µl pre-blocked streptavidin beads and incubated for 
two hours at room temperature on the rotator.   
Immediately before use, the 2x blocking buffer was removed from the deep 96-well 
plate used for panning and the two (200 µl) 96-well plates used for elution.  100 µl 
glycine [0.2 M, pH 2.2] was aliquoted per target into the pre-blocked wells of one 
elution plate and 100 µl triethylamine aliquoted per target into the pre-blocked 
wells of the second elution plate.   
The tubes containing the streptavidin beads with the biotinylated target bound 
were centrifuged at 800 xg for one minute and immobilised on a magnet and 
washed with 2x blocking buffer, repeating three times.  The tubes containing the 
pre-panned phage were centrifuged at 800 xg for one minute and immobilised on a 
magnet with the supernatant removed into the appropriate tube containing the 
target protein bound to streptavidin beads.  The beads were resuspended and 
transferred to the pre-blocked wells of the deep 96-well plate.    
2.5.2.1. Standard panning 
The KingFisher Flex protocol ‘Phage_display_pH_elution’ was selected (table 2.6) 
and the plates placed into the machine in the appropriate order.  Approximately 
one hour before elution of phage a fresh culture of ER2738 cells was setup using 
the overnight culture as previously described (section 2.4.2) and incubated at 37 °C, 
230 rpm.  Phage were eluted and used to infect a day culture of ER2738 cells as 
previously described (section 2.5.1.1). 
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Table 2.6 KingFisher Flex 'Phage_display_pH_elution' protocol 
Protocol Step Plate Volume (ul) Settings 
Tipcomb  96 DW tip 
comb 
  
Pick-Up: Tipcomb KingFisher 96 
KF plate 
  
Collect Beads Plate: Binding 
Microtiter DW 
96 plate 
 Collect count 1 
Collect time (s) 1 
Binding Plate: Binding 
Microtiter DW 
96 plate 
300 Beginning of Step 
Release beads [hh:mm:ss]: 00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 00:00:10 
Speed: fast 
Mix time [hh:mm:ss]: 00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 1 Plate: Wash 1 
Microtiter DW 
96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 2 Plate: Wash 2 
Microtiter DW 
96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 3 Plate: Wash 3 
Microtiter DW 
96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Wash 4 Plate: Wash 4 
Microtiter DW 
96 plate 
950 Beginning of Step 
Release beads [hh:mm:ss]: 00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 00:01:00 
Speed: slow 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
pH Elution Plate: pH 
elution 
KingFisher 96 
KF plate 
100 Beginning of Step 
Release beads [hh:mm:ss]: 00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 00:07:30 
Speed: slow 
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Postmix[hh:mm:ss]: 00:00:05 
Speed: Bottom mix 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Triethylamine 
Elution 
Plate: 
Triethylamine 
KingFisher 96 
KF plate 
100 Beginning of Step 
Release beads [hh:mm:ss]: 00:00:00 
Mixing/Heating Parameters 
Mix time [hh:mm:ss]: 00:03:30 
Speed: slow 
Postmix[hh:mm:ss]: 00:00:05 
Speed: Bottom mix 
End of step 
Collect beads, count: 5 
Collect time (s): 30 
Leave: Tipcomb 96 DW tip 
comb 
  
 
2.5.3. Third panning round      
The third panning round was performed as described in the first panning round 
(section 2.5.1) with the Streptavidin coated (HBC) 8-well strips replaced with 
NeutrAvidin Coated (HBC) 8-well strips and 200 µl phage containing supernatant 
(or 8 µl purified phage) from second panning round used.   
When preparing plates following elution of phage, a range of volumes were plated, 
eg; 100, 10, 1, 0.1 µl and incubated overnight at 37 °C.   
2.5.4. Phage ELISA 
2.5.4.1. Preparation of Streptavidin coated ELISA plates 
Streptavidin coated ELISA plates were prepared in advance of performing phage 
ELISA’s as follows and stored at 4 ⁰C for up to one week or -80 ⁰C for longer 
periods.  50 µl of a 5 µg/ml Streptavidin in PBS was aliquoted per well of a 96-well 
F96 Maxisorp Nunc-Immuno Plate and incubated for at least four hours at room 
temperature or 4 ⁰C overnight. 
2.5.4.2. Preparation of phage from individual binders 
200 µl 2TY containing 100 µg/ml carbenicillin was aliquoted into the appropriate 
number of wells in a 96-well V-bottom plate (Greiner).  Individual colonies from the 
final panning round were used to inoculate the wells and incubated overnight at 37 
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°C, 1050 rpm in an incubating microplate shaker (Heidolf Incubator 1000 and 
Titramax 1000).  The following day, 200 µl 2TY media with 100 µg/ml carbenicillin 
was aliquoted into a new 96-well V-bottom deep well plate and 25 µl of the 
overnight culture transferred into the corresponding well and incubated for one 
hour at 37 °C, 1050 rpm.  M13K07 helper phage (titre ca.1014/ml) was diluted 
1/1000 in 2TY with 100 µg/ml carbenicillin and 10 µl added per well and incubated 
for 30 minutes at room temperature, 450 rpm.  A kanamycin stock (25 mg/ml) was 
diluted 1/20 in 2TY media with 100 µg/ml carbenicillin and 10 µl added per well 
and incubated overnight at room temperature, 750 rpm.  The following morning 
the phage infected culture plate was centrifuged at 3,500 xg for ten minutes and 
phage containing supernatant transferred directly to the previously prepared ELISA 
plate (section 2.5.4.1) for binding to the target protein.  
20 µl of the original overnight culture was used to inoculate 5 ml 2TY media 
containing 100 µg/ml carbenicillin and grown at 37 °C overnight.  The following day 
plasmid DNA was recovered using a Miniprep kit (section 2.2.5). 
2.5.4.3. Performing phage ELISA 
Prior to use, 200 µl 2x blocking buffer was added per well of the pre-prepared 
streptavidin plates (section 2.5.4.1) and the plates incubated overnight at 37 °C.  
The following day the wells were washed once with PBST on a plate washer (TECAN 
Hydrospeed).  The biotinylated target protein was diluted to an appropriate 
dilution factor (1/1000-1/100) in 2x blocking buffer and 50 µl added per well.  
Control wells were left without bound target or with the appropriate biotinylated 
negative screen target protein at the same concentration.  The plates were 
incubated at room temperature for one hour on a vibrating platform shaker.  Wells 
were washed once with PBST on a plate washer and 10µl 10x blocking buffer 
aliquoted per well.  40 µl of previously prepared phage containing supernatant 
(section 2.5.1.2) was added per target containing well and corresponding control 
well and incubated at room temperature for one hour on a vibrating platform 
shaker.  Each well was washed once with PBST on a plate washer and 50 µl of a 
1/1000 dilution of anti-Fd-Bacteriophage-HRP antibody (Seramun Diagnostica 
GmbH) aliquoted per well before incubation for a further hour at room 
94 
 
temperature on a vibrating platform shaker.   Each well was washed ten times with 
PBST on a plate washer and 50 µl TMB (SeramunBlau® fast TMB/substrate solution, 
Seramun) aliquoted per well and allowed to develop for three minutes.  
Absorbance per well was measured at 620 nm using a Multiskan Ascent 96/384 
Plate Reader (MTX Lab Systems Inc). 
2.5.5. Subcloning Affimer sequences from phagemid vector into 
bacterial expression vector 
Affimers were subcloned from the parent phagemid vector, pBSTG1-Adh, into a 
bacterial expression vector, pET11a, using the primer sequences, forward shorter 
and pDHisIID-final-rev or pDHis-C-rev, when cloning with an added cysteine. 
Sequences are shown in table 2.4.  Cloning was carried out as described in section 
2.3. 
2.6. Identification of pairs of Affimers  
Affimers cloned with the C-terminal cysteine were expressed in 100 ml cultures 
using BL21 DE3(plysS) cells for purification using the batch method as described in 
section 2.4.3.2.  They were labelled via the C-terminal cysteine with biotin, HRP or 
fluorescence labels (section 2.4.5). 
2.6.1. Phage sandwich ELISA  
Streptavidin plates were prepared as described in section 2.5.4.1 and blocked 
overnight in 200 µl 2x blocking buffer at 37 °C.  The following day the plate was 
washed once with PBST in a plate washer and 50 µl of 2x blocking buffer aliquoted 
into each well.  1 µl of the biotinylated Affimer was bound to the streptavidin plate 
for one hour at room temperature on a vibrating shaker.   The plate was washed 
once with PBST on a plate washer and 40 µl of 2x blocking buffer and 10 µl 0.5 M 
biotin added to each well and incubated overnight 4 °C.   
The following day the plate was washed once with PBST on a plate washer.  Non-
biotinylated target protein was diluted 1:200 in 2x blocking buffer and 50 µl added 
to each well for one hour at room temperature.  10 µl of the phage containing 
supernatant was added to the corresponding wells and incubated for two hours at 
room temperature.  The plate was washed once with PBST on a plate washer and 
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50 µl of a 1:1000 dilution of anti-Fd-bacteriophage-HRP antibody (Seramun) added 
to each well and incubated at room temperature for one hour on a vibrating 
platform.  Phage binding was visualised with TMB as previously described (section 
2.5.4.3).  
2.6.2. Labelled recombinant protein sandwich ELISA 
Streptavidin plates were prepared as described in section 2.5.4.1 and blocked 
overnight in 200 µl 2x blocking buffer at 37 °C.  The following day the plate was 
washed once with PBST in a plate washer and 50 µl of 2x blocking buffer aliquoted 
into each well.  1 µl of the biotinylated Affimer was bound to the streptavidin plate 
for one hour at room temperature on a vibrating shaker.   The plate was washed 
once with PBST on a plate washer and 40 µl of 2x blocking buffer and incubated 
overnight 4 °C.   
The plate was washed once with PBST on a plate washer.  Non-biotinylated target 
protein was diluted 1:200 in 2x blocking buffer and 50 µl added to each well for 
one hour at room temperature.  1 µl of HRP labelled Affimer or Alexa Fluor® 
labelled Affimer was added to the corresponding wells and incubated for two hours 
at room temperature.  HRP labelled Affimer binding was visualised with TMB as 
previously described (section 2.6.4.2), Alexa Fluor® labelled Affimer binding was 
analysed by measurement on a plate reader (PolarStar Optima by BMG Labtech) 
Alexa Fluor® 488 was excited at 490nm and Alexa Fluor® 546 was excited at 532 
nm. 
2.6.3. Gold nanoparticle pairs assay 
2.6.3.1. Magnetic bead pulldowns 
20 µl streptavidin MyOne T1 beads (ThermoFisher Scientific) per reaction were 
incubated overnight in 2x blocking buffer (at room temperature with rotation).  The 
magnetic beads were immobilised on a magnet and the blocking buffer removed 
and replaced with 100 µl fresh 2x blocking buffer per 20 µl of beads.  The beads 
were then incubated with the biotinylated Affimers (section 2.4.5.1) at 5 µl of 
1mg/ml Affimer per 20 µl of beads for 30 minutes at room temperature with 
rotation.  Excess Affimer was removed with three washes in PBST with suspension 
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on the magnetic rack.  The Affimers bound to the magnetic beads were incubated 
with the target protein diluted to 0.5 mg/ml in pig serum (serum was diluted 1:1 
with PBST) for 30 minutes at room temperature with rotation.  The magnetic beads 
were washed three times in PBST to remove excess target with immobilisation of 
the beads on the magnet.  Binding of the target protein to the Affimer was 
confirmed by SDS-PAGE and western blot analysis (sections 2.4.4.1, 2.4.4.3). 
2.6.3.2. Binding of Affimers to gold nanoparticles 
Streptavidin functionalised gold nanoparticles (GNPs) (Innova Biosciences) were 
diluted to OD 0.1 in PBST and incubated with 5 µl of 1 mg/ml biotinylated Affimer 
for 30 minutes at room temperature with rotation.  The GNPs were washed three 
times with PBST to remove any excess Affimer with centrifugation at 9000 xg for 6 
minutes.   
2.6.3.3. ELISA using Affimers bound to gold nanoparticles 
Binding of the Affimers to the GNPs and ability to detect the target protein was 
determined using an ELISA method.  GNPs coated with Affimers were incubated 
with or without 1 µl of 1mg/ml target protein for 30 minutes with rotation.  The 
GNPs were washed three times with PBST by centrifugation, five minutes at 9000 
xg.  The GNPs were then incubated with 50 µl anti-his-HRP (1:10,000) for 30 
minutes before washing three times in PBST.  The binding of anti-his-HRP was 
visualised by adding 50 µl TMB and measuring the A600 using a Multiskan Ascent 
96/384 Plate Reader (MTX Lab Systems Inc). 
2.6.3.4. Gold nanoparticle/magnetic beads pairs assay 
The Affimer coated magnetic beads, following incubation with the target protein 
were washed three times in PBST, after the final wash, the magnetic beads were 
resuspended in 50 µl of the Affimer labelled gnp.  The beads were incubated at 
room temperature for 30 minutes with rotation.  To identify any Affimers which 
may function as pairs the magnetic beads were immobilised on a magnet and the 
supernatant removed into a 96 well plate.  The absorbance spectra of the sample 
was measured from 400-900 nm using a Clariostar plate reader (BMG Lab Tech). 
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2.7. Lateral flow based biosensor development 
2.7.1. Striping of Affimers/antibodies onto nitrocellulose membrane 
1 mg/ml solution of Affimer or antibody was prepared and, using a sequencing tip, 
striped in a line across the Hi-Flow Plus HF135 nitrocellulose membrane cards 
(Merck Millipore).  Any regions of thick deposition were marked so as not to be 
used and the cards dried at 37 °C overnight.   
2.7.2. Detection of Affimers on nitrocellulose membrane 
Biotinylated Affimers were adsorbed onto nitrocellulose membrane before drying 
the membrane overnight at 37 °C (section 2.7.1).  The Affimers were detected using 
anti His-HRP (1:1000) (Invitrogen™) for 30 minutes at room temperature before the 
membrane was washed three times and exposed in accordance to the western blot 
procedure (section 2.4.4.3).   
2.7.3. Affimers working as pairs in a lateral flow device 
Affimers and anti-his6 antibody were immobilised onto the nitrocellulose 
membrane cards as described in section 2.7.1.  10 µl of OD1 Affimer coated GNPs 
were incubated with 1 µl of 1mg/ml target protein and washed as described in 
section 2.6.3.3.  The GNPs were resuspended to OD1 and transferred to a 96 well 
plate.  Nitrocellulose membrane cards were cut into strips which were incubated 
with the resuspended GNPs for 30 minutes. 
2.8. Bioinformatics analysis 
Online software Clustal Omega Multiple Sequence Alignment (EMBL-EBI) was used 
for confirmation of DNA sequences following cloning and for the alignment of 
protein sequences.  Sequence data was obtained National Centre for Biotechnology 
Information (NCBI) (www.ncbi.nlm.nih.gov) for alignment with cloning data.  
Numerical data was analysed in Microsoft® Excel.  
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Production of novel Affimer reagents targeted to 
the PRRSV N protein  
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3. Production of novel Affimer reagents targeted to 
the PRRSV N protein  
3.1. Introduction 
The PRRSV nucleocapsid (N) protein is an RNA binding protein which associates 
with the viral RNA genome (Daginakatte and Kapil, 2001).  The N protein is the 
major immunogenic protein of PRRSV comprising 40% of the virion (Meulenberg et 
al., 1995), as such it makes the N protein a desirable target for detection in a 
diagnostic test for virus infection.  
The proposed diagnostic test uses novel non-antibody binding proteins, termed 
Affimers, as the binding reagents in a lateral flow-based device (LFD) (Chen and 
Yang, 2015b).  Affimers are 91 amino acid scaffold proteins which contain two 
variable loop regions, each of which are nine amino acids in length, giving a current 
library size of 1x1010 clones (Tiede et al., 2014).  The production of a biosensor 
which can detect the PRRSV N protein in clinical samples will serve as a proof of 
principle for the use of these reagents in LFDs.  
LFDs are a rapid and simple method of detecting numerous targets in a non-
laboratory setting in a semi-quantitative manner, as such the applications are wide 
reaching (Sajid et al., 2014).  Detection targets can include pathogens, hormones, 
drugs and metabolites, as long as a suitable antibody can be raised against the 
target (Posthuma-Trumpie et al., 2009; Corstjens et al., 2012; Morales-Narváez et 
al., 2015; Song et al., 2014).  It is possible to extend the use of LFDs by multiplexing, 
allowing the detection of multiple pathogens on one device, or multiple strains of a 
single pathogen (Zhao et al., 2016; Chen et al., 2016; Yang et al., 2015a).  Whilst 
antibodies are fantastic reagents for use in a wide variety of molecular biology 
techniques, they do have limitations, most importantly, the use of animals in their 
production.  Substantial numbers/species of animals are required to produce 
antibody reagents dependent on the amounts of reagent required, the intended 
use and phylogenic relationship between the antigen and the animal species 
(Leenaars and Hendriksen, 2005).  The replacement of antibodies in LFDs with 
Affimers will allow for the reduction in production time for reagents as well as the 
complete elimination of animals from the production process.      
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The most familiar LFD is the pregnancy test, detecting the human chorionic 
gonadotrophin hormone (hCG) in urine (Leuvering et al., 1980).  This is a widely 
used diagnostic test performed in a home setting without prior sample 
preparation.  Other examples of LFDs in a clinical setting using the direct detection 
of antigens were early developed glucose detection (Free et al., 1957) and more 
recently for the detection of cryptococcal antigen in HIV patients (Tang et al., 2015; 
Workman et al., 2009).  A number of Food and Drug Administration (FDA) approved 
assays are available from Chembio Diagnostic Systems Inc for the detection of HIV 
and associated infections, as well as a United States Department of Agriculture 
(USDA) approved test for TB; DDPP® HIV 1/2 Assay, DPP® HIV-Syphilis Assay, Chagas 
STAT-PAK®Assay, DPP® VetTB Assay.  Although this is not an exhaustive list, it 
outlines the variety of clinical uses for LFDs in both a human and agricultural clinical 
setting.   
The use of LFDs in agricultural settings is already widespread.  They are used 
routinely in the dairy industry for the monitoring of reproductive cycles, to produce 
an efficient reproductive regime within a herd and to maximise the returns within 
the business (Nebel et al., 1987).  For example, the LFDs are used for the detection 
of progesterone levels in cow’s milk, allowing for the monitoring of the oestrus 
status and to detect early non-pregnant animals.  Along with the human pregnancy 
test, this also demonstrates the use of a clinical sample, in this case milk, requiring 
no preliminary sample preparation (Samsonova et al., 2015).  Most LFDs for use 
outside of laboratories use antibodies which recognise different epitopes on a 
target protein for its detection with a colourimetric change.  The colourimetric 
change is provided by the surface plasmon resonance of the gold colloid which is 
conjugated to one of the antibodies (Verma et al., 2015) as detailed in section 
1.5.1. 
Currently, the use of LFDs for the detection of viruses is mainly focussed upon the 
detection of antibodies raised against the virus during infection.  This provides a 
result which does not necessarily confirm current infection, rather a level of 
immunity to the virus and, therefore, the detection of viral proteins directly is a 
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more advantageous method to employ in a LFD, particularly for the detection of 
economically relevant infectious diseases (Corstjens et al., 2012).  
The use of Affimers as alternative reagents to antibodies in the LFD proposed in 
this study is a novel application of these non-antibody binding proteins.  Affimers 
are a relatively new advancement in the area of non-antibody binding proteins and 
so their documented uses are limited but promising in areas such as label free 
biosensing, cellular imaging techniques and detection of small organic compounds 
(Raina et al., 2015; Bedford et al., 2017; Arrata et al., 2017; Wang et al., 2017; 
Koutsoumpeli et al., 2017).  They are extremely small in comparison to their 
antibody counterparts, approximately 12 kDa versus 150 kDa, and have so far been 
adopted in a number of wide ranging studies including, additive reagents for 
nanomaterial fabrication and inhibition of protein-protein interactions (Rawlings et 
al., 2015; Kyle et al., 2015).  Work is also ongoing to investigate the use of these 
reagents for the detection of pathogens directly, as well as the detection of a 
number of medically important proteins, a number of these are discussed in a 
recent paper published in eLife as well as the use of Affimers to investigate 
intracellular signalling, inhibition of extracellular receptor function, modulation of 
ion channels and in vivo and fixed cell imaging, including super resolution imaging 
(Tiede et al., 2017). 
The requirement for non-antibody binding proteins is centred on the improvement 
upon the currently available antibody alternatives, the main requirement being the 
limitation of the use of animals in the production of these antibody reagents.  Non-
antibody binding proteins can be produced at similar concentrations seen for 
conventional in vitro antibody production, 100 mg/L antibody can be achieved 
using cell culture technology (Kunert and Reinhart, 2016), using recombinant 
protein expression systems, Affimers can be expressed and purified to greater than 
95% purity with a yield of 83.3 mg/L on average (Tiede et al., 2017).  The 
production of any protein in a bacterial expression system is more economical than 
mammalian expression systems based on comparable reagent and consumable 
costs (Verma et al., 1998).  The removal of the use of animals in the process of 
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antibody production through the use of recombinant expression systems is also a 
more ethical approach to reagent manufacture.  
The primary method for producing Affimers is the use of phage display techniques 
before cloning the relevant protein sequences into bacterial protein expression 
vectors enabling expression of the reagents as required.  This reduces 
manufacturing costs and times relative to antibody production (Skerra, 2007).  The 
main functional improvements made when considering the design of non-antibody 
binding proteins is to reduce or eliminate the number of cysteine residues, this 
simplifies the basic structure of the Affimer and ensures there are no homodimer 
formations.  Furthermore, it also increases the binding affinity to the target 
molecule as well as decreasing the size of the binding protein, reducing the 
redundancy seen in many antibodies.  This is because only a small region is 
involved in the binding with the target protein relative to the size of the antibody 
(Justino et al., 2015; Löfblom et al., 2010).  The reduction in size of the binding 
protein also lends the reagents to be used in different molecular biology 
applications where conventional antibody size poses a direct challenge, for 
example as detection reagents in super resolution microscopy.  This has been 
explored with the use of nanobodies labelled with organic dyes targeting GFP 
tagged proteins (Ries et al., 2012).  The production of a non-antibody reagent for 
the use in LFDs should result in an improvement in time-to-result as well as 
sensitivity of the test, as a direct result of the reagent being able to move through 
the device components at a faster flow rate.  
This chapter discusses the production of target PRRSV N proteins and subsequently 
Affimer reagents raised against them to be used in the development of a LFD 
capable of detecting the viral N protein in clinical samples.  First, recombinant 
PRRSV N proteins were produced using bacterial expression vectors and purified 
using chromatography techniques.  Second, Affimers specific for the PRRSV target 
protein were identified using phage display techniques.  This approach was used 
for two distinct N proteins, from a highly pathogenic and a low pathogenic strain of 
PRRSV, with a view to producing a LFD which could distinguish between the two 
viral strains.   
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3.2. Expression of his8-tagged recombinant low 
pathogenic PRRSV N protein 
Initially, a low pathogenic strain of the PRRSV N protein (NLP) was used to perform 
Affimer screening.  This protein was expressed from a pTriEx 1.1 vector kindly 
provided by Prof Julian Hiscox (University of Liverpool).  The his8-tagged 
recombinant N protein was expressed in BL21(DE3)pLysS cells for four hours using 
IPTG induction at 37 °C.  Samples were taken hourly to monitor protein expression 
by SDS-PAGE and Coomassie blue staining (figure 3.1).  The viral protein was 
expressed well over a four hour period and so the four hour time point was chosen 
for future expression experiments.  The recombinant protein was purified from the 
bacterial cell lysate using nickel ion affinity chromatography with fractions analysed 
by SDS-PAGE and Coomassie blue staining (figure 3.2).  Analysis of each elution 
showed that the protein from the 240 mM imidazole elution contained the fewest 
bacterial contaminants and was therefore taken forward for the Affimer screening 
without further purification steps. 
 
 
Figure 3.1 Analysis of bacterially expressed NLP-his8.  A four hour time course of induction was 
performed to determine the optimum time of expression of the target protein in BL21(DE3)pLysS 
cells.  Bacteria were induced with IPTG after reaching OD 0.4 (as well as an uninduced control) and 
samples taken hourly for four hours (hpi: hours post induction).  Samples were analysed by SDS-
PAGE and Coomassie blue staining.  NLP-his8 is expressed well over four hours as indicated by the 
arrow at 15 kDa.  The protein was not expressed in the uninduced sample.    
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Figure 3.2 Purification of NLP-his8 from bacterial lysate.  The PRRSV N protein was solubilised and 
purified from bacterial cell lysate using nickel ion affinity chromatography.  The N protein was 
eluted using an increasing concentration of imidazole, 80-400 mM.  The N protein was eluted in the 
240, 320 and 400 mM elution fractions as indicated by the arrow with the 240 mM elution fraction 
being taken forward for use in further experiments.  
 
3.3. Affimer screening against his8-tagged recombinant 
low pathogenic PRRSV N protein 
Affimer screening was performed using biotinylated NLP-his8 protein to identify 
specific binding Affimers to be taken forward as reagents for the LFD.  Following 
three rounds of phage display panning using the phage library (data not shown), 24 
potential binders were further characterised to investigate their binding to the 
target protein.  Firstly, they were tested for their ability to bind to the target 
protein immobilised onto a streptavidin coated plate in a phage ELISA.  Each target 
Affimer was expressed on the pIII minor coat protein of bacteriophage M13, as in 
the screening rounds and incubated with the target protein or an empty well of the 
plate in order to identify any non-specific binders.  Detection of bound phage was 
performed using an HRP conjugated anti-fd bacteriophage antibody and TMB 
visualisation, resulting in a characteristic blue colour change when phage is present 
(figure 3.3a).  The visualisation of the ELISA plate (figure 3.3a) shows that the 24 
binders identified in this screen bind to NLP-his8 and not to the streptavidin plate.  
This was confirmed when the A600 absorbance readings for the plate were also 
measured (figure 3.3b).   
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Figure 3.3 Affimer Screen against NLP-his8 using phage display. (a) Following three phage display 
panning rounds, 24 colonies were picked and a phage ELISA performed.  Each colony represented 
one Affimer and these were screened against the target or against an empty control well.  Phage 
binding was probed using anti-Fd bacteriophage-HRP antibody and visualisation with TMB.  All 
colonies picked for phage ELISA showed binding to the target protein in preference to the control 
wells.  (b)  Absorbance measurements were taken of the wells and show the phage binding to the 
target protein in preference to the blank control wells. 
 
Upon sequencing of these 24 binders, five unique binders were identified, where 
the two variable loop regions contained the unique sequences for each Affimer 
(table 3.1).   
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Table 3.1 Loop sequences of unique binders to NLP-his8 
Affimer Loop 1 Loop 2 Number of 
appearances 
1 V Q L V D L T W L  N H L L E N P F D 19 
15 W E P L E Q Q H R L T V I N Y N I L  1 
16 W I A E E P G V V R Y L M G H W M W 2 
17 H Y Y G Q F L Y H  R K N L L Q E F K 1 
23 H D P F E M P V Q L F I Y G R H M L 1 
 
The Affimers that were found to contain unique loop sequences were 1, 15, 16, 17 
and 23 and the number of times they were identified are shown in table 3.1.  
Affimer 1 was identified a total of 19 times within the pool of 24 Affimers 
sequenced in this case, suggesting that this was a highly specific binder with a 
strong binding capability.  The three remaining Affimers appear in the sequencing 
data once and Affimer 16 appears twice which may suggest lower binding 
capability for each of these Affimers, although this is not investigated in this study.         
3.4. Cloning of N protein from a high pathogenic strain of 
the virus into bacterial expression vectors 
A TArget Clone vector encoding the gene for the N protein from a high pathogenic 
strain (NHP) of PRRSV was obtained from Dr Cheng-bao Wang (Northwest A&F 
University, China).  Cloning into a variety of bacterial expression vectors was 
performed in order to improve upon the protein expression levels seen with the 
expression of NLP from the pTriEx 1.1 vector, used in the previously discussed 
experiments (section 3.2).  PCR primers designed to incorporate BamHI and NotI 
restriction sites were used in the amplification of the NHP gene from the TArget 
Clone vector.  The PCR product is shown in figure 3.4, with a product of 372 bp, as 
expected.  
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Figure 3.4 PCR amplification of NHP gene.  The gene encoding the N protein from a highly 
pathogenic strain of PRRSV was PCR amplified from a TArget Clone vector kindly provided by Dr 
Cheng-bao Wang.  The PCR product was analysed by agarose gel electrophoresis a product of 
approximately 400 bp produced as indicated by the arrow (gene size: 372 bp).    
 
The vectors chosen for these expression trials were pTriEx 1.1 (initially used for 
expression of NLP), pGEX6p1, pET28a and pET28a-SUMO in order to utilise a 
number of different epitope tagging methods and promoters.  The successful 
cloning of this gene into these expression vectors is shown in figure 3.5 by 
diagnostic digests.  Successful clones were confirmed by sequencing analysis (GATC 
Biotech AG, data not shown).   
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Figure 3.5 Cloning NHP gene into bacterial expression vectors.  The gene encoding NHP was cloned 
into (a) pGEX-6p-1 (b) pTriEx 1.1, (c) pET28a and (d) pET28a-SUMO bacterial expression vectors 
using restriction enzymes BamHI and NotI.  Digests were performed using these enzymes to confirm 
the presence of the DNA insert of the correct size as indicated by the arrows (372 bp) before 
sequencing was performed to confirm the correct sequence.   
 
3.5. Expression of NHP-his from bacterial expression 
vectors 
Expression trials using the different expression vectors for this protein were 
undertaken in parallel.  The pTriEx 1.1 vector was chosen as it had previously 
resulted in the successful expression of NLP.  However, when expression was 
carried out using the same conditions, four hour induction and expression with 
IPTG, there was no detectable expression of NHP-his8 as shown in figure 3.6. 
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Figure 3.6 Expression of NHP-his8 from pTriEx 1.1 vector.  A four hour time course of induction was 
performed to determine the optimum time of expression of the NHP in BL21(DE3)pLysS cells.  
Bacteria was induced with IPTG after reaching OD 0.4 (as well as an uninduced control) and samples 
taken hourly for four hours.  Samples were analysed by SDS-PAGE and Coomassie blue staining.  The 
protein was not expressed in the induced time course with the bacterial lysate showing comparable 
banding patterns to the uninduced control.  There is no increase in protein expression of a protein 
at the expected molecular weight, 15 kDa. (hpi: hours post induction).        
 
pGEX-6p-1 was chosen in an attempt to provide an epitope tag that would aid 
solubility of the expressed protein.  It was hypothesised that expressing the viral 
protein as a fusion with a highly soluble protein would result in a higher level of 
expression as a result of the increased transcription and translation of the N 
terminal GST-tag.  The expression trials were carried out for four hours with IPTG 
induction at 37 °C and expression was analysed by SDS-PAGE and Coomassie blue 
staining (figure 3.7).  With the use of this vector, GST-NHP was seen to express well 
over the four hour time course, with four hours providing sufficient protein 
expression for Affimer screening.   
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Figure 3.7 Expression of GST-NHP from pGEX-6p-1 vector.  A four hour time course of induction 
was performed to determine the optimum time of expression of GST-NHP in BL21(DE3)pLysS cells.  
Bacteria were induced with IPTG after reaching OD 0.4 and samples taken hourly over four hours.  
Samples were analysed by SDS-PAGE and Coomassie blue staining.  The GST-NHP protein was 
expressed in the induced time course, as indicated by the arrow, at the expected molecular weight, 
39 kDa, well over the four hours (hpi: hours post induction).  
 
Following the four hour time course, the protein was purified from the bacterial 
cell lysate using glutathione-based affinity purification shown in figure 3.8.  The 
samples taken over the purification steps include the soluble and insoluble 
fractions, as well as 5 elution fractions.  The GST-NHP protein was found to be 
contained within the insoluble protein fraction and therefore upon purification, 
there was no soluble protein eluted (figure 3.8a).  This was compared to the 
purification of GST alone, which although was expressed at a low level in this 
experiment, was seen to be expressed in the soluble fraction of the bacteria and 
subsequently eluted across the 5 elution fractions (figure 3.8a).  Additional 
optimisation of this protein expression was carried out with expression at 30⁰C 
overnight followed by purification (figure 3.8b), however, although more protein 
appeared to be expressed, this remained insoluble and therefore was not purified 
in the glutathione elutions.  
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Figure 3.8 Expression trials of GST and GST labelled NHP and analysis by SDS-PAGE and Coomassie 
blue staining. (a) Recombinant GST and GST-NHP were expressed for 4 hours at 37⁰C in 
BL21(DE3)pLysS cells and purified using Glutathione Sepharose™ beads.  GST was expressed and 
eluted at 26 kDa.  Recombinant GST-NHP was expressed at 39 kDa, however, it appears that the 
protein is insoluble and was therefore not purified. (b) Recombinant GST-NHP was then expressed 
overnight at 30⁰C in BL21(DE3)pLysS cells and again purified using Glutathione Sepharose™ beads, 
however, again GST-NHP was expressed in the insoluble fraction.   
 
Optimisation of protein expression was next undertaken in order to improve the 
solubility of GST-NHP.  This was carried out using a number of different bacterial 
expression strains in parallel (figure 3.9).  BL21-Gold(DE3), BL21-CodonPlus-RIL and 
BL21-CodonPlus-RP cells were chosen in the first instance.  BL21-Gold(DE3) were 
chosen to try to increase protein expression levels to see if this would increase the 
amount of protein found in the soluble fraction, however, across the four hour 
expression time course, protein expression was seen to be lower than that of the 
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BL21(DE3)pLysS cells previously used.  BL21-CodonPlus-RIL cells were used to 
increase protein expression due to the encoding of additional tRNAs and to try to 
increase soluble protein levels as a result of this increased protein expression.  
Unlike BL21-Gold(DE3) cells, BL21-CodonPlus-RIL cells showed an increase in 
protein expression levels across the four hour time course, however this was still at 
reduced levels compared with the BL21-pLysS cells.  BL21-CodonPlus-RP cells 
showed good expression of GST-NHP with the highest expression being seen two 
hours post IPTG induction.      
 
Figure 3.9 Optimising protein solubility using different E.coli strains.  GST-NHP was expressed in 
different strains of E.coli in order to determine the ideal strain for the expression of soluble protein 
(as indicated by the arrows).  BL21-Gold(DE3) cells showed poor expression of the recombinant GST-
NHP protein across the four hour time course.  BL21-CodonPlus-RIL cells showed an improved 
expression of the recombinant protein over the four hour time course compared to the BL21-
Gold(DE3) cells. BL21-CodonPlus-RP cells showed the best expression two hours post induction of 
the recombinant protein. (hpi: hours post induction). 
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Figure 3.10 Analysis of soluble and insoluble fractions of bacterial lysate expressing GST-NHP in 
various cell types.  Following lysis and sonication of the E.coli expressing GST-NHP, the soluble and 
insoluble fractions were taken and analysed for protein content using SDS-PAGE and Coomassie 
blue staining.  For all of the cell types the majority of the recombinant protein is present in the 
insoluble fractions as indicated by the arrow.  
 
Following the four hour expression time courses, the bacteria were harvested and 
lysed before the insoluble and soluble fractions were sampled and analysed by 
SDS-PAGE and Coomassie blue staining as shown in figure 3.10.   
GST-NHP was present predominantly in the insoluble fraction of all of the cell lines 
used in this experiment and could therefore not be purified directly at sufficient 
concentrations.  BL21(DE3)pLysS cells contained the most insoluble protein, with 
BL21-CodonPlus-RIL cells contained soluble and insoluble GST-NHP.  The 
subsequent purification of GST-NHP from this expression system resulted in 
negligible protein concentration (data not shown) and this was not considered a 
viable expression system for this protein.    
To further investigate the solubility problems with this protein, pET28a was chosen 
to provide expression under the control of a T7 promoter with a his6-epitope tag.  A 
three hour time course was taken at 37 °C to determine the optimal time for 
maximum protein expression within this system.  As shown in figure 3.11, samples 
were taken hourly before and after induction and analysed by SDS-PAGE and 
Coomassie blue staining.  An increase in expression of NHP-his6 over the three hour 
time course was observed although not to the same extent as seen with a GST-tag. 
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Figure 3.11 Expression of NHP-his6 from pET28a.  A three hour time course of induction was 
performed to determine the optimum time of expression of NHP-his6 in BL21(DE3)pLysS cells.  
Bacteria was induced with IPTG after reaching OD 0.4 and samples taken hourly for three hours.  
Samples were analysed by SDS-PAGE and Coomassie blue staining.  The NHP-his6 protein was 
expressed in the induced time course at the expected molecular weight, 15 kDa, over the three 
hours as indicated by the arrow. (hpi: hours post  induction). 
 
The three hour time point was chosen for maximum expression for this protein and 
the bacteria were lysed and the his6-tagged NHP protein purified using nickel ion 
affinity chromatography.  Samples were taken at a number of purification stages to 
determine the location of the recombinant protein.  Upon analysis with SDS-PAGE 
and Coomassie blue staining (figure 3.12), similar to GST-NHP, it was found 
primarily in the insoluble protein fraction.  It was therefore not possible to purify 
sufficient protein, although protein was shown to elute in the 240-400 mM 
imidazole elution fractions.   
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Figure 3.12 Purification of NHP-his6 from pET28a vector.  NHP-his6 was solubilised and purified 
from bacterial cell lysate using nickel ion affinity chromatography.  NHP-his6 was eluted using an 
increasing concentration of imidazole, 80-400 mM.  The protein was eluted in the 240, 320 and 400 
mM elution fractions as indicated by the arrow. 
 
The final vector investigated in the optimisation of NHP expression was pET28a-
SUMO.  Like pGEX-6p-1, pET28a-SUMO was chosen to provide an N terminal his-
SUMO-tag which should improve protein solubility, a consistant challenge with the 
expression of this protein.  The same time course of four hours was undertaken to 
express the protein from pET28a-SUMO in BL21(DE3)pLysS cells at 37 °C.  The 
recombinant fusion protein was shown to be expressed over the time course at 
around 25 kDa, as expected, when compared to the uninduced control expression 
(figure 3.13).   
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Figure 3.13 Expression of SUMO-NHP from pET28a-SUMO.  A four hour time course of induction 
was performed to determine the optimum time of expression of SUMO-NHP in BL21(DE3)pLysS 
cells.  Bacteria was induced with IPTG after reaching OD 0.4 and samples taken hourly for four hours 
(as well as an uninduced control).  Samples were analysed by SDS-PAGE and Coomassie blue 
staining.  The protein was expressed in the induced time course at the expected molecular weight, 
25 kDa, over the four hours as indicated by the arrow. (hpi: hours post induction). 
 
Expression levels were lower than those seen during the expression of GST-NHP, 
however, the SUMO-tagged protein was expressed in the soluble fraction of the 
bacteria and therefore allowed SUMO-NHP to be easily purified using nickel affinity 
chromatography using the C terminal his6-tag (figure 3.14).  The eluted protein was 
found in the 240, 320 and 400 mM imidazole elutions, with the 320 and 400 mM 
elutions providing the purest and highest concentration elutions.  Further 
expression trials were carried out (data not shown) resulting in a higher level of 
protein expression if SUMO-NHP was expressed at 30 °C overnight and so this 
condition was used for future expression and purification experiments.  
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Figure 3.14 Purification of SUMO-NHP from pET28a-SUMO vector.  The protein was purified from 
bacterial cell lysate using nickel ion affinity chromatography and analysed by SDS-PAGE and 
Coomassie blue staining.  The protein was eluted using increasing concentrations of imidazole, 80-
400 mM and was eluted in the 240, 320 and 400 mM elution fractions as indicated by the arrow.  
The 300 and 400 mM fractions were taken forward for further experiments.  
 
3.6. Cloning of N protein from the PRRSV low pathogenic 
strain into pET28a-SUMO expression vector 
Following the successful expression and purification of SUMO-NHP, it was decided 
to enter a similarly tagged NLP protein into expression trials in order to increase 
the number of Affimer reagents raised against this target protein.  Following 
subsequent sequence analysis, a large translated amino acid excess (approximately 
87 bp) from the pTriEx 1.1 plasmid was shown to be present in the NLP-his8 
protein.  This originated from the use of an upstream start codon resulting in the 
addition of the 29 amino acids at the N terminus of the PRRSV N protein.  As such, 
it was not known if the Affimers already raised (section 3.3) were binding to the 
target protein or the excess amino acids.  The use of a SUMO-tagged protein 
allowed for the identification of those Affimers which only bound to the target 
protein with the use of a negative SUMO screen to eliminate any SUMO binders.   
Therefore, NLP was PCR amplified, using primers designed to contain BamHI and 
NotI restriction sites, producing a product of approximately 370 bp, from the pTriEx 
1.1 vector (figure 3.15a), and cloned into pET28a-SUMO.  Insertion of the gene was 
confirmed using restriction enzyme digestion with BamHI and NotI (figure 3.15b) 
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and by sequencing to confirm the correct gene sequence (GATC Biotech AG, data 
not shown).       
 
Figure 3.15 PCR amplification of NLP from pTriEx 1.1 vector and diagnostic digest confirming 
presence of target gene in expression plasmid. (a)  The gene encoding the N protein from the low 
pathogenic strain of PRRSV was PCR amplified from the pTriEx 1.1 plasmid previously used in this 
study (kindly provided by Prof Hiscox).  The PCR product was analysed by agarose gel 
electrophoresis resulting in an approximately 400 bp product as indicated by the arrow.   (b) 
Following ligation into pET28a-SUMO, successful gene insertion was confirmed by restriction digest 
using BamHI and NotI, an insert of the correct size was observed as indicated by the arrow.  
Sequencing was performed to ensure there were no mutations in the viral gene DNA using a T7 
promoter primer.  
 
The pET28a-SUMO-NLP vector was transformed into E.coli strain BL21(DE3)pLysS.  
Protein expression was induced overnight with IPTG at 30 °C to maximise 
expressed protein levels, as shown with SUMO-NHP.  During the subsequent 
purification process, samples were taken at all points and analysed by SDS-PAGE 
and Coomassie blue staining (figure 3.16).  SUMO-NLP was shown to express well 
overnight and the nickel ion affinity purification protocol allowed elution in 
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increasing concentrations of imidazole.  SUMO-NLP was shown to elute in 
imidazole concentrations of 240 and 320 mM, similar conditions to the SUMO-NHP 
fusion protein.  The 240 mM fraction was used for further experiments as this 
produced the cleanest fraction with the absence of breakdown products and 
contaminants which were present in a number of the other elution fractions.  No 
further purification steps were undertaken.  
 
Figure 3.16 Purification of SUMO-NLP.  SUMO-NLP was expressed overnight at 30 ⁰C in 
BL21(DE3)pLysS cells using IPTG induction.  The protein was solubilised and purified using nickel ion 
affinity chromatography and fractions were analysed using SDS-PAGE and Coomassie blue staining.  
Elutions were performed with increasing concentrations of imidazole, 80-400 mM as indicated by 
the arrow.  SUMO-NLP was eluted in elutions 3 and 4 with elution 3 used for further experiments.  
 
3.7. Affimer screening against recombinant PRRSV N 
proteins 
Both purified recombinant fusion proteins, SUMO-NHP and SUMO-NLP, were then 
entered into Affimer screening to identify Affimers that were able to recognise the 
viral proteins.  In order for the screening to eliminate the possibility of the Affimers 
binding to the SUMO-tag, the screens were performed in the presence of 
recombinantly expressed SUMO, known as a negative screen.  
Screening of target proteins with the Affimer library was carried out in 
collaboration with the Bioscreening Technology Group at the University of Leeds 
using phage display techniques.   
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Biotinylation of the target recombinant proteins was required for the 
immobilisation of these proteins throughout the screening process. Biotinylation 
was carried out using EZ-Link-NHS-SS-Biotin to biotinylate amines within the target 
protein. Successful biotinylation of target proteins was investigated by both SDS-
PAGE followed by western blotting and by ELISA.  Both of these assays showed 
biotinylation was successful for SUMO-NHP, SUMO-NLP and SUMO (figure 3.17). 
The screening of both target recombinant fusion PRRSV N proteins was carried out 
in the presence of excess SUMO protein which acted as a negative screen and 
removed the Affimers which were specific to the SUMO-tag and not for the target 
protein.  This negative screen was carried out at all stages and all subsequent 
experiments were performed with a SUMO control to further confirm that the 
Affimers were specific for the target PRRSV proteins and not the SUMO-tag.   
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Figure 3.17 Biotinylation of target proteins for Affimer screening.  Target proteins were 
biotinylated using EZ-Link-NHS-SS-Biotin and successful labelling was determined using western 
blotting (a)  Biotinylated protein can be seen for SUMO-NLP, SUMO and SUMO-NHP as indicated by 
the arrows (the higher molecular weight bands indicated are protein dimers).  This was further 
confirmed using ELISA (b-c) where a dilution series was performed and the biotinylated proteins 
detected using streptavidin-HRP.  The absorbance readings show a suitable level of biotinylation of 
all target proteins.  
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3.8. Affimer screening against SUMO-NHP 
Following three screening rounds against SUMO-NHP, a selection of binders were 
taken forward for further analysis to confirm specificity and binding to the target 
protein.  In this case 48 binders, and sequence identification was performed as 
previously described (section 3.3 NLP-his8 screen).  The phage ELISA (figure 3.18a) 
was performed in either the presence of target protein or SUMO immobilised to 
the plate and any Affimers which reacted in both plates could be discounted from 
further investigation due to binding to the SUMO-tag.  Of the 48 binders chosen 
from this screen, four Affimers were shown to bind to the SUMO-tag and a number 
of Affimers were unable to bind to the target.  This was confirmed by analysing 
A600 measurements of the wells (figure 3.18b).   
 
Figure 3.18 Affimer screen against SUMO-NHP.  (a) Following three phage display panning rounds, 
48 colonies were picked and a phage ELISA performed.  Each colony represented one Affimer and 
these were screened against the target or against an empty control well.  Phage binding was probed 
using anti-Fd bacteriophage-HRP antibody and visualisation with TMB.  Four colonies picked for 
phage ELISA showed binding to the control SUMO wells and were discounted from further 
investigation.  (b)  Absorbance measurements were taken of the wells and show the phage binding 
to the target protein in preference to the blank control wells. An arbitrary cut off was used to 
determine which Affimers would undergo sequence analysis.  
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The ELISA assay identified a number of Affimers which could be eliminated from 
the study as well as the Affimers which required further investigation (31 were 
successfully sequenced).  Affimers B8, B10, B11 and D2 were discounted as they 
appeared to bind to the SUMO-tag, Affimers A1, A3, A4, A6, B1, B4, B12, C1, C5, C6, 
D11 and D12 were also eliminated as they did not appear to bind to the target well 
in the phage ELISA.  The remaining Affimers were analysed for loop sequence 
identity and to determine the number of unique binders which were identified as 
shown in table 2 (GATC Biotech AG).  
 
Table 3.2 Loop sequences of unique binders to SUMO-NHP. 
Affimer Loop 1 Loop 2 Number of 
appearances 
A2 L E V N M M W V D P G P Y P Q E F S 1 
A5 V E I E H M W E D F A E N H S W P I 7 
A7 I E E W D M W M D D N R P F S R V E 8 
A10 L E V N M M W D D Q P D V E T L M Y 1 
A11 I E I N E M W D D H R S P T H A V K 2 
B6 W E E Y Y M W F D N D W F N N Q W Y 6 
B7 F E M I Y M W N D P E R D Y R S T W 2 
C4 F E E T F M W F D N G D S S Y E T F 1 
C12 V E L D G M W D D G T E T L T D K R 1 
D7 V Q L V D L T W L N H L L E N P F D 1 
D9 I E L T N M W D D R V W N S E N A N 1 
 
Like the Affimers which were identified against the his6-tagged NLP protein, there 
appears to be sequence similarity between the eight unique SUMO-NHP Affimers.  
This is especially evident in the first variable loop region where there is a conserved 
MWXD, where X is either a hydrophobic (valine, methionine) or negatively charged 
amino acid (glutamic acid, aspartic acid). 
3.9. Affimer screening against SUMO-NLP 
In order to increase the number of Affimers available for NLP, the SUMO fusion 
protein was screened using the second pan phage from the screen which was 
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carried out against the his6-tagged NLP protein.  This allowed for an already 
enriched library to be screened with the intention of eliminating any Affimers 
which bound to the SUMO-tag.  One panning round was performed and 48 binders 
were chosen for further investigation.  These were entered into a phage ELISA and 
presented to either SUMO-NLP or SUMO immobilised onto a plate.  The phage 
ELISA identified 47 binders which appeared to bind to the target and not the 
SUMO-tag (figure 3.19).  The ELISA allowed binder B8 to be discounted as a non-
binder to either the target protein or the SUMO-tag.  The high number of binders 
identified as positive hits was expected due to the enriched nature of the initial 
library used in this screen.  
 
Figure 3.19 Affimer screen against SUMO-NLP.  (a) Following three phage display panning rounds, 
48 colonies were picked and a phage ELISA performed.  Each colony represented one Affimer and 
these were screened against the target or against an empty control well.  Phage binding was probed 
using anti-Fd bacteriophage-HRP antibody and visualisation with TMB. (b)  Absorbance 
measurements showed the phage binding to the target protein in preference to the blank control 
wells.  
 
As the phage ELISA suggested that the Affimers bound well to the target protein, 
due to the high absorbance readings it was not possible to determine the Affimers 
with increased specificity.  Therefore, all 47 Affimers underwent sequence analysis 
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to identify any unique binders with five Affimers identified as unique, the 
remaining 36 Affimers sequenced had the same unique sequences as those 
identified in the original screen.  The loop regions of these additional five binders 
are shown in table 3.3.    
Table 3.3 Loop sequences of unique binders to SUMO-NLP  
Affimer Loop 1 Loop 2 Number of 
appearances 
SUMO-NLP A8 P Y S Y L W H F D G D L Y I L P L I 1 
SUMO-NLP B3 A E W L P I Y E Q D Y S K K P W M P 1 
SUMO-NLP B7 H Y Y G Q F L Y H R K N L L Q E F K 4 
SUMO-NLP D9 V Q L V D L T W L  N H L L E N P F D 4 
SUMO-NLP D12 F Y A D W L N H F Q H E S G R F M N 1 
 
3.10. Discussion 
3.10.1. Protein expression and purification 
In this chapter a number of expression and purification challenges were identified 
with both of the target N proteins used.  Expression levels and solubility of the 
expressed proteins was investigated using recombinant tags as well as a range of 
expression systems and conditions.   
Initially, five Affimers were identified as binding proteins against his-NLP.  However, 
further analysis of this protein revealed that there was a 20 amino acid excess at 
the C terminus before the His tag, derived from the cloning method used although 
it was possible to determine if the Affimers were binding to this region by returning 
to the panning stages, it was not known if this additional sequence would cause a 
conformational change to the protein.  If this was the case, the Affimers may have 
been identified due to conformational binding to a novel structure not found in the 
wild type protein.  As a result of this, the NLP and NHP proteins were cloned using a 
number of epitope tags and promoter sequences. 
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The most successful expression system used for NHP was the Tac promoter in 
conjunction with a GST fusion tag from the pGEX6p1 vector.  However, this 
resulted in a high level of insoluble protein expression using BL21(DE3)pLysS cells at 
37°C for four hours.  Protein production may have been too rapid and the resulting 
recombinant protein being incorrectly folded in the E.coli.  Expression of this fusion 
protein was undertaken in different E.coli strains, BL21-Gold(DE3), BL21-
CodonPlus-RIL and BL21-CodonPlus-RP cells, to try to improve protein solubility.  
The properties of these bacterial strains combined with the highly soluble GST tag 
was hypothesised to increase the total recombinant protein levels, increasing the 
percentage of the total soluble recombinant protein (Esposito and Chatterjee, 
2006).  GST fusion has been used in the improvement of protein solubility since its 
introduction as an expression system in 1988 (Smith and Johnson, 1988) and has 
been used to improve solubility and expression of Hantavirus N protein (Mir and 
Panganiban, 2004). 
 BL21-Gold(DE3) cells are able to express recombinant proteins at high levels, and 
were chosen to attempt to improve the percentage of soluble N protein.  However, 
the protein levels were lower than that observed using BL21(DE3)pLysS cells.  BL21-
CodonPlus-RIL cells contain extra genes encoding for the tRNAs of argU (AGA, 
AGG), ileY (AUA), leuW (CUA) which are often poorly expressed in alternative BL21 
strains where they are a limiting factor in the translation of proteins.  The use of 
this strain of bacteria showed protein expression of a similar level to 
BL21(DE3)pLysS cells.  The NHP protein sequence is approximately 18% 
arginine/isoleucine/leucine and so it was expected that this approach may  
increase the protein expression compared to other BL21 strains.  BL21-CodonPlus-
RP cells encode additional genes for argU (AGA, AGG), proL (CCC), the protein 
sequence for NHP is approximately 15% arginine/proline residues and the 
expression of the recombinant protein in these cells was comparable to 
BL21(DE3)pLysS and BL21-CodonPlus-RIL cells and again, higher than the BL21-
Gold(DE3) cells.  The presence of GST-NHP in the soluble fractions of some of these 
E.coli strains may suggest that further optimisation of the conditions may improve 
the ratio of soluble to insoluble protein, however, upon purification the protein 
could not be obtained at high enough concentrations for requirements. 
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The addition of a SUMO-tag has shown to increase solubility and protein 
expression in a number of expression systems both in prokaryotic and eukaryotic 
systems  (Lee et al. 2008; Panavas et al. 2009; Wang et al. 2010).  SUMO fusion 
have also been used in the production of virus like particles, for example FMDV 
(Lee et al., 2009), outlining the versatility of this system.  However, solubility 
challenges continued for both NHP and NLP when using the SUMO tag.   
The relative expression levels of the SUMO-tagged recombinant protein was lower 
compared to the GST tagged recombinant protein, however, the expression of 
SUMO-NLP and SUMO-NHP resulted in the expression of a highly soluble protein.  
Unfortunately, following cleavage of the SUMO-tag under dialysis conditions, the 
viral proteins were no longer soluble. Optim®1000 analysis was performed 
investigate the solubility of the precipitated protein (data not shown) to determine 
dialysis conditions for cleavage of the SUMO-tag from the protein.  A selection of 
the most favourable dialysis conditions were performed (data not shown) however 
the cleaved protein remained insoluble.  Future experiments were performed 
without cleavage of the SUMO-tag.  Whilst not ideal, numerous studies have shown 
that a SUMO-tag does not adversely affect protein function and can be used to 
dramatically improve the solubility, provide protection from proteolytic 
degradation and improve protein expression due to enhance mRNA stability and 
mRNA copy number (Butt et al. 2005; Malakhov et al. 2004).  A number of viral N 
proteins have been successfully expressed with this modification for example, Rift 
valley fever virus N protein (Raymond et al., 2010), SARS coronavirus N protein 
(Zuo et al., 2005) and Crimean-Congo haemorrhagic fever virus N protein (Carter et 
al., 2012).   
3.10.2. Affimer screening and analysis 
The final pool of Affimers raised against the two SUMO-tagged recombinant 
proteins, as well as those raised against the his6-tagged NLP protein, were analysed 
for sequence similarity.  Interestingly, it is possible to begin to infer properties of 
these Affimers from this information combined with the ELISA data before any 
further experimental analysis by evaluating the number of times each Affimer 
appeared in the sequencing data and the absorption reading from the ELISA plate.  
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The appearance of Affimer 1 raised against NLP-his6 19 times out of the 24 Affimers 
sequenced, suggests this may be the strongest binder to the target protein and 
that the remaining four Affimers against this target have a lower binding capacity 
than Affimer 1 although this requires further biophysical analysis in order to 
determine the Kd values for these interactions.  It is also possible that Affimer 1 
was expressed more efficiently by the phage than the other Affimers meaning that 
there was a higher concentration of this phage within the sample which correlates 
with a higher number of hits to the target protein.  It is not possible to determine 
this, however, without performing phage titring.  Affimer 17 does not seem to bind 
as strongly to the target as the other Affimers which have much higher absorbance 
readings although this could be investigated in further experiments as it may also 
be due poor expression of Affimer 17 bateriophage in comparison to the other 
Affimers.  The binding of the Affimers in the context of a bacteriophage may result 
in a skewed result for binding due to steric hindrance provided by the bulky 
bacteriophage.  Therefore, future experiments used purified Affimers expressed 
recombinantly in E.coli in order to eliminate the presence of the large 
bacteriophage complex. 
The Affimers raised against SUMO-NHP show a similarity in the first variable loop 
region where there is a conserved MWXD suggesting this is a vital interaction 
region with the target protein.  The Affimers may bind at the same epitope, 
although this is not confirmed by epitope mapping.   The Affimers appear to have 
variable binding abilities to each other in the phage ELISA despite this similarity in 
amino acid sequence, this may suggest that the binding may also be conformation 
dependent.  However, the binding kinetics have not been investigated for these 
Affimers. 
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4. Determining the specificity of the Affimer 
reagents to the target proteins 
4.1. Introduction 
Lateral flow devices (LFDs) provide a reliable and specific test result in a short time 
scale and can be easily used in the field, removing the requirement for extensive 
laboratory testing of clinical samples.  The most important feature of reagents used 
in a LFD is therefore their specificity to the target to be detected.  High specificity is 
essential to prevent cross-reactivity to other proteins within a clinical sample, for 
example, components of blood, plasma, urine or saliva; this can be overcome with 
the use of filter membranes onto which the sample can be loaded within the LFD.  
Such filters are commercially available (GE Healthcare Life Sciences) and are 
designed to filter out undesirable components of the clinical sample and are 
specific to sample type; blood, plasma, saliva, urine.  Examples of these filters 
include GF/DVA, used in devices to analyse saliva samples which has been applied 
to HIV diagnostics (Rohrman and Richards-Kortum, 2012) and LF1, MF1 and VF2 
glass fibre filters used for serum and whole blood samples (Songjaroen et al., 2012; 
Biagini et al., 2006; Choi et al., 2015).  Fusion 5 is new to the market and replaces 
the need for modular filters by combining the filter into a single layer matrix 
membrane (Aller Pellitero et al., 2016).  Replacement of these different filter 
components allows for multiple devices to be produced which can detect the same 
target protein in different clinical samples.  It is also important that specificity is 
provided against homologous proteins from other pathogens.  In the case of this 
study, the nucleocapsid (N) proteins from other strains of PRRSV or other related 
arteriviruses.  Moreover, it is important to be able to distinguish between viruses 
which can cause clinically similar diseases but are less economically relevant and 
have lower morbidity levels.  For example a LFD capable of differentiating between 
the clinically indistinguishable vesicular stomatitis (VS) and swine vesicular disease 
(SVD) from foot and mouth disease virus (FMDV) would be of value (Yang et al., 
2015a).  FMDV is one of the most economically devastating viral infections of 
cloven-hoofed animals, it is highly contagious and has a high mortality rate 
(Salguero et al., 2005).  In the case of PRRSV, it is essential for detection to be rapid 
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and reliable in order to contain any outbreaks of this highly contagious porcine 
virus.  This is particularly useful when the test is performed before the movement 
or introduction of new animals into the herd to prevent the introduction of the 
virus to naïve animals.  Other porcine diseases can be similar in clinical symptoms 
such as porcine parvovirus (Mengeling et al., 2000), leptospirosis (Ramos et al., 
2006) and erysipelas (Hoffmann and Bilkei, 2002).  However, it is possible to 
vaccinate naïve herds against these infections before the introduction of new 
animals.     
For the production of a LFD which can distinguish between two strains of a virus, as 
proposed in this study, it is essential that the detection reagent is able to recognise 
multiple strains of a viral protein (serotyping).  In order to perform a test to this 
effect, two labelled reagents are required, one which is able to detect all viral 
strains and a second which can recognise a specific strain.  As a result, there is a 
requirement for the Affimers used in the LFD to function as pairs.  Moreover, they 
must recognise different epitopes on the target proteins to prevent competing with 
each other for binding.  LFDs have been developed for the use of serotyping, again 
with FMDV being used as a proof of principle, using antibodies as detection 
reagents (Morioka et al., 2015; M. Yang et al., 2015a).  A multiplex assay using 
monoclonal antibodies has also been developed for the detection of the 
enteropathogenic bacteria Yersinia species Y. enterocolitica and Y. 
pseudotuberculosis which allows the appropriate administration of antibiotics 
(Laporte et al., 2015).   
The identification of pairs of reagents which recognise the same target protein at a 
different epitope can be carried out in a number of ways, the simplest and quickest 
being the enzyme-linked immunosorbent assay (ELISA) (Avrameas and Gulibert, 
1972).  The sandwich ELISA technique is commonly used in molecular biology 
laboratories in a wide variety of applications, particularly for diagnostic purposes in 
both human and animal clinical samples (Ferris and Dawson, 1988; Laviada et al., 
1992; Gonzalez et al., 2008; Saliki et al., 2006; Vashist et al., 2014; Shukla et al., 
2009).  ELISAs involving the detection of viral N proteins have been developed over 
the last decade (Singh et al., 2004; Jansen van Vuren and Paweska, 2009; Xu et al., 
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2007; Lau et al., 2004; Yadav et al., 2009; He et al., 2005) and so the use of this 
technique as a basis for the identification of pairs of Affimer reagents against the N 
protein of PRRSV is well grounded.   
This chapter discusses the cross-reactivity of the Affimers identified in Chapter 3 
between the two viral strains of the PRRSV N protein, as well as methods employed 
to identify pairs of reagents based upon ELISA techniques.  Firstly cross-reactivity of 
the Affimers with the SUMO tagged N proteins was investigated using phage ELISA 
based assays to reduce the number of reagents taken forward for pair 
identification.  Once a reduced number of Affimers had been identified for each 
target N protein, the reagents were prioritised using further ELISA and pulldown 
assays to discriminate between two viral N proteins which are similar in both 
structure and sequence to be used in the development of a novel Affimer based 
point of care (POC) biosensor.  
4.2. Cross-reactivity between Affimers raised against 
PRRSV strains 
To investigate the cross-reactivity of Affimers raised against each strain of the 
PRRSV N protein, phage ELISAs were performed, as described in sections 3.3 and 
3.7, where the phage expressed Affimers were incubated with either strain of the 
SUMO-N protein, as well as the SUMO-tag (figure 4.1).  This determined the 
preference of the Affimers to the specific SUMO-N protein shown using the 
absorbance readings taken from the phage ELISA (figure 4.1b).  The Affimers used 
in this ELISA were taken from a pool enriched for NLP-his8.  Pan 2 phage from the 
original NLP-his8 screen was used to screen SUMO-NLP (section 3.3) and so it was 
expected that they would show a preference for SUMO-NLP over SUMO-NHP.  Not 
surprisingly the results show that the Affimers did indeed bind more strongly to 
SUMO-NLP compared to SUMO-NHP (figure 4.1a).  No Affimer binding was 
observed to the SUMO-tag as expected.  The phage ELISA data was analysed in 
combination with the sequencing data previously gathered for this set of Affimers 
(data not shown) and three binders were taken forward (B3, B7, D12) as strong 
binders to SUMO-NLP but weak binders to SUMO-NHP as indicated (figure 4.1b*).  
Their unique loop sequences are listed in table 4.1, combined with the Affimers 
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previously raised against NLP-his8 (Affimers 1, 15, 16, 17 and 23) for further 
characterisation.  Affimer A12 (Figure 4.1b*) was also taken forward from as a 
binder able to recognise both PRRSV SUMO-N proteins, its unique loop sequences 
are shown in table 4.2.  The remaining Affimers were not taken forward due to lack 
of unique loop sequences or inability to sufficiently discriminate between the two 
PRRSV N proteins.  
 
Figure 4.1 Cross-reactivity of Affimers between PRRSV viral strains.  The phage expressed Affimers 
raised against SUMO-NLP were incubated with either SUMO-NLP or SUMO-NHP and a phage ELISA 
performed.  Phage binding to the target protein was confirmed by detection with an anti-
bacteriophage antibody labelled with HRP and visualisation with TMB.  (a)  The Affimers showed a 
preference for SUMO-NLP in this assay, although cross-reactivity was seen between the PRRSV viral 
strains.  There was no binding of Affimers to the SUMO tag.  (b)  Absorbance readings confirmed a 
preference for SUMO-NLP.  Three Affimers were taken forward for further analysis as binders 
against SUMO-NLP, B3, B7 and D12 (*).  A12 was taken forward as a binder which was able to 
recognise both strains of the viral N protein (*). 
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Table 4.1 Final list of Affimers raised againt SUMO-NLP 
 
The same phage ELISA as described in section 3.3 was then performed using the 48 
Affimers raised against SUMO-NHP to determine the specificity of this pool of 
binders to SUMO-NHP over SUMO-NLP (figure 4.2).  There were fewer Affimers 
identified as binders from this ELISA (figure 4.2a) compared to the enriched Affimer 
library used in the SUMO-NLP screen (figure 4.1) and the same four Affimers were 
identified as binders to the SUMO-tag in both SUMO-N protein plates (figure 4.2a), 
these were eliminated from further investigation.  Again, as expected, there is a 
preference for the PRRSV N protein to which the Affimers were raised, in this case 
SUMO-NHP, although to a lesser extent than in the equivalent SUMO-NLP ELISA.  
The Affimers identified as binders which bound preferentially to SUMO-NHP over 
SUMO-NLP (figure 4.2b*) (A2, B7, C11, C12, D9) were taken forward for further 
investigation and their unique loop sequences are listed in table 4.2.  These 
Affimers did show less specificity to the PRRSV viral strains than those identified in 
table 4.1 and so some cross reaction maybe expected in future assays.  Based on 
sequence identification, A5 and A7 (figure 4.2b*) were also taken forward because 
they showed a preference for both PRRSV viral strains.  A7 in particular was a 
strong binder to both target proteins.  For the purposes of the LFD it is necessary to 
also have non discriminate reagents which are able to detect the presence of the 
PRRSV viral N proteins from multiple strains.   
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Figure 4.2 Cross-reactivity of Affimers between viral strains. The phage expressed Affimers raised 
against SUMO-NHP were incubated with either SUMO-NHP or SUMO-NLP and a phage ELISA 
performed.  Phage binding to the target protein was confirmed by detection with an anti-
bacteriophage antibody labelled with HRP and visualisation with TMB.  (a)  The Affimers showed a 
preference for SUMO-NHP although cross-reactivity was seen between the PRRSV viral strains.  (b)  
Absorbance readings confirmed a preference for SUMO-NHP.  Six Affimers were taken forward for 
further analysis as binders against SUMO-NHP, A2, A5, B7, C11 and D12(*).  A7 (*) was taken 
forward as an Affimer which did not show preference for either SUMO-NLP or SUMO-NHP.  
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Table 4.2 Final list of Affimers raised against SUMO-NHP 
 
4.3. Cloning of Affimers into expression vectors and 
bacterial expression 
The Affimers listed in tables 4.1 and 4.2 were then PCR amplified using primers 
containing NheI and NotI restriction sites (table 2.5) and cloned into a pET11a 
expression vector (data not shown).  The cloning protocol was performed in 
parallel using primers which inserted a C-terminal cysteine (the only cysteine in the 
protein) or primers lacking this modification.  Successful insertion of the Affimers 
into pET11a was confirmed by sequence analysis using a T7 primer (GATC Biotech 
AG, data not shown).   
Affimer expression constructs, containing the additional cysteine were then 
transformed into BL21(DE3)pLysS cells and expression carried out at 30°C, with IPTG 
induction, overnight.  Affimers were purified by nickel ion affinity chromatography 
using the C-terminal his6-tag with a representative SDS-PAGE and Coomassie stain 
shown in figure 4.3 (Affimer 17) alongside the elution fractions of all of the 
Affimers.  Only elutions from Affimers which remained soluble are shown, as those 
that were insoluble upon purification were discounted from further analysis.  
Affimer reagents were purified in concentrations ranging from 1 mg/ml to 5 mg/ml 
and protein concentration was determined using a BSA standard (data not shown) 
before diluting the Affimers to 1 mg/ml for use in future assays.  
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Figure 4.3 Purification of Affimers from bacterial cell lysates.  (a) Affimers were expressed and 
purified from bacterial cell lysate using nickel ion affinity chromatography and elution with 300 mM 
imidazole.  Purification fractions of the proteins which remained soluble were analysed by SDS-
PAGE and Coomassie blue staining (representative figure, Affimer 17) with the highest 
concentration fraction taken forward.  (b)  Elution fractions of Affimers to determine the highest 
concentration fraction. 
 
4.4. Identification of pairs of Affimer reagents to the 
PRRSV N proteins 
Pairs of reagents are required for the production of a LFD, encompassing a capture 
and detection Affimer.  In order to identify potential pairs of Affimers against the 
PRRSV N proteins, ELISA and pulldown assays were used where the detection 
Affimers were analysed using different tags and expression methods.  
The bacterially expressed and purified Affimers were initially biotinylated using 
biotin-maleimide following the reduction of the single cysteine residue using TCEP 
resin, resulting in the addition of a single biotin molecule on the free cysteine 
residue.  Following the removal of excess biotin, the addition of the biotin molecule 
was confirmed using an ELISA-based method, detected with streptavidin-HRP as 
described in section 3.7 (data not shown).   
Firstly, the detection Affimer was presented to the target protein as a phage 
expressed molecule using the biotinylated Affimers as capture molecules.  The 
purified and biotinylated capture Affimers were immobilised onto a streptavidin 
coated 96 well plate and incubated with the relevant PRRSV SUMO-N protein 
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before the addition of the detection Affimer expressed on the surface of the phage, 
with detection using anti-bacteriophage-HRP and TMB as illustrated (figure 4.4a).  
Biotinylated Affimers were immobilised vertically down the columns of the 96 well 
plate, with the bacteriophage expressed Affimers being added across the rows of 
the plate.  This allowed for each Affimer to be tested as both a capture and a 
detection reagent, as the Affimers may display different sensitivities depending on 
whether they are immobilised or available in solution.  From the ELISA plate (figure 
4.4b), all chosen Affimers appear to work well as pairs.  However, results suggest 
that this method of identification of pairs was not ideal, due to poor 
reproducibility, perhaps due to the quality and quantity of phage expressed 
Affimers used in each replicate. 
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Figure 4.4 Phage ELISA to show Affimer pairs with SUMO-NHP Affimers (representative figure). (a) 
Schematic representation of ELISA, biotinylated Affimers were immobilised on a streptavidin coated 
plate.  The target protein was captured by the immobilised Affimer and the captured target was 
detected by an Affimer expressed on a phage.  Binding of pairs was confirmed by detection of 
bound phage using an anti-bacteriophage antibody.  (b) A representative ELISA plate: pair binding 
was confirmed by the addition of TMB and measuring the absorbance.  Positive pairs were 
identified with the blue colour change to the wells.  Replicates of this assay were not analysed due 
to variability between ELISA plates and so average absorbance readings and pairs could not be 
identified.  
 
In order to overcome the variability between batches of phage, Affimers expressed 
and purified from bacteria were used as both capture and detection reagents, to 
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provide standard concentrations of protein in an attempt to enhance 
reproducibility of the assay.  The detection method of the following ELISAs were 
varied by the addition of labels to the single cysteine residue engineered into the 
Affimer protein sequence, HRP for direct detection with TMB and Alexa Fluor®-488 
or Alexa Fluor®-546 for detection with a fluorescence plate reader.  The detection 
of the PRRSV SUMO-N proteins using purified and directly labelled protein was 
preferred to the secondary detection of phage expressing Affimers as direct 
detection will be used in the LFD and the bulky phage may have masked binding of 
Affimers due to steric hindrance, resulting in the variable ELISA results.  
Figure 4.5a shows the detection method using HRP-labelled Affimers with the 
addition of TMB for detection of target binding.  Here, the biotinylated Affimers 
were immobilised onto the streptavidin coated plates and incubated with target 
PRRSV SUMO-NHP protein before the addition of HRP-labelled Affimers.  As with 
the phage ELISA (figure 4.4), the biotinylated Affimers were immobilised vertically 
down the columns and the HRP-labelled Affimers were added across the rows of 
the plate.  The representative image of a HRP ELISA shown in figure 4.5b indicates a 
number of positive hits for pairs of Affimers against the SUMO-NHP protein.  In this 
case, Affimer B7 as a capture Affimer with Affimer A12 as a detection Affimer, 
Affimer D9 as a capture Affimer with Affimer C11 as a detection Affimer and 
Affimer A7 as a capture Affimer with Affimer A2 as a detection Affimer being the 
strongest pairs indicated in this assay.  Interestingly, the use of these Affimers in 
reverse (swapping the detection and capture Affimer) resulted in a greatly reduced 
reaction upon the addition of TMB, suggesting that the reagents were less sensitive 
in this orientation.  However, as with the previously described phage ELISA (figure 
4.4), the reproducibility of this assay was not reliable.  The control wells in this 
assay (Affimer binding to an immobilised target protein) were highly variable 
between experiments, suggesting that the HRP-Affimer binding was not optimal 
when presented to the immobilised target protein.   
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Figure 4.5 ELISA to identify Affimer pairs with SUMO-NHP Affimers labelled with HRP 
(representative figure). (a) Schematic representation of ELISA, biotinylated Affimers were 
immobilised on a streptavidin coated plate.  The target protein was captured by the immobilised 
Affimer and the captured target was detected by an Affimer labelled with HRP. (b) Pair binding was 
confirmed by the addition of TMB and measuring the absorbance of the wells.  As with figure 4.4, 
variability between replicates of this assay did not allow for pairs to be identified and therefore 
average absorbance readings are not shown. 
 
Figure 4.6a illustrates the use of Affimers as pairs with the detection reagents when 
labelled with a fluorescent tag, in this case, Alexa Fluor®-488 or 546.  The binding of 
the Affimers in a pairwise manner in the presence of target protein was confirmed 
by reading the fluorescence intensity on a plate reader.  Initially, two fluorescent 
tags were used to determine the optimum labelling and detection method with 
regards to assay sensitivity.  Here, an Affimer was chosen as a detection reagent, in 
this case SUMO-NHP B7, to be labelled with either Alexa Fluor®-488 or 546.  
SUMO-NHP B7-488 was incubated as a detection reagent and following wash steps, 
to remove any unbound Affimer, the fluorescence intensity of the ELISA plate was 
measured (figure 4.6b).  The fluorescence intensities showed no variability 
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throughout the assay and the positive and negative controls (plus or minus 
immobilised target protein incubated with fluorescently labelled Affimer) did not 
appear to have been successful with this detection method.  Moreover, the 
fluorescence intensity values are very high for this ELISA, which may indicate that 
the wash steps were not sufficient to remove the unbound Affimer.  The same 
experiment was performed using SUMO-NHP B7-546 (figure 4.6c) with more 
promising results, the positive and negative controls appear to have been 
successful and a number of pairs were possibly identified, B7 with A5, B7 with A7 
and B7 with D9.  Alexa Fluor®-546 was chosen as the label to be taken forward for 
the labelling of further Affimer reagents.  Figure 4.6d shows Affimer SUMO-NLP 15-
546 incubated with capture Affimers and target proteins.  Again, a number of pairs 
may be indicated for example, Affimer 15 as a detection Affimer with Affimers 17, 
B3 and D12 as capture Affimers.  However, as with the other ELISA methods 
described in this chapter, the variability between the assay results meant there was 
little confidence in the ability of the chosen Affimers to function as pairs of 
reagents in a LFD.  
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Figure 4.6 ELISA using fluorescently labelled Affimers. (a) Schematic representation of ELISA, 
biotinylated Affimers were immobilised on a streptavidin coated plate.  The target protein was 
captured by the immobilised Affimer and the captured target was detected by an Affimer labelled 
with a fluorescent label. (b)  Biotinylated Affimers against SUMO-NHP were immobilised on the 
streptavidin plate and target binding was confirmed using Affimer B7 labelled with Alexa Fluor®-488 
(c)  Biotinylated Affimers against SUMO-NHP were immobilised on the streptavidin plate and target 
binding was confirmed using Affimer B7 labelled with Alexa Fluor®-546 (d) Biotinylated Affimers 
against SUMO-NLP were immobilised on streptavidin coated plates and target binding was 
confirmed using Affimer 15 labelled with Alexa Fluor®-546. 
 
As a result of the variable data collected from a number of different ELISA assays, 
pulldown assays were performed using Affimers immobilised on magnetic beads 
and incubated with target proteins presented in a clinically relevant sample (pig 
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serum) as shown in figure 4.7a.  Experiments were performed using both SUMO-N 
proteins in order to determine the cross-reactivity of the Affimers in the presence 
of other proteins present in the pig serum.  Moreover, it also compared the cross-
reactivity highlighted in the earlier ELISA experiments (figures 4.1 and 4.2).  
Pulldown assays proved to be far more reproducible than the previously described 
ELISAs.  Figure 4.7b shows the results of the pulldown assay performed in pig 
serum spiked with SUMO-NLP, using Affimers raised against this target protein.  
None of the Affimers showed any binding to the SUMO protein used as a control, 
ensuring the Affimers recognised the untagged region of NLP.  These results 
confirm the findings of the ELISA shown in figure 4.1, highlighting the specificity of 
the Affimers to NLP.  The Affimers which showed specificity to the target protein 
via pulldown assays were 1, 15, B3, B7 and D12 and when compared to the 
previous ELISA data (figures 3.3, 4.1), the binding to the target protein was 
confirmed.  Affimers 1 and 15 in particular showed a strong reaction in the ELISA 
assay using the his-NLP protein as a target.  Affimer 17 showed reduced affinity in 
the same ELISA and again this was confirmed in pulldown assays, in fact showing no 
binding capability.  However, Affimer 23 was a surprising result as it initially 
displayed good binding to his-NLP (figure 3.3).  Upon the addition of the SUMO-tag, 
binding ability is lost in pulldown assays.  The poor binding of Affimers 17 and 23 
could be attributed to the addition of the SUMO tag which when immobilised onto  
magnetic beads (1 µm) may block the binding sites for these two Affimers, 
although this requires further investigation.  Combining all the data from the 
multiple assays, Affimers B3, B7 and D12 bind the target NLP protein efficiently and 
were taken forward.  
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Figure 4.7 Pulldown analysis of Affimer binding to SUMO-NLP. (a) Schematic representation of 
pulldown assay. Affimers raised against SUMO-NLP were biotinylated and bound to streptavidin 
coated magnetic beads and incubated with SUMO-NLP in the presence of pig serum.  (b) Binding of 
the target protein was analysed using SDS-PAGE and western blot analysis.  No Affimers showed any 
binding to the SUMO tag, Affimers 1, 15, B3, B7 and D12 were able to pulldown SUMO-NLP.  
 
As previously mentioned, the ability of the Affimer reagents to discriminate 
between the two viral strains is desirable for the production of a LFD allowing the 
sensor to determine which viral strain an animal is infected with.  Therefore, the 
same pulldown assay was performed using the Affimers raised against SUMO-NLP 
incubated with SUMO-NHP (figure 4.8).  The Affimers that bound in this assay are 
1, 15, 23 and D12, showing some cross-reactivity of the Affimers between the two 
viral strains.  The Affimers which were originally raised against his-NLP (1, 15, 17 
and 23) had not previously been investigated for their ability to bind to SUMO-NHP 
by ELISA and so were included in the pulldown assays, to ensure they were able to 
bind to both of the SUMO-tagged proteins.  D12 was the only other Affimer in the 
assay pulldown which showed cross-reactivity.  The ELISA data (figure 4.1) 
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suggested that this Affimer was more specific for SUMO-NLP than SUMO-NHP.  The 
ability of the Affimer to detect both target proteins is, however, desirable as a non-
discriminate Affimer is also required for the assembly of a LFD.  
 
Figure 4.8 Pulldown analysis of Affimer cross-reactivity between viral strains.  Affimers raised 
against SUMO-NLP were biotinylated and bound to streptavidin coated magnetic beads and 
incubated with SUMO-NHP in the presence of pig serum.  Binding of the target protein was analysed 
using SDS-PAGE and western blot analysis.  Affimers 1, 15, 23 and D12 were able to bind to SUMO-
NHP.  
 
The same pulldown assays were also performed for the SUMO-NHP Affimers where 
they were incubated with either SUMO-NHP (figure 4.9) or SUMO-NLP (figure 
4.10).  As with the previous pulldown experiments, these pulldowns were 
performed in pig serum, in order to provide a clinically relevant buffer.  The 
Affimers which were able to identify SUMO-NHP were Affimers A2, A5, A7, B7, C11 
and D9 (figure 4.9).  Results also concluded that the Affimers only bound the target 
N protein, as they showed no binding affinity to the SUMO tag, further confirming 
the data collected from initial phage ELISAs (figure 4.2).   
147 
 
 
Figure 4.9 Pulldown analysis of Affimer binding to SUMO-NHP.  Affimers raised against SUMO-NHP 
were biotinylated and bound to streptavidin coated magnetic beads and incubated with SUMO-NHP 
in the presence of pig serum.  Binding of the target protein was analysed using SDS-PAGE and 
western blot analysis.  Affimers A2, A5, A7, B7, C11 and D9 were able to bind SUMO-NHP and none 
of the Affimers were shown to bind to the SUMO tag.  The non-specific bands are thought to be 
proteins from the pig serum which interact with the Affimers. 
 
Pulldown assays were also performed using SUMO-NLP target protein as a test for 
cross-reactivity (figure 4.10).  A number of Affimers displayed the ability to 
recognise both strains of the viral N proteins, A2, A5, A7, C11 and D9.  However, B7 
was not able to recognise the low pathogenic strain of the viral protein and A12 
was able to recognise only the low pathogenic strain of the protein, which is 
contrary to the ELISA data shown in figure 4.1 where this Affimer had shown 
preference for both of the viral N proteins.  A summary of the binding of the target 
N proteins to the Affimers in pulldown assays is show in table 4.3.  The three 
Affimers chosen to be taken forward are highlighted in purple text.  
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Figure 4.10 Pulldown analysis of Affimer binding to SUMO-NLP.  Affimers raised against SUMO-
NHP were biotinylated and bound to streptavidin coated magnetic beads and incubated with 
SUMO-NLP in the presence of pig serum.  Binding of the target protein was analysed using SDS-
PAGE and western blot analysis.  Affimers A2, A5, A7, A12, C11 and D9 were able to bind SUMO-NLP 
but none of the Affimers showed binding to the SUMO tag.  The non-specific bands are highlighted 
as Affimers eluted from the streptavidin beads or are thought to be proteins from the pig serum 
which interact with the Affimers.    
 
Table 4.3 Summary of Affimer binding to target proteins in pulldown assays 
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4.5. Discussion 
This chapter describes the analysis of the Affimers raised against the two viral N 
proteins to investigate the cross-reactivity of the Affimers when challenged with 
recognising the two strains of the proteins and to identify Affimers able to 
discriminate between the two strains.    
Initially, the phage ELISA method was used as a preliminary investigation into the 
specificity of Affimers to the two viral strains of the N protein in order to identify 
the Affimers to be cloned into bacterial expression vectors for further analysis.  The 
binding of the Affimers to each of the target proteins in these ELISAs was used in 
conjunction with the unique loop regions of the Affimers identified in table 3.2 and 
3.3 to further reduce the number of Affimers taken forward for investigation based 
upon specificity to the target.  
The ELISA data showed that there was cross-reactivity between the viral proteins. 
This is not unexpected due to the amino acid sequence similarity between the two 
N proteins.  Moreover, it is highly likely that the Affimers are also recognising 
structural conformations likely to be conserved between the two viral strains.  
Although the entire crystal structure of the PRRSV N protein is yet to be solved, a 
truncated structure of the 65 C-terminal amino acids of the North American strain 
VR-2332 is available (Doan and Dokland, 2003).  The amino acid similarity in this 
region between the two viral N proteins in this study is high, with only 5 amino acid 
differences within the region (figure 1.18), suggesting that the overall structural 
similarity will be high.     
When considering the unique loop regions of the Affimers taken forward in tables 
4.1 and 4.2, it is important to observe that there is sequence similarity between the 
Affimers raised against each N protein.  However, within each of the tables, we can 
observe amino acid sequences which are more common as previously discussed in 
Chapter 3 (section 3.8).  It may therefore be hypothesised that the interactions 
between the Affimers target proteins are at a small number of regions on the 
protein and not spread at multiple locations.  This is especially likely when 
considering SUMO-NHP Affimers which show less sequence diversity.    
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Expression constructs allowed the expression of the chosen Affimers (tables 4.1 
and 4.2) in bacterial systems.  Cloning was performed in parallel to produce two 
expression constructs for each Affimer, one engineered to express Affimers 
containing a C-terminal cysteine and one without (Tiede et al., 2014).  This is the 
only cysteine residue in the Affimers allowing for targeted modification for labelling 
purposes exploited in this chapter.  Affimers expressed and containing this C-
terminal cysteine appeared to be less stable than those without, readily forming 
disulphide bonds with other Affimers and precipitating out of solution at high 
concentrations.  This was overcome by the dilution of the purified proteins and 
addition of any modifications promptly following purification to protect the 
reactive amino acid.  Disulphide bonds are ordinarily a stabilising feature when 
found within proteins, providing thermodynamic stability, loss of conformational 
entropy of the unfolded state and restriction of motion of unstructured regions 
(Dombkowski et al., 2014).  This has been exploited with additional cysteine 
residues being engineered into a protein sequence to introduce a stabilising 
disulphide bond (Wetzel et al., 1988; Kim et al., 2012; Wedemeyer et al., 2000).  A 
number of Affimers were excluded from further investigation as they were 
particularly unstable following purification; SUMO-NLP 16 and A8 and SUMO-NHP 
C12.  In addition to time restraints preventing investigation into stability, it was also 
observed from sequence analysis of the loop regions that these three Affimers 
contain a high proportion of hydrophobic residues which could promote protein 
aggregation (Fink, 1998).  However, hydrophobic residues are also present in 
Affimers which do not show severe aggregation upon storage, this may be due to 
differential folding of the main structure and variable loops.  If the Affimers are 
forming disulphide bonds via their free cysteines then this may be exasperated by 
the presence of hydrophobic regions (Fink, 1998).   
The modifications added to the C-terminal cysteine of the purified Affimers in the 
assays in this chapter are maleimide additions where the label was HRP (Thermo 
Fisher Scientific), Alexa Fluor®-488 or 546 (Invitrogen) or biotin (Sigma Aldrich).  
The label of choice is conjugated to a maleimide compound which is highly 
electrophilic and has a high selectivity for reduced thiol residues, in this case the 
single cysteine residues (Kim et al., 2008; Chalker et al., 2009).  Following desalting 
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to remove excess maleimide label, the proteins can be used in ELISA and pulldown 
assays as described.   
Three sandwich ELISA methods were used to identify pairs of Affimers able to 
recognise the two viral N proteins; phage ELISA, ELISA using HRP-labelled Affimers 
and a fluorescence ELISA.  The phage ELISA method used purified biotinylated 
Affimers immobilised on a streptavidin coated plate then incubated with target 
protein and detection of pairs determined using a phage expressed Affimer 
detected with anti-bacteriophage antibody-HRP and TMB.  The variability observed 
between replicates of this assay was large and possibly attributed to the 
production of phage expressed Affimers.  Without knowing the phage titre, it was 
not possible to quantify the number of phage used in each replicate causing 
variability in results.  Although the calculation of phage titre is itself straightforward 
(Swanstrom and Adams, 1951), using plaque assays, it was not possible to perform 
this assay as the phage used in these experiments was packaging deficient and 
would therefore not form plaques.  It was also hypothesised that the variability of 
the assay was due the capture of the target protein in an unfavourable position 
obscuring the binding sight for the bulky phage expressed detection Affimer.  This 
was further investigated using a solution based assay, by immobilising the capture 
Affimers onto a streptavidin coated bead before being incubated with the target 
protein and then the phage expressed detection Affimer, allowing more flexible 
binding conditions. 
In order to improve the reliability of these assays, the use of a known 
concentration of both capture and detection Affimer was needed.  ELISAs were 
performed with purified and HRP or fluorescently-labelled Affimers of known 
concentrations.  Input protein concentrations for each replicate were the same 
when compared to the variability of the phage ELISA, as well as providing a direct 
read out of detection Affimer binding rather than indirect detection of the phage 
expressed Affimer with an antibody.  The protocol was also significantly faster 
allowing for rapid optimisation and identification of pairs more quickly.  However, 
the reliably of these assays was not significantly improved upon compared to the 
phage ELISA previously discussed.  As with the phage ELISA, the binding of the 
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target protein to the immobilised capture protein could be a contributing factor to 
the variability of binding, this is addressed in chapter 5. 
The pulldown assay experiments discussed in this chapter eliminated Affimers 
likely to detect both of the target PRRSV N proteins and identified those taken 
forward specific to one N protein or another.  Three Affimers were taken forward, 
B3 detecting SUMO-NLP, B7 detecting SUMO-NHP and D12 able to detect both of 
the viral N proteins.  Simplifying the assay to determine the best binders against 
the target proteins, further reduced the pool of Affimers investigated for pairs of 
reagents and allowed for more optimisation of future assays.  These Affimers were 
investigated as functioning pairs in the final chapter of the project.   
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Determining pairs of Affimers and development 
of a novel Affimer based lateral flow device 
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5. Determining pairs of Affimers and development 
of a novel Affimer based lateral flow device 
5.1. Introduction 
Modifications of lateral flow devices (LFDs) using alternatives to antibodies have 
been developed over the last decade with the application of various reagents such 
as DNA or RNA aptamers (Chen and Yang, 2015b; Gopinath et al., 2016; Xu et al., 
2009; Liu et al., 2009; Shim et al., 2014).  Additional modifications also involve the 
replacement of antibody components with other reagents, for example Affimers® 
(Affimers) (Avacta® Life Sciences), Affibodies® (Löfblom et al., 2010), DARPins 
(Stumpp and Amstutz, 2007), other peptide aptamers (Reverdatto et al., 2015) or 
Avimers (Jeong et al., 2005).  These antibody alternatives have already been 
utilised in multiple molecular medicine applications; as tissue targeting vehicles 
(Tolmachev et al., 2007), enzyme inhibitors (Attucci et al., 2006), as alternatives to 
small molecule inhibitors (Silverman et al., 2005) or in cancer treatment (Mamluk 
et al., 2010; Stahl et al., 2013).  They have also shown promising results in in vivo 
imaging and diagnostics (Yang et al. 2015; Gong et al. 2010; Nordberg et al. 2007; 
Tiede et al. 2017), and as antibody alternatives in molecular biology for example 
ELISAs (Miranda, et al., 2011), immunofluorescence (Lyakhov et al., 2010), 
immunohistochemistry (Lundberg et al., 2007) and as reagents to investigate 
protein structures (Flütsch et al., 2014; Scholz et al., 2014).   
Despite the wide ranging uses of these non-antibody binding proteins within 
scientific research, they have not been exploited to their full potential in the 
development of point of care (POC) diagnostics.  The success of these reagents as 
replacements for antibodies in such wide ranging applications provides confidence 
that Affimers would be suitable to replace antibodies within a LFD.   The basis of 
this study is to investigate whether Affimers are suitable reagents to use in LFDs as 
direct replacements of antibodies, in order to provide a diagnostic which shows 
improved sensitivity and selectivity, compared to the antibody containing 
alternative.   
As previously described, commercially available LFDs are based upon a high protein 
binding nitrocellulose membrane which has a control line antibody and a test line 
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antibody immobilised, as well as a low protein binding cellulose based membrane,  
where a third antibody is immobilised (Posthuma-Trumpie et al., 2009).  These 
component parts are shown in figure 1.19.  It is proposed that the Affimers would 
be used in the same manner as antibodies in these devices.  This chapter therefore 
examines the ability of the previously identified Affimers to function as a pair of 
reagents to identify the target recombinant N protein.  As such the Affimer pairs 
are required to recognise the targets at different epitopes on the protein surface.  
The identification of pairs of reagents was carried out using a gold 
nanoparticle/magnetic bead assay, adapted from Zhou et al. 2015.  Upon 
identification, the pairs of Affimers were then assessed for their applicability within 
a basic LFD, comprising a simple dipstick assay.   
5.2. Gold nanoparticle and magnetic bead pulldown assay 
for identification of Affimer pairs 
The previous chapter identified Affimers that were able to distinguish between the 
two viral N proteins (B3 and B7) as well as an Affimer which was able to bind to 
both N proteins, (D12).  To determine the best combination for pairs of Affimers, a 
sandwich assay was performed using magnetic beads and gold nanoparticles 
(GNPs), based on an assay by Zhou et al. (2015).  Here the capture Affimer (B3/B7) 
was immobilised onto magnetic beads and the detection Affimer (D12) was 
immobilised on GNPs.  Successful pairs of Affimers would be confirmed when a 
complex was formed as illustrated in figure 5.1a and the gold was ‘pulled out’ of 
solution onto a magnet via the magnetic beads.  Figure 5.1b shows the ultraviolet-
visible absorption spectra of the supernatant from the sandwich assay, following 
the incubation of the magnetic bead/gold nanoparticles functionalised with B7/D12 
with either SUMO-NLP, SUMO-NHP, SUMO or no target and immobilisation of any 
formed complex onto a magnet.   
Initially as a proof of principle for this assay, B7 was utilised.  Affimer B7 shows a 
preference to SUMO-NHP compared to SUMO-NLP in previous pulldown assays 
(figure 4.9).  Therefore, the sandwich assay should show a reduction in the amount 
of gold in the supernatant following the addition of SUMO-NHP target protein, as 
opposed to the addition of SUMO-NLP or SUMO.  Results confirm this theory, 
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(figure 5.1b) as illustrated by the representative absorption spectra, where a 
decrease in the peak at 520 nm (peak absorption value) upon the addition of 
SUMO-NHP was observed.  Figure 5.1c shows the quantification of three replicates 
of the sandwich assay as a percentage of the control (no added target).  Here 
results show that upon the addition of SUMO-NHP there is a significant decrease in 
the peak at 520 nm (p=0.03), which confirms the formation of the Mag-Affimer-
Target-Affimer-Au complex and the successful pair interaction of B7 and D12, with 
detection of SUMO-NHP within a sample.   
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Figure 5.1 Gold nanoparticle-magnetic bead based assay to determine pairs of Affimers against 
PRRSV N proteins (B7/D12).  (a) Schematic representation of Affimer binding to target N protein in 
a pair wise manner. If the Mag-Affimer-Target-Affimer-Au complex is formed, upon immobilisation 
on a magnet, the gold will be removed from the supernatant. Removal of GNPs from solution can be 
confirmed by measuring the absorption spectrum of the supernatant. (b) Ultraviolet-visible 
absorption spectrum of supernatant containing GNPs.  The removal of the gold from the 
supernatant is observed by the reduction of the peak at 520 nm, indicating a successful pair, B7 and 
D12 were a successful pair to detect the presence of SUMO-NHP. (c)  The reduction in peak was 
quantified as a percentage of the control (no target), with a significant decrease in the peak upon 
the addition of SUMO-NHP when Affimer D12 is bound to the GNP and B7 to the magnetic bead 
(p=0.03).        
 
The same sandwich assay was performed using B3 conjugated to magnetic beads 
and D12 conjugated to GNPs (figure 5.2).  Again, the two Affimers appear to be 
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able to detect SUMO-NHP in this sandwich assay, with a reduction in the peak 
value at 520 nm upon the addition of this target into the assay (figure 5.2a).  This 
was quantified from three replicates with a significant decrease in the peak value 
compared to the control (p=0.005) (figure 5.2b).  However, this result was not 
expected, as it was hypothesised that this pair of Affimers should only recognise 
SUMO-NLP, as the target NLP was consistently detected in the pulldowns with the 
magnetic bead bound Affimers, in contrast to SUMO-NHP.  However, as a result of 
these two sandwich assays, it was concluded that both of the combinations of 
these Affimers would be suitable to detect SUMO-NHP in solution and were 
therefore taken forward for incorporation into the LFD.  
 
Figure 5.2 Gold nanoparticle-magnetic bead based assay to determine pairs of Affimers against 
PRRSV N proteins (B3/D12).  (a)  Ultraviolet-visible absorption spectrum of supernatant containing 
GNPs.  The removal of the gold from the supernatant is observed by the reduction of the peak at 
520 nm, indicating a successful pair, B3 and D12 were a successful pair to detect the presence of 
SUMO-NHP. (b)  The reduction in peak was quantified as a percentage of the control (no target), 
with a significant decrease in the peak upon the addition of SUMO-NHP when Affimer D12 is bound 
to the GNP and B3 to the magnetic bead (p=0.005).        
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5.3. Development of a control line on nitrocellulose 
dipsticks 
In order for a LFD to be developed for the detection of PRRSV N proteins, it is 
important to incorporate an internal control line into the device.  This confirms the 
success of the assay and is independent of the appearance of the test line within 
the assay.  This control line is able to identify the detection reagent within the 
assay (in this case, D12 bound to the GNP) and confirms to the user that this 
reagent has migrated sufficiently up the nitrocellulose membrane.  In the case of 
this assay, an anti-his antibody was chosen for the control line component, as the 
Affimer bound to the GNP was labelled with a his6-tag for purification.  The use of 
an antibody is not ideal, as the purpose of the study was to eliminate antibodies 
from the device, replacing them with Affimers, however, it is not possible to raise 
an anti-Affimer Affimer.  Therefore, due to time constraints, which did not allow for 
additional cloning of the Affimers, a his-specific antibody was used to detect the 
his6 tagged affimers bound to the gold nanoparticles.  Figure 5.3 illustrates the first 
optimisation steps of the control line using an anti-his antibody.  Figure 5.3a is a 
schematic representation of the production of a dipstick strip containing a control 
line.  Strips were prepared by diluting the anti-his antibody to the dilution shown 
(1:1000 or 1:250) and striping the antibody onto the membrane using a sequencing 
tip.  The membrane was dried overnight and dipsticks prepared by cutting the 
membrane into 0.5 cm strips.  The streptavidin coated GNPs were prepared with 
Affimer D12 immobilisation using biotin labelling of the single cysteine present on 
the sub-cloned Affimer and diluted to OD 1 or OD 0.5 before incubating the GNP 
with the dipsticks.  Figure 5.3b shows the results of the incubation of the dipsticks 
with the GNPs functionalised with Affimer D12, with no control line appearing at 
the indicated position for either the 1:1000 or 1:250 dilution of antibody regardless 
of the concentration of GNPs.  It was hypothesised that the concentration of 
antibody used on the membrane was too dilute for the GNPs to be detected.  
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Figure 5.3 Optimisation of the control line for lateral flow device.   (a) Schematic representation of 
lateral flow device using a control line.  An anti-his antibody was striped onto the nitrocellulose 
membrane which detects the C-terminal his6-tag of the Affimer bound to the GNP. (b) The anti-his 
antibody was striped at a dilution of 1:1000 or 1:250.  The Affimer bound to the gold nanoparticle 
was diluted to OD 1 or OD 0.5.  The strips were incubated with the GNPs for 30 mins.  
 
Figure 5.4 shows further optimisation of the control line on the LFD, using 1 mg/ml 
of the anti-his antibody, which was undiluted from the original stock.  Following the 
incubation of the Affimer functionalised GNPs with the indicated target protein 
(SUMO-NHP, SUMO-NLP, SUMO or no target), or a dipstick which did not contain 
striped antibody, a positive control line appeared at the position of the anti-his 
antibody on the SUMO-NHP and no target dipsticks.  It was expected the line would 
appear on the dipsticks incubated with SUMO-NHP, SUMO-NLP, SUMO and no 
target protein, however, this was not observed.  The detection in this case was of 
the his6-tagged Affimers which accounts for the line appearing on the no target 
strip.    
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Figure 5.4 Further optimisation of control lines on lateral flow device.  Undiluted anti-his antibody 
(1 mg/ml) was striped and dried onto the nitrocellulose membrane and D12 bound to GNPs was 
incubated with the target proteins as indicated.  GNPs were incubated with the nitrocellulose strips 
and detection of the bound Affimer confirmed by the appearance of a pink line at the site of the 
antibody.  
 
As there was no control line on the dipsticks which had been incubated with GNP-
D12 in the presence of target proteins, an ELISA was performed to determine if the 
antibody was able to gain access to the his6-tag on the immobilised Affimer in 
solution in the presence of the target protein (figure 5.5.).  GNP-D12 was incubated 
with the target protein and a 1:10000 dilution of anti-his-HRP antibody was added 
to the solution.  Following washing, the binding of the antibody was visualised 
using TMB and quantified using a microplate reader (figure 5.5).  The ELISA 
confirmed the previous result (figure 5.4) on the dipsticks, that in the presence of 
the target proteins, there was little binding of the antibody to the Affimer 
immobilised on the GNP.  The lack of wash steps between the addition of the target 
protein and the antibody was hypothesised to be the cause of the poor detection 
by the antibody.  It is likely the antibody was binding to the excess his6-tagged 
target and removed during subsequent wash steps.  
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Figure 5.5 Solution based ELISA to confirm the detection of the Affimer C-terminal his6-tag by the 
anti-his antibody.  D12 was bound to the GNPs and incubated with the target proteins as indicated.  
Anti-his-HRP antibody was added to the solution and binding was detected with the addition of TMB 
to give a blue colour reaction and quantified using a plate reader.  
 
In order to overcome this issue, an additional wash step was performed to remove 
the excess target protein before the addition of the anti-his-HRP antibody.  Figure 
5.6 shows the ELISA plate following the additional wash steps in the protocol and 
quantification using the microplate reader.  The removal of the excess target 
protein results in an increase in antibody binding to the immobilised Affimer (or the 
His6-tagged protein bound to the immobilised Affimer), and the visualisation of this 
binding using TMB when GNP-D12 is incubated with the target protein.  
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Figure 5.6 Optimisation of solution based ELISA to confirm the detection of the Affimer C-terminal 
his6-tag by the anti-His antibody.  D12 was bound to the GNPs and incubated with the target 
proteins as indicated.  GNPs were washed three times before the addition of the anti-His-HRP 
antibody was added to the solution and binding was detected with the addition of TMB to give a 
blue colour reaction and quantified using a plate reader.  
 
The additional wash step protocol was then incorporated into the assay using the 
anti-his antibody immobilised on the dispstick (figure 5.7).  Removal of the excess 
target resulted in the formation of control lines as expected on the dipsticks where 
anti-his was present.  The no target control shows that it is the Affimer which is 
bound to the GNP which can be detected and not the his6-tagged recombinant 
protein.  However, it is expected that the target proteins contribute to the binding 
when they are present in complex with the Affimer and it is not possible to 
distinguish which his-tag is recognised.  
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Figure 5.7 Control lines with optimised wash steps for detection of the Affimer C-terminal his6-tag 
by the anti-his antibody.  Undiluted anti-his antibody was striped and dried onto the nitrocellulose 
membrane and D12 bound to GNPs incubated with the target proteins as indicated.  GNPs were 
incubated with the nitrocellulose strips and detection of the bound Affimer confirmed by the 
appearance of a pink line at the site of the antibody.  
 
5.4. Addition of Affimer test line on nitrocellulose 
dipsticks 
At present, it was unknown if the Affimers could be successfully adsorbed onto the 
nitrocellulose membrane and remain functional.  Therefore, they were immobilised 
onto the membrane using the same protocol for immobilising the antibody control 
line, before being detected using an anti-his-HRP antibody.  The membrane was 
then developed using a similar technique to western blotting in order to determine 
if the Affimers could be successfully immobilised on the membrane by drying, 
before being rehydrated (figure 5.8).  The chosen Affimers were successfully 
adsorbed onto the membrane, and importantly, remained on the membrane upon 
the addition of buffer and rehydration.  Importantly, they could be detected via the 
his-tag specific antibody.   
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Figure 5.8 Immobilisation of Affimers onto nitrocellulose membrane.  Purified Affimer was 
immobilised to nitrocellulose membrane and dried for 1 hour at 37°C.  The successful 
immobilisation was confirmed with detection of the C terminal his6-tag of the Affimer using an anti-
his antibody.  A his6-tagged protein (SUMO-NLP) and buffer control were used.   
 
Following the successful immobilisation of the Affimer onto the membrane, 
dipsticks were prepared containing both an Affimer test line (B3 or B7) and an anti-
his control line (figure 5.9).  These dipsticks were then incubated with GNPs 
functionalised with D12 and the indicated target proteins.  Faint control lines were 
visible on the dipsticks as indicated (*) for the dipsticks prepared with B3, however, 
no control lines were visible on the dipsticks prepared with B7.  It was hypothesised 
that the dilution of the GNPs was too dilute in the presence of the target protein 
and so the dipsticks were saturated with buffer before the GNPs could migrate up 
the membrane.  It is also possible that the presence of excess free target protein 
(with the his8-tag) was again interfering with the binding of the captured Affimer 
and GNPs at the site of the anti-his-antibody as previously discussed (figure 5.4.).  
Results showed a very faint line at the B7 test line for SUMO-NLP and SUMO-NHP.  
This could also be attributed to the distribution of the GNPs over both the control 
lines and the test line being too low, where as in the previous control line only 
dipsticks (figure 5.7) the GNPs were concentrated only at the anti-his-antibody line 
giving an enhanced signal. 
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Figure 5.9 Addition of Affimer test line.  D12 bound to GNPs was incubated with the target proteins 
as indicated.  GNPs were washed three times before being incubated with the nitrocellulose strips 
striped with B3 (a) or B7 (b) and detection of the bound Affimer confirmed by the appearance of a 
pink line at the indicated position.  A faint line can be seen at the positions (*). 
 
Due to the reduced signal at the control line seen in figure 5.9 upon the addition of 
an Affimer control line, further optimisation of the test protocol was carried out.  
Here, the excess target was removed using further wash steps, as with the ELISA 
(figure 5.6) and an increase in the concentration of the labelled GNPs was used (20 
µl of OD1 instead of 10 µl OD1).  The addition of the solution containing the target, 
bound to GNP-D12, to the dipsticks with immobilised anti-his-antibody and Affimer 
B3 resulted in the appearance of the control lines as expected on all dipsticks with 
the exception of the dipstick which contained no antibody (figure 4.10).  This 
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suggests that in the dipstick format, the Affimers B3 and D12 are not able to 
function as pairs of reagents for the detection of SUMO-NLP or SUMO-NHP, which 
is contradictory to the GNP/magnetic bead assay (figure 5.2), which had initially 
shown that this pair of Affimers were able to detect SUMO-NHP.   
 
Figure 5.10 Optimisation of Affimer capture line using B3.  D12 bound to gold nanoparticles was 
incubated with the target proteins as indicated.  The GNPs were washed three times to remove 
excess target protein before being incubated with the nitrocellulose strips striped with B3.  D12 
bound to GNPs was detected at the control lines on all strips (*) except where there was no anti-his 
present.  
 
Figure 5.11 shows further optimisation of the Affimer test line using Affimers B7 
and D12; again the concentration of the GNPs and the number of washes were 
increased to remove the excess target and to increase the signal.  The dipsticks are 
representative of three replicates and show that these Affimers are able to detect 
the presence of SUMO-NLP and SUMO-NHP within the sample, with the 
confirmation of a successful test by the appearance of the control antibody line.  
This test has confirmed that it is possible to use Affimers as replacements for 
antibodies within a lateral flow device and thereby proving the hypothesis of the 
study.  
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Figure 5.11 Optimisation of Affimer capture line using B7.  D12 bound to GNPs was incubated with 
the target proteins as indicated.  The GNPs were washed three times to remove excess target 
protein before being incubated with the nitrocellulose strips striped with B7.  D12 bound to GNPs 
was detected as indicated (*).  The presence of the lower line on the SUMO-NLP and SUMO-NHP 
strips indicates the detection of these target proteins within the sample (*). 
 
5.5. Discussion 
The use of a GNP/magnetic bead assay (Zhou et al., 2015) to determine the ability 
of the identified Affimers to function as pairs of reagents was significantly more 
reliable than the previously discussed ELISA methods (Chapter 4).  It was confirmed 
that D12 was able to function as a pair with both B3 and B7 able to detect SUMO-
NHP within a sample.  Although this was a solution based assay, it was assumed 
that the functionality of the Affimers would remain upon their immobilisation onto 
a solid state platform.  Despite this, a number of challenges were presented with 
the development of the LFD.  As the Affimer reagents had never been used in this 
application before, optimisation of the required protein concentrations was 
required as well as the required concentration of the GNPs and target protein.   
The most important component of a LFD is the internal control line which confirms 
that the test has been performed successfully, independent of the appearance of 
the test line.  It is important that this line appears on every LFD used as a test and if 
it is absent, the test must be discounted.  Unfortunately it is not possible to raise an 
Affimer against an Affimer due to the similarity in structure and sequence despite 
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the changes in loop sequences.  Therefore, an alternative test line was required for 
the control line in this test.  The ideal method for producing a reagent for the test 
line in this case would be to clone a large tag onto the detection Affimer (D12) for 
example, maltose binding protein (MBP), GST or SUMO and raising an Affimer 
against the tag which would then be used as a control line.  Affimers have been 
raised against the yeast SUMO proteins, confirming that this would be an example 
of a suitable tag to use in the development of a suitable control line in the future 
(Tiede et al., 2014).  However, for the purpose of this LFD and as a proof of 
principle, an antibody control line was chosen, in this case an anti-his-antibody to 
detect the his6-tag on the detection Affimer.  This was chosen as it is already well 
documented that antibodies can be used in LFDs following the patent of the 
immobilisation of antibodies in this manner (Grubb & Glad., 1979).  However, this 
control line was not ideal due to the his6-tag present on the target proteins for 
purification, N-terminal to the SUMO-tag.  This presented a challenge with the use 
of an anti-his-antibody as the control line.  The target protein that is not captured 
by the Affimer-GNP is able to migrate up the nitrocellulose membrane faster than 
the target protein captured by the Affimer on the GNP due to the size discrepancy.  
Therefore, if there is excess target present in the sample, the control line is 
saturated with uncaptured target protein by the time that the captured target 
reaches the antibody and the colourimetric change cannot be detected (Verma et 
al., 2015).  Although this poses a problem in the development of the biosensor in 
this study, it is overcome with the detection of native, untagged viral proteins 
within a clinical sample.   
The results presented in this chapter demonstrate for the first time the use of 
novel non-antibody binding proteins in a LFD for the detection of a viral protein 
within a sample.  Although preliminary experiments do not conclusively 
demonstrate the ability of the Affimers chosen in this study to discriminate 
between the two PRRSV viral strains, they do provide exciting data as to the scope 
for the use of these reagents within a LFD.  The Affimers were successfully 
immobilised onto a solid state platform and they remained at the immobilisation 
site upon rehydration as well as remaining functional in their ability to detect the 
target proteins.  These key features of reagents used in LFDs lead us to believe that 
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further optimisation of the Affimers on a LFD platform will provide scope for the 
production of a wealth of these POC devices against a wide variety of pathogens in 
the future.  
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6.  Discussion and future perspectives 
This thesis investigated the suitability of novel Affimer reagents for use in point of 
care (POC) lateral flow devices (LFDs) for the direct detection of PRRSV N protein in 
clinical samples.  PRRSV was chosen as the proof of principle viral infection as it is a 
hugely economically damaging infection of swine and is under reported and poorly 
controlled in many regions of the world (Lunney et al., 2010).  This is partly due to 
the poor identification by animal producers but also as a result of poor biosecurity 
and lack of viable preventative and treatment measures, such as vaccines and anti-
viral reagents (Arruda et al., 2016).  The situation is further worsened by the lack of 
affordable, reliable and fast diagnostic tests available in the worst affected areas, 
allowing the virus to spread undetected between large numbers of animals (Chand 
et al., 2012).  Therefore, in addition to assessing the suitability of Affimers in LFDs, 
the thesis demonstrated the feasibility of developing a cheap POC device for 
PRRSV, which is not currently available.  This proof of concept study has shown 
Affimers can be used as replacements for antibodies in basic LFDs, for the direct 
detection of a viral protein, in this case the swine virus PRRSV N protein as the 
detection antigen.  Compared to antibodies, Affimers are cheaper and easier to 
produce and remove the requirement of animals in the production process, making 
them a desirable alternative reagent for this purpose.  The findings suggest that 
Affimers are indeed strong candidates for antibody alternatives in LFDs. 
This is the first study to investigate the application of non-antibody binding 
proteins in a LFD.  To this point the LFD has been developed to the stage of a 
functional dipstick device.  In order to progress to a fully integrated LFD, further 
components are required.  These include the addition of a conjugate pad 
containing the detection reagent as well as the assembly of the device into the 
plastic casing to produce the final POC device.  The detection reagent also requires 
further development, in this thesis an antibody detection reagent was used.  For 
the elimination of antibodies from the device entirely, it would be possible to use a 
detection Affimer tagged with a protein, for example Sumo or GFP and raise an 
Affimer against the protein tag to use as the control line reagent in replacement of 
the antibody.  
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6.1. PRRSV Affimers - application in LFDs 
The production of the Affimer reagents against PRRSV N proteins was relatively 
straightforward with two pools of reagents produced, one for each of the two viral 
strains of N protein, collected from three successive screening rounds.  It was 
anticipated that the screening of these proteins to identify Affimer reagents would 
result in a level of cross reactivity of Affimers between the two strains due to high 
sequence homology (the two strains chosen in this study have a sequence 
homology of 93.5%).  As expected, some cross-reactivity was observed within the 
pools of Affimers, likely because the Affimers were binding in a structure or 
sequence specific manner, conserved between the proteins.  Although the aim was 
to produce Affimers to discriminate between the two proteins, this cross-reactivity 
was useful as the LFD required a reagent that could detect both of the target 
proteins.  Despite the cross-reactivity, a total of 5 Affimers were able to 
differentiate between strains, identifying one specific strain of the viral N protein.    
This highlights a significant advantage of the Affimer technology.  Although this 
pool of Affimers was able to detect the N proteins in solution, it was unknown if 
they would remain functional following dehydration prior to immobilisation onto a 
nitrocellulose membrane.  To add further complexity, it was proposed that the 
device would detect the N protein from both PRRSV strains on one strip.  A further 
problem to address was the ability of the Affimers to detect the target protein in 
the context of swine serum to ensure the device was clinically relevant.  The study 
has shown that these issues have been addressed and successfully overcome, with 
the Affimers functioning as detection reagents once immobilised and dehydrated, 
as well as in the presence of a clinically relevant sample containing ‘contaminating 
proteins’ which may have interfered with Affimer-N protein interactions.  
Since first documented in 2014 (Tiede et al., 2014), Affimers have been raised 
against over 300 target proteins/molecules and their suitability for a number of 
uses has been quickly established (Tiede et al., 2017).  It can be argued that Affimer 
reagents are not only competitors against antibodies, but also other non-antibody 
binding proteins discussed in this study.  These other binding proteins have 
predominantly been shown to function as potential replacements for therapeutic 
antibodies, however, AdNectins™, Affibodies, DARPins and nanobodies have also 
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been used in a number of molecular biology techniques (Kim et al., 2017; Gilbreth 
et al., 2011; Binz et al., 2004; Moon et al., 2016; de Bruin et al., 2016; Platonova et 
al., 2015; Ries et al., 2012).  Affimers, however, have shown great potential for use 
as direct antibody replacements in a number of molecular biology techniques, 
whilst also being candidates for therapeutic reagents for example targeted delivery 
of drugs, pending further investigation (Tiede et al., 2017; Xie et al., 2017; Bedford 
et al., 2017; Johnson et al., 2012). 
When considering the commercial value of these reagents, it is important to 
appreciate their clinical relevance; Affimers have already been raised against Zika 
virus.  There was recently a much discussed and unprecedented Zika virus outbreak 
affecting the South Pacific region, with a strong correlation observed between 
infection during pregnancy and birth defects (Sarno et al., 2016).  Due to the 
locality of the infection, which closely aligns with the regions affected by dengue 
fever virus, it was nearly impossible to diagnose infection beyond the acute phase 
as they share common symptoms, however, the added complication of 
asymptomatic Zika infection also hampers diagnostic testing (Weaver et al., 2016).  
With this in mind, Affimer reagents were raised against a Zika virus target protein.  
Three Affimer binders were identified 13 weeks after receiving the viral target.  Like 
the Affimers identified in this study, the binders were raised against a viral protein, 
in this case NS1.  The reagents were tested for specificity and cross-reactivity 
between closely related viruses (dengue virus, yellow fever virus, West Nile virus 
and Japanese encephalitis virus) and were shown to be specific for Zika virus 
(Avacta, 2016).  The ability of the Affimers to distinguish reliably between closely 
related viruses and those that share similar symptoms is an important step forward 
in the case of Zika virus diagnosis.  The incorporation of these reagents into a 
suitable diagnostic platform, such as LFDs as used in this study, would allow for 
rapid and accurate diagnosis, particularly useful for couples in, and travellers 
returning from, affected regions when planning pregnancies.      
Although this study investigates the implementation of Affimers into a LFD, it is not 
the first time these reagents have been incorporated into diagnostic platforms.  
Affimers have been shown in label free biosensors where electric impedance is 
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measured.  The binding of IL-8 was detected without the requirement for labelled 
reagents, upon binding of IL-8 to the immobilised Affimer the change in electrical 
impedance was measured.  This was performed using spiked serum as the clinical 
sample, similar to the approach taken with the clinical sample used in this study.  
This supports the results shown in this study and illustrates that the Affimers are 
sensitive enough to detect antigen concentrations in the pM region when 
immobilised (Raina et al., 2015; Sharma et al., 2016).  The LFD designed in this 
study did not eliminate the use of antibodies entirely due to time constraints and 
the aim of illustrating Affimers can function in this platform.  However, the 
production of a combinational chemiluminescence assay using Affimers and 
antibodies has been shown for the detection of a hepatocellular carcinoma 
biomarker (GPC3).  The Affimer was used as a capture reagent and the antibody as 
the detection reagent, comparing the results of the combination assay with the 
dual antibody assay.  The nature of the Affimer reagents, specificity for the target 
protein, meant that the Affimer-antibody assay was able to distinguish between 
the carcinoma it had been produced to detect whilst eliminating other liver 
diseases from the diagnosis.  The improvement of sensitivity was increased by 36-
65% in the dual antibody assay to 62.5% in the combination assay while specificity 
was shown to be improved to 92.3% from a range of between 55-100% in the dual 
assay (Xie et al., 2017).  The increase in specificity and sensitivity is likely due to the 
greater sensitivity of the Affimers to the target antigen compared to the antibody 
counterpart as a result of the initial screening process carried out to identify 
suitable Affimer reagents.  This combination approach has shown that Affimers can 
at least compete and perhaps outperform antibodies in commonly used assays.  It 
would be interesting to explore any further improvement to specificity using a dual 
Affimer assay.     
Until now, the preferred application of non-antibody binding proteins in diagnostic 
techniques has been their incorporation into ELISA assays, due to their sensitivity 
(Hausammann et al., 2013).  As such it has previously been more common to find 
DNA or RNA aptamers as replacements for antibodies in LFDs and other diagnostics 
(Chen and Yang, 2015a; van den Kieboom et al., 2015).   
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Ordinarily, LFDs detecting any viral infection use antibodies directed against the 
host antibody response to an infection as this is usually easier to detect than the 
pathogen itself.  Due to the intracellular nature of viral lifecycles it is likely that in 
the context of infection there is a much higher concentration of these antibodies 
within the clinical samples than the viral antigens themselves.  However, in the 
case of PRRSV, antibody response to an infection can take more than a week and 
commonly longer for detectable N protein antibodies (Ferrin et al., 2004).  
Considering the N protein is the major immunogenic protein, it is therefore likely 
that early detection of this virus would be impossible at the pen-side by detecting 
the antibody response alone.  Conversely, it is possible to detect very small viral 
loads in clinical samples using techniques such as PCR, where viremia can be 
detected as early as 12 hours post infection (Rossow et al., 1995).  However this 
cannot be performed pen-side and is invariably more costly due to staff and 
reagent costs.  Detection of viremia at such early time points post infection would 
suggest that viral antigens may be detectable by a device targeted at them at 
similarly early time points.  With this in mind, the PRRSV N protein was chosen as 
the candidate for early and direct viral detection.  The protein is the ideal 
candidate, as well as comprising a large proportion of the virion (40%), it is also 
produced in excess of its structural requirements, due to its additional roles in virus 
biology (Meulenberg et al., 1995).  As high levels of antibodies are produced 
against the N protein during infection it was likely that it could be detected at 
sufficient levels in clinical samples, as was shown with a number of other virus N 
proteins (Singh et al., 2004; Xu et al., 2007; Jansen van Vuren and Paweska, 2009; 
Lau et al., 2004). 
The novel nature of Affimer reagents meant that it was unknown how they would 
perform in many aspects of the LFD development process.  As well as being 
immobilised, they also were required to migrate along a membrane whilst 
maintaining their ability to recognise their target protein.  A key feature of the 
device is the immobilisation and dehydration of the Affimer reagents at the test 
line site.  It was not known if this would result in the proteins becoming denatured 
or if they would be able to maintain functionality once rehydrated.  Importantly, 
the Affimers were indeed shown to maintain their binding ability to the target 
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sample upon rehydration, suggesting that they retained their structural integrity 
during the dehydration and rehydration processes.  Due to time constraints of the 
study, the Affimers dehydrated on the membranes were not stored for longer than 
24 hours before rehydration and so it is not possible to comment on the long term 
storage stability of these reagents.  It is likely that the Affimers will be stable once 
immobilised onto the nitrocellulose membrane for a number of weeks if not 
months if they are kept at an ambient temperature and not exposed to moisture.  
Their small size lends itself to compact packing onto the membrane and along with 
their beta-barrel structured nature we can infer that unfolding is not likely to occur 
if stored correctly.  Antibody based tests have been shown to be stable for 2 years 
post manufacture if stored according to the manufacturer’s instructions (Life Assay 
Diagnostics. 2010).  Affimers have been shown to be stable in solution up to 
approximately 100 °C (Tiede et al., 2014), suggesting they would be suitable for use 
in both temperate and tropical temperatures, vital for the incorporation into a 
diagnostic against PRRSV which is a global disease.  This is also important regarding 
their use in this format for tropical diseases, where diagnostics containing 
antibodies, are often less stable at high temperatures, compared to the Affimer.   
The detection Affimer conjugated to GNPs was not evaluated for its response to 
dehydration onto a conjugate pad in this study, although it is likely that this would 
not be a disadvantage to the Affimer functionality, considering the results of the 
non-conjugated counterparts.  The LFDs were tested as LF dipsticks with the 
conjugate Affimer provided in solution.  This allowed the samples to be tested 
more quickly and removed the variables associated with the conjugate Affimer also 
be immobilised during early testing, when the basic functioning of the Affimer 
reagents was not known in this format.  Despite this, LF dipstick tests would also be 
a suitable user-friendly pen-side test.  It would be possible to provide a sample of 
the detection reagent in solution to be added to the clinical sample before 
incubation with the test dip-stick.  This present work has shown that Affimers have 
strong potential for use in the development of LFDs for the detection of viral 
proteins in clinical samples which can be easily and quickly expanded to multiple 
economically and clinically relevant diseases.   
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The most important feature of these tests, next to antigen recognition, is device 
sensitivity.  It is important that the maximum sensitivity is achieved in order to 
provide early and conclusive diagnosis.  The sensitivity of Affimers in LFD was not 
evaluated in this study and so the lower detection limit is currently unknown for 
the PRRSV N protein in a clinical sample, although this has previously been 
mentioned to be in the pM region for other Affimers (Raina et al., 2015).  Of 
course, as there is currently no alternative antibody based detection device for this 
infection, it is not possible to draw a comparison of the sensitivity and specificity of 
the LFD.  It would therefore be interesting to produce an Affimer LFD that could be 
used to provide a direct comparison, for example, human pregnancy tests 
detecting hCG.  Alongside sensitivity, it is also important that the LFD is able to 
accurately diagnose the correct infection.  Although this is straightforward for the 
host specific arterivirus PRRSV, it may not be so simple for viruses that infect 
multiple hosts or share common symptoms, for example FMDV and swine vesicular 
disease (SVD), which are often clinically indistinguishable.  Both of these diseases 
are notifiable in the UK, but it is vital when considering the response to correctly 
diagnose the infection (Gov.uk. 2015).    
The sample used in this study was swine serum spiked with recombinant protein 
and therefore it is necessary to test this diagnostic approach using a virus-infected 
sample.  A range of samples (urine, semen, faeces and blood) also needs to be 
investigated, as well as the requirement for simple sample processing for example 
the incorporation of filters into the device.  A number of patented filtration devices 
are available, particularly for the filtration of whole blood samples, which could be 
employed in the LFD (Patent Numbers: (US)5240862 (Koenhen and Scharstuhl, 
1989), (WO)9610177 (Scharstuhl and Shaikh, 1995), (WO)9603194 (Pall and 
Manteuffel, 1995)). 
Although this study was performed using two viral strains of PRRSV, the results will 
be vast and far reaching.  This proof of concept study has shown that Affimers can 
be raised against an economically important target in order to improve upon the 
diagnosis of a damaging disease.  Perhaps more excitingly, these devices and 
technology have multiple clinical applications for the detection of not only 
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veterinary illnesses, but also human diseases.  Affimers have already been 
identified against a number of cancer biomarkers and viral proteins (Xie et al., 
2017; Tiede et al., 2017).  The simplicity of the LFD construction compliments the 
relatively rapid screening process required to isolate a pool of Affimer reagents 
against a target protein.  The combination of the two lends itself to the production 
of diagnostic devices against diseases which could ordinarily only be detected in 
the laboratory.  An example of this could be the production of a LFD which can 
detect the presence of Ebola virus.  The location and nature outbreaks of this virus 
means that there are often very few laboratory resources for the analysis of 
samples using PCR, ELISA or virus isolation (Broadhurst et al., 2016).   
6.2. Use of Affimers to overcome antibody limitations 
The production process of Affimers can also overcome the difficulty of mutagenic 
viruses and viruses with homologous proteins.  RNA viruses like PRRSV are highly 
mutagenic and so it is not guaranteed that the reagents (Affimers or antibodies or 
DNA or RNA aptamers) used in diagnostic tests will always identify the proteins of 
interest during a prolonged outbreak.  If a mutation occurs during an outbreak at 
the epitope of the protein where the reagent binds the test becomes redundant.  
Phage display production of Affimers offers a clear advantage over antibody 
production in this case.  A number of proteins (strains of proteins or individual viral 
proteins) can be screened at the same time reducing the time to produce reagents.  
The Affimer production process can also be exploited in this instance, screening of 
target proteins often produces an excess of binders and Affimers from each 
screening round is stored.  These stores can be revisited if a mutation occurs, 
without beginning the process from scratch, to identify Affimers which recognise a 
different protein sequence or structural region of the mutated/homologous target 
antigen.  If using antibodies in this way, depending on the method of antibody 
production, it is feasible that each mutated protein would have to be used to 
inoculate individual animals, making the process lengthy and ethically 
controversial.  This is also a consideration for targets screened as peptides rather 
than proteins as mutations may not occur in the screened peptide sequence for 
further screening post mutation.  The production of Affimer based LFDs can also be 
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easily modified to detect a number of viral antigens giving increased sensitivity and 
the reduction in false positive or false negative results.  A multiplex system can also 
be employed to include a number of Affimers binding to different epitopes of one 
protein as it is unlikely that a mutation would occur at the covered epitopes at the 
same time, hence prolonging the life of the device during an outbreak.  Multiplex 
devices using antibodies have been produced to detect mycotoxins (Song et al., 
2014), antibiotic detection (Chen et al., 2016) and multiple FMDV strains (M. Yang 
et al., 2015b) and DNA aptamers used in papillomavirus detection (Xu et al., 2014).   
The screening process of Affimers can also incorporate the addition of negative 
screening, if a protein is known to have homologues of a similar structure or 
sequence, these homologous proteins can be used within the screening rounds to 
eliminate Affimers in the pool of reagents which bind to both the target and 
homologous proteins, further raising specificity and reducing false positive results 
on the final test.  It is also difficult to obtain this kind of specificity within the 
antibody production process as only one antigen can be use in the inoculation in 
order to prevent cross-reactivity.   
In addition to the improved specificity of Affimer reagents compared to antibodies, 
there is also the consideration of the impact of Affimers on the reduction of the use 
of animals in the production process of detection reagents.  Antibody production 
for research and development processes uses a large number of animals, ordinarily 
1-3 per target (of which not all immunisations are successful and repetition is 
required using higher numbers).  Commercial development of Affimers is underway 
at Avacta for Affimer use as therapeutics and reagents for research and diagnostic 
applications and it is predicted that current use of these Affimer reagents could 
reduce the number of procedures carried out on animals by between 360 and 960 
per year.  This would increase dramatically with widespread uptake of the 
technology with the potential to remove the need for animal procedures entirely 
(CRACKIT, 2015). 
6.3. Affimers and clinical diagnostic applications 
Affimer based LFDs have huge potential for use in a clinical setting for the diagnosis 
of cancer, a prominent disease which is increasing in prevalence.  Although the 
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treatments for this disease are improving, the prognosis of this disease in a lot of 
cases would be dramatically improved with early diagnosis (Miller et al., 2016).  
Often cancer diagnosis is made following the biopsy of a solid tumour and this can 
be associated with late diagnosis.  However, it is known that there are a huge 
numbers of endogenous proteins that are upregulated in cancerous cells, many 
more than can be discussed (Hanahan and Weinberg, 2000; Singh et al., 2017; 
Hanahan and Weinberg, 2011).  It is possible to detect some of these hallmarks of 
cancer in the blood (Werner et al., 2016; Xie et al., 2017).  Therefore the 
identification of Affimers against these proteins provides ideal candidates for the 
production of a LFD that could detect the presence of cancerous cells rapidly and in 
a non-invasive manner.  Again, as with viral infections, such tests can be made 
multiplex to detect a number of upregulated proteins on one device to provide 
improved accuracy of diagnosis.  Previously this analysis would have been 
performed in the laboratory using techniques such as PCR, flow cytometry and 
mass spectrometry.  The production of reliable point-of-care diagnostics for such 
important diseases would not only improve prognosis of patients from early 
diagnosis but also reduce the cost of laboratory testing and potentially reduce 
treatment costs.   
Prostate cancer has been diagnosed with the assistance of a blood test for a 
number of years using the levels of prostate-specific antigen (PSA).  PSA is found in 
the serum of most men, however, it is upregulated in many patients suffering 
prostate cancer (above 4 ng/ml).  Although a quantitative analysis of the PSA levels 
is required in the diagnosis of prostate cancer, the vast research into this protein 
and its relation to prostate cancer provides a basis for the development of a 
multiplex test which, when used in combination with other techniques, would 
enhance the diagnostic process.  In the case of prostate cancer, it may be 
advantageous to combine the detection of PSA with another prostate cancer 
biomarker such as α-Methylacyl coenzyme A racemase (AMACR) or thymosin β15.  
It is possible to detect these proteins in a urine sample, a suitable sample for LFDs 
(Bolduc et al., 2007; Ploussard and de la Taille, 2010; Hutchinson et al., 2005).  
Affimers raised against these proteins and incorporated into a LFD would provide a 
more conclusive test for the presence of prostate cancer before more invasive 
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approaches are taken.  Critically, the relatively low cost of the production of 
Affimer-based LFDs means that they are highly suitable as diagnostics in the 
developing world where more expensive diagnostics are not currently available.  
Ultimately, the restriction of Affimer use in LFD is the ability to raise reagents 
against the protein of interest and the availability of relevant proteins within 
clinical samples.  Therefore, the potential of these reagents is vast; it is possible to 
modify the production process for difficult target proteins, for example using small 
exposed peptide regions of membrane bound proteins which are difficult to purify 
(Tiede et al., 2017).        
6.4. Additional uses of N protein Affimer reagents 
As well as the use of these Affimer reagents in the development of diagnostic 
devices for PRRSV, they are also potential candidates for the detailed study of the 
molecular biology of PRRSV.  There is currently no suitable structural information of 
the entire PRRSV N protein (Doan and Dokland, 2003).  However, it is possible that 
the Affimers could be used to aid in the crystallisation process of the complete N 
protein as chaperones of folding.  Binding of these reagents could constrain less 
structured regions of the protein, promoting crystal packing whilst in addition also 
identifying the binding sites of the Affimers.  Using protein scaffolds as chaperones 
in the crystallisation process, has been previously successful using other non-
antibody binding proteins (nanobodies, AdNectins™ and DARPins) (Rasmussen et 
al., 2011; Staus et al., 2016; Gilbreth et al., 2011; Bukowska and Grütter, 2013; 
Schilling et al., 2014).  Epitope binding of the Affimers to the N proteins in this 
study is not known and so it is yet to be determined if the reagents are binding in a 
conformation specific or sequence specific manner.  It may be possible to perform 
in silico docking of these Affimers using the truncated structure of the N protein 
available.  In addition to structural investigation, it would be interesting to employ 
these reagents in the study of virus biology.  Affimers have been expressed in cells 
in tissue culture to investigate intracellular signalling pathways (Tiede et al., 2017), 
and it would be interesting to probe their function in disrupting the viral life cycle 
of PRRSV.  It is likely that the expression of Affimers targeting the N protein in cell 
culture would result in the attenuation of the virus as a result of the disruption of 
183 
 
virus assembly, as the N protein is a major structural protein.  It may also provide 
further insights into the role of the N protein in the host cell response to infection, 
attenuating the activity of the N protein using Affimer binding, it may be possible 
to determine the role the N protein has on immune evasion and response.  
Expression of recombinant N protein alongside the Affimers and analysis of 
protein-protein interactions would also be interesting to investigate.  As previously 
mentioned, in 2012 a proteomic study was performed using the PRRSV N protein to 
investigate N protein-host cell interactions (Jourdan et al., 2012).  Using the 
generated Affimers to try to disrupt of the N protein-host cell interactions may 
provide further clues as to the function of the N protein in addition to its structural 
role.  It may also be possible to further probe the trafficking of the N protein in and 
out of the nucleus and nucleolus using Affimers if they are able to block the NLS 
regions of the protein (Rowland and Yoo, 2003).  This would be exciting in the 
context of viral lifecycle as it is currently unknown why the N protein traffics 
through these sub-cellular regions.  To date, NLS null PRRSV N proteins have been 
utilised to probe the role of the N protein in the nucleus and nucleolus.  Results 
showed that virus replication was attenuated, however, there was a high rate of 
reversion to wild type nucleolar localised protein, suggesting an essential role of 
the nuclear/nucleolus on PRRSV biology (Lee et al., 2006).  Using the Affimer 
reagents would overcome the problem of reversion to wild type and perhaps 
provide a greater insight into the requirement of this trafficking.   
Affimers also hold the potential for use as therapeutic reagents for PRRSV, for 
which there are no available anti-viral drugs.  Affimers have been shown to 
function as tools for in vivo imaging, following injection into the body (Tiede et al., 
2017).  The successful delivery of Affimers to the location of the tumour to be 
imaged, suggests that it would be possible to target Affimers against essential 
proteins of PRRSV.  As viral replication occurs intracellularly, it is unlikely that 
Affimers targeting the N protein would not be relevant for this approach unless an 
efficient method of Affimer delivery into cells can be developed.  Currently is it 
possible to transfect plasmids encoding Affimers into cells in vitro, however, 
delivery of these scaffolds through the cell membrane is more difficult.  A number 
of approaches have been taken for the delivery of proteins into the cell for 
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therapeutic means, for example, the use of biodegradeable polymersomes, 
liposomes and cell-penetrating oligopeptides and these could be investigated for 
the delivery of Affimers intracellularly (Liu et al., 2010; Aryasomayajula et al., 2017; 
Tashima, 2017).  The simplest method by which the Affimers could be delivered to 
cells would be by the addition of a cell-penetrating peptide (CPP), the most widely 
studied being the trans-activator of transcription factor (TAT) from HIV-1 (Frankel 
and Pabo, 1988).  Since the discovery of TAT, the delivery of target molecules into 
cells has been further developed and small molecule mimics have been used for 
efficient transport of proteins into the cell (Okuyama et al., 2007).  Recently a 
patent was filed (US 9657064 B2) using the ZEBRA CPP from Epstein-Barr virus to 
deliver protein cargo to cells.   Whilst the delivery method would have to take into 
consideration the targeting of Affimers to affected cells, the specificity shown by 
these molecules to their target proteins is very high, reducing the likeliness of off 
target effects if the Affimers encountered non affected cells.  The reduction of off 
target effects is highly desirable for the treatment of diseases such as cancer, 
where current chemotherapy drugs are non-specific for cancer cells.  The 
successful delivery of an Affimer targeted against cancer cells could revolutionise 
the treatment of these diseases.  
In addition to the intracellular delivery of Affimers targeting PRRSV, during acute 
infection, Affimers that bind to the envelope glycoproteins of PRRSV may be 
functional in the prevention of virus entry into cells, reducing viremia, virus 
shedding, clinical symptoms and length of infection.  In the case of veterinary 
diseases like PRRSV, Affimers are likely to be suitable ‘drugs’ as they are very small 
and it is predicted that the clearance of these proteins from the body swift, 
important for animals entering the food chain (Tiede et al., 2017).  If Affimers were 
shown to possess anti-viral properties, this would not only be an advantage to 
PRRSV but also other viruses previously discussed such as, Zika and Ebola as well as 
influenza.  Targeting a virus using multiple Affimers covering a broad spectrum of 
viral proteins or against a number of epitopes of fewer proteins has the potential 
to be more successful than using small molecule inhibitors that can often become 
redundant quickly during infection due to mutation rates of viruses.  
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Perhaps the most exciting find of this study is the confirmation of a new application 
of Affimers as molecular biology tools.  As the uses of these reagents are more 
widely explored, it is becoming evident that they are able to match or outcompete 
antibodies in the majority of applications; they are user friendly, can be easily 
validated and above all are renewable, ethical resources. 
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